{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "cfbac882",
   "metadata": {},
   "source": [
    "### RAG Pipeline1 - Data Ingestion to Vector DB"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "e5ad37ee",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from langchain_community.document_loaders import PyPDFLoader, PyMuPDFLoader, DirectoryLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from pathlib import Path"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "caddd7fb",
   "metadata": {},
   "source": [
    "##### Loading PDF documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "8ee66cac",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Found 5 PDF files to process\n",
      "\n",
      "Processing: brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf\n",
      "  ✓ Loaded 67 pages\n",
      "\n",
      "Processing: malnutrition.pdf\n",
      "  ✓ Loaded 11 pages\n",
      "\n",
      "Processing: nice_hypertension_guideline_summary.pdf\n",
      "  ✓ Loaded 3 pages\n",
      "\n",
      "Processing: parkinsons-disease-in-adults-pdf-1837629189061.pdf\n",
      "  ✓ Loaded 31 pages\n",
      "\n",
      "Processing: motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf\n",
      "  ✓ Loaded 45 pages\n",
      "\n",
      "Total documents loaded: 157\n"
     ]
    }
   ],
   "source": [
    "### Read all the pdf's inside the directory\n",
    "def process_all_pdfs(pdf_directory):\n",
    "    \"\"\"Process all PDF files in a directory\"\"\"\n",
    "    all_documents = []\n",
    "    pdf_dir = Path(pdf_directory)\n",
    "    \n",
    "    # Find all PDF files recursively\n",
    "    pdf_files = list(pdf_dir.glob(\"**/*.pdf\"))\n",
    "    \n",
    "    print(f\"Found {len(pdf_files)} PDF files to process\")\n",
    "    \n",
    "    for pdf_file in pdf_files:\n",
    "        print(f\"\\nProcessing: {pdf_file.name}\")\n",
    "        try:\n",
    "            loader = PyPDFLoader(str(pdf_file))\n",
    "            documents = loader.load()\n",
    "            \n",
    "            # Add source information to metadata\n",
    "            for doc in documents:\n",
    "                doc.metadata['source_file'] = pdf_file.name\n",
    "                doc.metadata['file_type'] = 'pdf'\n",
    "            \n",
    "            all_documents.extend(documents)\n",
    "            print(f\"  ✓ Loaded {len(documents)} pages\")\n",
    "            \n",
    "        except Exception as e:\n",
    "            print(f\"  ✗ Error: {e}\")\n",
    "    \n",
    "    print(f\"\\nTotal documents loaded: {len(all_documents)}\")\n",
    "    return all_documents\n",
    "\n",
    "# Process all PDFs in the data directory\n",
    "all_pdf_documents = process_all_pdfs(\"../data\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4f1a8497",
   "metadata": {},
   "source": [
    "#### Chunking document text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "a0d5ba43",
   "metadata": {},
   "outputs": [],
   "source": [
    "def split_documents(documents,chunk_size=1000,chunk_overlap=200):\n",
    "    \"\"\"Split documents into smaller chunks for better RAG performance\"\"\"\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=chunk_size,\n",
    "        chunk_overlap=chunk_overlap,\n",
    "        length_function=len,\n",
    "        separators=[\"\\n\\n\", \"\\n\", \" \", \"\"]\n",
    "    )\n",
    "    split_docs = text_splitter.split_documents(documents)\n",
    "    print(f\"Split {len(documents)} documents into {len(split_docs)} chunks\")\n",
    "    \n",
    "    # Show example of a chunk\n",
    "    if split_docs:\n",
    "        print(f\"\\nExample chunk:\")\n",
    "        print(f\"Content: {split_docs[0].page_content[:200]}...\")\n",
    "        print(f\"Metadata: {split_docs[0].metadata}\")\n",
    "    \n",
    "    return split_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "09d6cc64",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Split 157 documents into 394 chunks\n",
      "\n",
      "Example chunk:\n",
      "Content: Brain tumours (primary) \n",
      "and brain metastases in \n",
      "over 16s \n",
      "NICE guideline \n",
      "Published: 11 July 2018 \n",
      "Last updated: 29 January 2021 \n",
      "www.nice.org.uk/guidance/ng99 \n",
      "© NICE 2025. All rights reserved. Sub...\n",
      "Metadata: {'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 0, 'page_label': '1', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 0, 'page_label': '1', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Brain tumours (primary) \\nand brain metastases in \\nover 16s \\nNICE guideline \\nPublished: 11 July 2018 \\nLast updated: 29 January 2021 \\nwww.nice.org.uk/guidance/ng99 \\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 1, 'page_label': '2', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Your responsibility \\nThe recommendations in this guideline represent the view of NICE, arrived at after careful \\nconsideration of the evidence available. When exercising their judgement, professionals \\nand practitioners are expected to take this guideline fully into account, alongside the \\nindividual needs, preferences and values of their patients or the people using their service. \\nIt is not mandatory to apply the recommendations, and the guideline does not override the \\nresponsibility to make decisions appropriate to the circumstances of the individual, in \\nconsultation with them and their families and carers or guardian. \\nAll problems (adverse events) related to a medicine or medical device used for treatment \\nor in a procedure should be reported to the Medicines and Healthcare products Regulatory \\nAgency using the Yellow Card Scheme. \\nLocal commissioners and providers of healthcare have a responsibility to enable the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 1, 'page_label': '2', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Agency using the Yellow Card Scheme. \\nLocal commissioners and providers of healthcare have a responsibility to enable the \\nguideline to be applied when individual professionals and people using services wish to \\nuse it. They should do so in the context of local and national priorities for funding and \\ndeveloping services, and in light of their duties to have due regard to the need to eliminate \\nunlawful discrimination, to advance equality of opportunity and to reduce health \\ninequalities. Nothing in this guideline should be interpreted in a way that would be \\ninconsistent with complying with those duties. \\nCommissioners and providers have a responsibility to promote an environmentally \\nsustainable health and care system and should assess and reduce the environmental \\nimpact of implementing NICE recommendations wherever possible. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 1, 'page_label': '2', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='impact of implementing NICE recommendations wherever possible. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 2 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 2, 'page_label': '3', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Contents \\nOverview ...................................................................................................................................... 5 \\nWho is it for? .......................................................................................................................................... 5 \\nRecommendations ....................................................................................................................... 6 \\n1.1 Investigation of suspected glioma .................................................................................................. 6 \\n1.2 Management of glioma ................................................................................................................... 7 \\n1.3 Follow-up for glioma ........................................................................................................................ 17'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 2, 'page_label': '3', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='1.3 Follow-up for glioma ........................................................................................................................ 17 \\n1.4 Investigation and management of meningioma ........................................................................... 20 \\n1.5 Follow-up for meningioma .............................................................................................................. 24 \\n1.6 Investigation of suspected brain metastases ............................................................................... 27 \\n1.7 Management of confirmed brain metastases ............................................................................... 28 \\n1.8 Follow-up for brain metastases ..................................................................................................... 32 \\n1.9 Care needs of people with brain tumours ..................................................................................... 34'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 2, 'page_label': '3', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='1.9 Care needs of people with brain tumours ..................................................................................... 34 \\n1.10 Neurorehabilitation needs of people with brain tumours ........................................................... 36 \\n1.11 Surveillance for the late-onset side effects of treatment .......................................................... 37 \\nTerms used in this guideline ................................................................................................................. 39 \\nRecommendations for research .................................................................................................40 \\nKey recommendations for research .................................................................................................... 40 \\nRationale and impact ................................................................................................................... 45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 2, 'page_label': '3', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Rationale and impact ................................................................................................................... 45 \\nInvestigations for suspected glioma: imaging .................................................................................... 45 \\nInvestigations for suspected glioma: molecular markers .................................................................. 46 \\nManagement of glioma: initial surgery for low-grade glioma ........................................................... 46 \\nManagement of glioma: further management of low-grade glioma ................................................ 48 \\nManagement of glioma: grade 3 glioma following surgery ............................................................... 49 \\nManagement of glioma: grade 4 glioma following surgery ............................................................... 50'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 2, 'page_label': '3', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Management of glioma: grade 4 glioma following surgery ............................................................... 50 \\nManagement of glioma: recurrent high-grade glioma ....................................................................... 51 \\nManagement of glioma: techniques for resection of glioma ............................................................. 52 \\nFollow-up for glioma ............................................................................................................................. 53 \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 3 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 3, 'page_label': '4', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Investigation of suspected meningioma ............................................................................................. 55 \\nManagement of confirmed meningioma following surgery or if surgery is not possible (or has \\nbeen declined) ....................................................................................................................................... 55 \\nFollow-up for meningioma .................................................................................................................... 57 \\nInvestigation of suspected brain metastases .................................................................................... 58 \\nManagement of confirmed brain metastases .................................................................................... 58 \\nFollow-up for brain metastases ........................................................................................................... 60'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 3, 'page_label': '4', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Follow-up for brain metastases ........................................................................................................... 60 \\nCare needs of people with brain tumours .......................................................................................... 61 \\nNeurorehabilitation needs of people with brain tumours .................................................................. 62 \\nSurveillance for the late-onset side effects of treatment ................................................................. 63 \\nContext ......................................................................................................................................... 64 \\nFinding more information and committee details .....................................................................66 \\nUpdate information ..................................................................................................................... 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 3, 'page_label': '4', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Update information ..................................................................................................................... 67 \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 4 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 4, 'page_label': '5', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='This guideline is the basis of QS203. \\nOverview \\nThis guideline covers diagnosing, monitoring and managing any type of primary brain \\ntumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and \\ncare, including standardising the care people have, how information and support are \\nprovided, and palliative care. \\nIn January 2021, we replaced our recommendation on surgical cavity radiosurgery and \\nradiotherapy with a link to the NHS England commissioning policy on stereotactic \\nradiosurgery and stereotactic radiotherapy to the surgical cavity following resection of \\ncerebral metastases. \\nWho is it for? \\n• Healthcare professionals involved in the multidisciplinary care of people with primary \\nbrain tumours or brain metastases \\n• Commissioners and providers of brain tumour services \\n• People using services for the diagnosis, management and care of a primary brain \\ntumour or brain metastases, and their families and carers'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 4, 'page_label': '5', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='• Commissioners and providers of brain tumour services \\n• People using services for the diagnosis, management and care of a primary brain \\ntumour or brain metastases, and their families and carers \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 5 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 5, 'page_label': '6', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Recommendations \\nPeople have the right to be involved in discussions and make informed decisions \\nabout their care, as described in NICE's information on making decisions about your \\ncare. \\nMaking decisions using NICE guidelines explains how we use words to show the \\nstrength (or certainty) of our recommendations, and has information about \\nprescribing medicines (including off label use), professional guidelines, standards and \\nlaws (including on consent and mental capacity), and safeguarding. \\n1.1 Investigation of suspected glioma \\nImaging for suspected glioma \\n1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and \\nT1 pre- and post-contrast volume) as the initial diagnostic test for suspected \\nglioma, unless MRI is contraindicated. \\n1.1.2 Refer people with a suspected glioma to a specialist multidisciplinary team at first \\nradiological diagnosis for management of their tumour.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 5, 'page_label': '6', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"glioma, unless MRI is contraindicated. \\n1.1.2 Refer people with a suspected glioma to a specialist multidisciplinary team at first \\nradiological diagnosis for management of their tumour. \\n1.1.3 Consider advanced MRI techniques, such as MR perfusion and MR spectroscopy, \\nto assess the potential of a high-grade transformation in a tumour appearing to \\nbe low grade on standard structural MRI. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on imaging for \\nsuspected glioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 6 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 6, 'page_label': '7', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Use of molecular markers to determine prognosis or guide \\ntreatment for glioma \\n1.1.4 Report all glioma specimens according to the latest version of the World Health \\nOrganization (WHO) classification of tumors of the central nervous system. As \\nwell as histopathological assessment, include molecular markers such as: \\n• IDH1 and IDH2 mutations \\n• ATRX mutations to identify IDH mutant astrocytomas and glioblastomas \\n• 1p/19q codeletion to identify oligodendrogliomas \\n• histone H3.3 K27M mutations in midline gliomas \\n• BRAF fusion and gene mutation to identify pilocytic astrocytoma. \\n1.1.5 Test all high-grade glioma specimens for MGMT promoter methylation to inform \\nprognosis and guide treatment. \\n1.1.6 Consider testing IDH-wildtype glioma specimens for TERT promoter mutations to \\ninform prognosis. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on use of molecular'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 6, 'page_label': '7', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"inform prognosis. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on use of molecular \\nmarkers to determine prognosis or guide treatment for glioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\n1.2 Management of glioma \\nInitial surgery for suspected low-grade glioma \\n1.2.1 The surgical expertise in the multidisciplinary team should include: \\n• access to awake craniotomy with language and other appropriate functional \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 7 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 7, 'page_label': '8', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='monitoring and \\n• expertise in intraoperative neurophysiological monitoring and \\n• access to neuroradiological support and \\n• access to intraoperative image guidance. \\n1.2.2 Consider surgical resection as part of initial management (within 6 months of \\nradiological diagnosis) to: \\n• obtain a histological and molecular diagnosis and \\n• remove as much of the tumour as safely possible after discussion of the \\npossible extent of resection at multidisciplinary meeting and with the person \\nwith the brain tumour, and their relatives and carers. \\n1.2.3 If surgical resection is not appropriate, consider biopsy to obtain a histological \\nand molecular diagnosis. \\n1.2.4 Consider active monitoring without a histological diagnosis, for lesions with \\nradiological features typical of very low-grade tumours, for example, DNET \\n(dysembryoplastic neuroepithelial tumour) or optic pathway glioma. \\n1.2.5 If people having active monitoring show radiological or clinical disease'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 7, 'page_label': '8', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"(dysembryoplastic neuroepithelial tumour) or optic pathway glioma. \\n1.2.5 If people having active monitoring show radiological or clinical disease \\nprogression, discuss this at a multidisciplinary team meeting and consider: \\n• surgical resection or \\n• biopsy if surgical resection is not possible. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on initial surgery for \\nsuspected low-grade glioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 8 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 8, 'page_label': '9', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Further management of newly diagnosed low-grade glioma \\n1.2.6 After surgery, offer radiotherapy followed by up to 6 cycles of PCV chemotherapy \\n(procarbazine, CCNU [lomustine] and vincristine) for people who: \\n• have a 1p/19q codeleted, IDH-mutated low-grade glioma (oligodendroglioma) \\nand \\n• are aged around 40 or over, or have residual tumour on postoperative MRI. \\n1.2.7 After surgery, consider radiotherapy followed by up to 6 cycles of PCV \\nchemotherapy for people who: \\n• have a 1p/19q non-codeleted, IDH-mutated low-grade glioma (astrocytoma) \\nand \\n• are aged around 40 or over, or have residual tumour on postoperative MRI. \\n1.2.8 Consider active monitoring for people who are aged around 40 or under with an \\nIDH-mutated low-grade glioma and have no residual tumour on postoperative \\nMRI. \\n1.2.9 Consider radiotherapy followed by up to 6 cycles of PCV chemotherapy for \\npeople with an IDH-mutated low-grade glioma who have not had radiotherapy \\nbefore if they have:'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 8, 'page_label': '9', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='MRI. \\n1.2.9 Consider radiotherapy followed by up to 6 cycles of PCV chemotherapy for \\npeople with an IDH-mutated low-grade glioma who have not had radiotherapy \\nbefore if they have: \\n• progressive disease on radiological follow-up or \\n• intractable seizures. \\n1.2.10 When delivering radiotherapy for people with IDH-mutated low-grade glioma, do \\nnot use a treatment dose of more than 54 Gy at 1.8 Gy per fraction. \\n1.2.11 Be aware that the prognosis for people with histologically confirmed IDH-\\nwildtype grade 2 glioma may be similar to that of people with glioblastoma if \\nother molecular features are consistent with glioblastoma. Take this into account \\nwhen thinking about management options. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 9 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 9, 'page_label': '10', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on further \\nmanagement of newly diagnosed low-grade glioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\nManagement of newly diagnosed grade 3 glioma following \\nsurgery or if surgery is not possible (or has been declined) \\n1.2.12 For guidance on using temozolomide for treating newly diagnosed grade 3 \\nglioma, see the NICE technology appraisal guidance on carmustine implants and \\ntemozolomide for the treatment of newly diagnosed high-grade glioma. \\n1.2.13 After surgery, offer sequential radiotherapy and 4 to 6 cycles of PCV \\nchemotherapy to people who have: \\n• a Karnofsky performance status of 70 or more and \\n• a newly diagnosed grade 3 glioma with 1p/19q codeletion (anaplastic \\noligodendroglioma).\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 9, 'page_label': '10', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='chemotherapy to people who have: \\n• a Karnofsky performance status of 70 or more and \\n• a newly diagnosed grade 3 glioma with 1p/19q codeletion (anaplastic \\noligodendroglioma). \\n1.2.14 Agree with the person with the anaplastic oligodendroglioma the order of PCV \\nchemotherapy and radiotherapy after discussing the potential advantages and \\ndisadvantages of each option with them (see table 1). \\nTable 1 Factors to take into account when deciding whether to have PCV or \\nradiotherapy first for management of anaplastic oligodendroglioma \\nPCV first Radiotherapy first \\nOverall survival No clinically important difference. No clinically important difference. \\nProgression-\\nfree survival No clinically important difference. No clinically important difference. \\nFertility \\npreservation \\nTrying to preserve fertility may cause \\na delay in the start of treatment. \\nAllows additional time for fertility \\npreservation without delaying \\ntreatment.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 9, 'page_label': '10', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Fertility \\npreservation \\nTrying to preserve fertility may cause \\na delay in the start of treatment. \\nAllows additional time for fertility \\npreservation without delaying \\ntreatment. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 10 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 10, 'page_label': '11', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"PCV first Radiotherapy first \\nPlanning \\ntreatment \\naround \\nimportant life \\nevents \\nInitially much less contact with the \\nhealth system, but potentially more \\nfatigue. \\nHarder to give a precise date for when \\nradiotherapy will start, as people's \\ntolerance of chemotherapy is less \\npredictable. \\nInitially much more contact with the \\nhealth system: daily visits to \\nradiotherapy department lasting \\nseveral weeks. \\nTiming of start of chemotherapy \\nmuch more predictable. \\n1.2.15 After surgery, offer radiotherapy followed by up to 12 cycles of adjuvant \\ntemozolomide to people who have: \\n• a Karnofsky performance status of 70 or more and \\n• a newly diagnosed IDH-wildtype or mutated grade 3 glioma without 1p/19q \\ncodeletion (anaplastic astrocytoma). \\n1.2.16 Do not offer nitrosoureas (for example, CCNU [lomustine]) concurrently with \\nradiotherapy to people with newly diagnosed grade 3 glioma. \\n1.2.17 If asked, advise people with an initial diagnosis of grade 3 glioma (and their\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 10, 'page_label': '11', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='radiotherapy to people with newly diagnosed grade 3 glioma. \\n1.2.17 If asked, advise people with an initial diagnosis of grade 3 glioma (and their \\nrelatives and carers, as appropriate) that the available evidence does not support \\nthe use of: \\n• cannabis oil \\n• immunotherapy \\n• ketogenic diets \\n• metformin \\n• statins \\n• valganciclovir. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 11 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 11, 'page_label': '12', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on management of \\nnewly diagnosed grade 3 glioma after surgery, or if surgery is not possible or the \\nperson declines surgery. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\nManagement of newly diagnosed grade 4 glioma (glioblastoma) \\nfollowing surgery or if surgery is not possible (or has been \\ndeclined) \\nThe recommendations in this section are also viewable as a visual summary. \\n1.2.18 For guidance on using temozolomide for treating newly diagnosed grade 4 glioma \\n(glioblastoma), see the NICE technology appraisal guidance on carmustine \\nimplants and temozolomide for the treatment of newly diagnosed high-grade \\nglioma. \\n1.2.19 Offer radiotherapy using 60 Gy in 30 fractions with concomitant temozolomide,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 11, 'page_label': '12', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='implants and temozolomide for the treatment of newly diagnosed high-grade \\nglioma. \\n1.2.19 Offer radiotherapy using 60 Gy in 30 fractions with concomitant temozolomide, \\nfollowed by up to 6 cycles of adjuvant temozolomide, for people aged around \\n70 or under who have: \\n• a Karnofsky performance status of 70 or more and \\n• had maximal safe resection, or biopsy when resection is not possible, for a \\nnewly diagnosed grade 4 glioma (glioblastoma). \\n1.2.20 Offer radiotherapy using 40 Gy in 15 fractions with concomitant and up to \\n12 cycles of adjuvant temozolomide for people aged around 70 or over who have: \\n• a Karnofsky performance status of 70 or more and \\n• a newly diagnosed grade 4 glioma (glioblastoma) with MGMT methylation. \\n1.2.21 Consider radiotherapy using 40 Gy in 15 fractions with concomitant and up to \\n12 cycles of adjuvant temozolomide for people aged around 70 or over who have: \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 11, 'page_label': '12', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='12 cycles of adjuvant temozolomide for people aged around 70 or over who have: \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 12 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 12, 'page_label': '13', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"• a Karnofsky performance status of 70 or more and \\n• a newly diagnosed grade 4 glioma (glioblastoma) without MGMT methylation \\nor for which methylation status is unavailable. \\n1.2.22 Consider best supportive care alone for people aged around 70 or over who have: \\n• a grade 4 glioma (glioblastoma) and \\n• a Karnofsky performance status of under 70. \\n1.2.23 For people with an initial diagnosis of grade 4 glioma (glioblastoma) not covered \\nin recommendations 1.2.19 to 1.2.22, consider the treatment options of: \\n• radiotherapy using 60 Gy in 30 fractions with concurrent and up to 6 cycles \\nof adjuvant temozolomide \\n• radiotherapy alone using 60 Gy in 30 fractions \\n• hypofractionated radiotherapy \\n• up to 6 cycles of temozolomide alone if the tumour has MGMT methylation \\nand the person is aged around 70 or over \\n• best supportive care alone. \\n1.2.24 Assess the person's performance status throughout the postoperative period and\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 12, 'page_label': '13', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"and the person is aged around 70 or over \\n• best supportive care alone. \\n1.2.24 Assess the person's performance status throughout the postoperative period and \\nreview treatment options for grade 4 glioma (glioblastoma) if their performance \\nstatus changes. \\n1.2.25 Do not offer bevacizumab as part of management of a newly diagnosed grade 4 \\nglioma (glioblastoma). \\n1.2.26 Do not offer tumour-treating fields (TTF) as part of management of a newly \\ndiagnosed grade 4 glioma (glioblastoma). \\n1.2.27 If asked, advise people with an initial diagnosis of grade 4 glioma (and their \\nrelatives and carers, as appropriate) that the available evidence does not support \\nthe use of: \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 13 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 13, 'page_label': '14', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"• cannabis oil \\n• immunotherapy \\n• ketogenic diets \\n• metformin \\n• statins \\n• valganciclovir. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on management of \\nnewly diagnosed grade 4 glioma (glioblastoma) following surgery, or if surgery is not \\npossible or the person declines surgery. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\nManagement of recurrent high-grade glioma (recurrent grade 3 \\nand grade 4 glioma) \\n1.2.28 When deciding on treatment options for people with recurrent high-grade glioma, \\ntake into account: \\n• Karnofsky performance status \\n• the person's preferences \\n• time from last treatment \\n• tumour molecular markers \\n• what their last treatment was. \\n1.2.29 Consider PCV or single agent CCNU (lomustine) as an alternative to \\ntemozolomide for people with recurrent high-grade glioma.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 13, 'page_label': '14', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='• tumour molecular markers \\n• what their last treatment was. \\n1.2.29 Consider PCV or single agent CCNU (lomustine) as an alternative to \\ntemozolomide for people with recurrent high-grade glioma. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 14 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 14, 'page_label': '15', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='1.2.30 For guidance on using temozolomide as an option for treating recurrent high-\\ngrade glioma, see the NICE technology appraisal guidance on temozolomide for \\nthe treatment of recurrent malignant glioma (brain cancer). \\n1.2.31 Consider best supportive care alone for high-grade glioma if other treatments are \\nnot likely to be of benefit, or if the person would prefer this. Refer to the NICE \\ncancer service guidance on improving supportive and palliative care for adults \\nwith cancer. \\n1.2.32 For people with focally recurrent high-grade glioma, the multidisciplinary team \\nshould also consider the treatment options of: \\n• further surgery \\n• further radiotherapy. \\n1.2.33 Do not offer bevacizumab, erlotinib or cediranib, either alone or in combination \\nwith chemotherapy, as part of management of recurrent high-grade glioma. \\n1.2.34 Do not offer tumour treating fields (TTF) as part of management of recurrent \\nhigh-grade glioma.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 14, 'page_label': '15', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='with chemotherapy, as part of management of recurrent high-grade glioma. \\n1.2.34 Do not offer tumour treating fields (TTF) as part of management of recurrent \\nhigh-grade glioma. \\n1.2.35 If asked, advise people who have recurrent high-grade glioma (and their relatives \\nand carers, as appropriate) that the available evidence does not support the use \\nof: \\n• cannabis oil \\n• immunotherapy \\n• ketogenic diets \\n• metformin \\n• statins \\n• valganciclovir. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 15 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 15, 'page_label': '16', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on management of \\nrecurrent grade 3 and grade 4 glioma (recurrent high-grade glioma). \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\nGenomic biomarker-based treatment for glioma \\nThe point at which to use genomic biomarker-based therapy in solid tumour treatment \\npathways is uncertain. See the NICE topic page on genomic biomarker-based cancer \\ntreatments. \\nTechniques for resection of glioma \\n1.2.36 If a person has a radiologically enhancing suspected high-grade glioma and the \\nmultidisciplinary team thinks that surgical resection of all enhancing tumour is \\npossible, offer 5-aminolevulinic acid (5-ALA)-guided resection as an adjunct to \\nmaximise resection at initial surgery.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 15, 'page_label': '16', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='possible, offer 5-aminolevulinic acid (5-ALA)-guided resection as an adjunct to \\nmaximise resection at initial surgery. \\n1.2.37 Consider intraoperative MRI to help achieve surgical resection of both low-grade \\nand high-grade glioma while preserving neurological function, unless MRI is \\ncontraindicated. \\n1.2.38 Consider intraoperative ultrasound to help achieve surgical resection of both low-\\ngrade and high-grade glioma. \\n1.2.39 Consider diffusion tensor imaging overlays in addition to standard \\nneuronavigation techniques to minimise damage to functionally important fibre \\ntracts during resection of both low-grade and high-grade glioma. \\n1.2.40 Consider awake craniotomy for people with low-grade or high-grade glioma to \\nhelp preserve neurological function. \\n1.2.41 Discuss awake craniotomy and its potential benefits and risks with the person \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 15, 'page_label': '16', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='help preserve neurological function. \\n1.2.41 Discuss awake craniotomy and its potential benefits and risks with the person \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 16 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 16, 'page_label': '17', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"and their relatives and carers (as appropriate) so that they can make an informed \\nchoice about whether to have it. Only consider the procedure if the person is \\nlikely not to be significantly distressed by it. \\n1.2.42 Involve other specialists as appropriate, such as neuropsychologists and speech \\nand language therapists, before, during and after awake craniotomy. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on techniques for \\nresection of glioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\n1.3 Follow-up for glioma \\n1.3.1 Offer regular clinical review for people with glioma to assess changes in their \\nphysical, psychological and cognitive wellbeing. \\n1.3.2 Base decisions on the timing of regular clinical reviews and follow-up imaging for \\npeople with glioma on: \\n• any residual tumour\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 16, 'page_label': '17', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"physical, psychological and cognitive wellbeing. \\n1.3.2 Base decisions on the timing of regular clinical reviews and follow-up imaging for \\npeople with glioma on: \\n• any residual tumour \\n• life expectancy \\n• the person's preferences (see table 2 for factors to discuss with them) \\n• treatments used before \\n• treatment options available \\n• tumour subtype. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 17 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 17, 'page_label': '18', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Table 2 Factors to take into account when deciding on frequency of follow-up for \\npeople with glioma \\nPossible advantages of more frequent follow-up Possible disadvantages of more frequent follow-up \\nMay identify recurrent disease earlier \\nwhich may increase treatment options or \\nenable treatment before people become \\nsymptomatic. \\nThere is no definitive evidence that \\nidentifying recurrent disease early improves \\noutcomes. \\nMay help provide information about the \\ncourse of the illness and prognosis. \\nMay increase anxiety if changes of uncertain \\nsignificance are detected on imaging. \\nSome people can find more frequent \\nimaging and hospital contact reassuring. \\nProvides an opportunity to identify \\npatient or carer needs (such as \\npsychosocial support and late side \\neffects of treatment). \\nSome people can find more frequent imaging \\nand hospital contact burdensome and \\ndisruptive – they feel their life revolves \\naround their latest scan. \\nThere may be a financial cost from taking'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 17, 'page_label': '18', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Some people can find more frequent imaging \\nand hospital contact burdensome and \\ndisruptive – they feel their life revolves \\naround their latest scan. \\nThere may be a financial cost from taking \\ntime off work and travelling to appointments. \\n– More imaging and follow-up is resource \\nintensive for the NHS. \\n1.3.3 Consider the follow-up schedule given in table 3 for people with glioma. \\n1.3.4 Consider standard structural MRI (defined as T2 weighted, FLAIR, DWI series and \\nT1 pre- and post-contrast volume) as part of regular clinical review for people \\nwith glioma, to assess for progression or recurrence, unless MRI is \\ncontraindicated. \\n1.3.5 Consider advanced MRI techniques, such as MR perfusion, diffusion tensor \\nimaging and MR spectroscopy, if findings from standard imaging are unclear \\nabout whether there is recurrence and early identification is potentially clinically \\nuseful. \\n1.3.6 For people with glioma having routine imaging:'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 17, 'page_label': '18', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='about whether there is recurrence and early identification is potentially clinically \\nuseful. \\n1.3.6 For people with glioma having routine imaging: \\n• explain to them, and their relatives and carers, that imaging can be difficult to \\ninterpret and results can be of uncertain significance and \\n• be aware that having routine imaging and waiting for the results may cause \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 18 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 18, 'page_label': '19', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"anxiety. \\n1.3.7 Consider a baseline MRI scan within 72 hours of surgical resection for all types of \\nglioma. \\n1.3.8 Consider a baseline MRI scan 3 months after the completion of radiotherapy for \\nall types of glioma. \\n1.3.9 Arrange a clinical review, including appropriate imaging, for people with glioma \\nwho develop new or changing neurological symptoms or signs at any time. \\nTable 3 Possible regular clinical review schedule for people with glioma depending on \\ngrade of tumour \\nGrade of tumour Clinical review schedule \\nGrade 1 \\nScan at 12 months, then: \\n• consider discharge if no tumour visible on imaging unless \\ncompletely resected pilocytic astrocytoma \\n• consider ongoing imaging at increasing intervals for 15 years \\nfor completely resected pilocytic astrocytoma \\n• consider if ongoing imaging is needed at a rate of once every \\n1 to 3 years for the rest of the person's life if the tumour is \\nvisible on imaging. \\n• Grade 2 1p/19q \\nnon-codeleted, \\nIDH mutated \\n• Grade 2 1p/19q\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 18, 'page_label': '19', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"1 to 3 years for the rest of the person's life if the tumour is \\nvisible on imaging. \\n• Grade 2 1p/19q \\nnon-codeleted, \\nIDH mutated \\n• Grade 2 1p/19q \\ncodeleted \\n• Grade 3 1p/19q \\ncodeleted \\n• From 0 to 2 years, scan at 3 months, then every 6 months \\n• From 2 to 4 years, review annually \\n• From 5 to 10 years, review every 1 to 2 years \\n• For more than 10 years and for the rest of life consider \\nongoing imaging every 1 to 2 years. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 19 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 19, 'page_label': '20', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Grade of tumour Clinical review schedule \\n• Grade 2 IDH \\nwildtype \\n• Grade 3 1p/19q \\nnon-codeleted \\n• Grade 4 \\n(glioblastoma) \\n• From 0 to 2 years, review every 3 to 6 months \\n• From 2 to 4 years, review every 6 to 12 months \\n• From 5 to 10 years, review annually \\n• For more than 10 years and for the rest of life - consider \\nongoing imaging every 1 to 2 years. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on follow up for \\nglioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\n1.4 Investigation and management of meningioma \\nInvestigation of suspected meningioma \\n1.4.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and \\nT1 pre- and post-contrast volume) as the initial diagnostic test for suspected \\nmeningioma, unless MRI is contraindicated.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 19, 'page_label': '20', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"T1 pre- and post-contrast volume) as the initial diagnostic test for suspected \\nmeningioma, unless MRI is contraindicated. \\n1.4.2 Consider CT imaging for meningioma (if not already performed) to assess bone \\ninvolvement if this is suspected. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on investigation of \\nsuspected meningioma. \\nFull details of the evidence and the committee's discussion are in evidence review B: \\ninvestigation, management and follow-up of meningioma. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 20 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 20, 'page_label': '21', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Management of confirmed meningioma following surgery or if \\nsurgery is not possible (or has been declined) \\n1.4.3 Base management of meningioma after surgery, or if surgery is not possible or \\nthe person declines surgery, on the extent of any surgery and grade of \\nmeningioma, as described in table 4. \\nTable 4 Treatment choices after surgery by extent, or no excision if surgery was not \\npossible, for different kinds of meningioma \\nGrade \\nCompletely \\nexcised (Simpson \\n1 to 3) \\nIncompletely excised (Simpson 4 to 5) \\nNo excision \\n(radiological only \\ndiagnosis) \\nRecurrent \\n1 \\nOffer active \\nmonitoring. \\nConsider further surgery (if \\npossible), radiotherapy or active \\nmonitoring. \\nConsider active \\nmonitoring or \\nradiotherapy. \\nConsider further \\nsurgery or \\nradiotherapy (if \\nnot previously \\nused). \\n2 \\nOffer a \\nchoice \\nbetween \\nactive \\nmonitoring \\nand \\nradiotherapy. \\nConsider further surgery (if \\npossible). Offer radiotherapy if \\nsurgery is not possible, including'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 20, 'page_label': '21', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='not previously \\nused). \\n2 \\nOffer a \\nchoice \\nbetween \\nactive \\nmonitoring \\nand \\nradiotherapy. \\nConsider further surgery (if \\npossible). Offer radiotherapy if \\nsurgery is not possible, including \\nif the person declines surgery, or \\nif the tumour is incompletely \\nexcised afterwards. \\nConsider active \\nmonitoring or \\nradiotherapy \\nConsider further \\nsurgery and \\noffer \\nradiotherapy (if \\nnot previously \\nused). \\n3 Offer \\nradiotherapy. \\nConsider further surgery (if \\npossible) and offer radiotherapy. \\nConsider active \\nmonitoring or \\nradiotherapy \\nConsider further \\nsurgery and \\noffer \\nradiotherapy (if \\nnot previously \\nused). \\n1.4.4 Before a decision is made on radiotherapy for meningioma, take into account: \\n• comorbidities \\n• life expectancy \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 21 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 21, 'page_label': '22', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"• neurological function \\n• oedema \\n• performance status \\n• rate of tumour progression \\n• size and location of tumour \\n• surgical and radiotherapy morbidity \\n• the person's preferences (see table 5 for factors to discuss with them) \\n• treatments used before. \\nTable 5 Factors to take into account when deciding on radiotherapy as treatment for a \\nsurgically treated meningioma \\nRadiotherapy No radiotherapy \\nControl of \\ntumour \\nThere is evidence that radiotherapy is \\neffective in the local control of a \\ntumour. \\nReceiving no radiotherapy means \\nthe tumour may continue to grow. \\nRisk of \\ndeveloping \\nsubsequent \\nsymptoms \\nControlling the tumour will reduce the \\nrisk of developing symptoms from the \\ntumour in the future. \\nIf the tumour grows, it can cause \\nirreversible symptoms such as \\nloss of vision. \\nRisk of re-\\ntreatment \\nLess risk of needing second surgery \\ncompared with no radiotherapy. \\nHigher risk of needing second \\nsurgery compared with \\nradiotherapy. \\nIf the tumour has progressed,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 21, 'page_label': '22', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Risk of re-\\ntreatment \\nLess risk of needing second surgery \\ncompared with no radiotherapy. \\nHigher risk of needing second \\nsurgery compared with \\nradiotherapy. \\nIf the tumour has progressed, \\nthen the surgery might be more \\ncomplex. \\nIf the tumour has progressed, \\nthen not all radiotherapy \\ntechniques may be possible. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 22 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 22, 'page_label': '23', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Radiotherapy No radiotherapy \\nEarly side \\neffects of \\ntreatment \\nEarly side effects from radiotherapy \\ncan include: \\n• fatigue \\n• hair loss \\n• headache \\n• nausea \\n• seizures \\n• skin irritation. \\nNo side effects from treatment. \\nLate side effects \\nof treatment \\nLate side effects from radiotherapy \\ncan include: \\n• effect on cognition \\n• risk of stroke \\n• risk of radionecrosis \\n• risk of second tumours \\n• cranial nerve effects \\n• hypopituitarism \\n• cataracts. \\nNo side effects from treatment. \\nManagement of \\nside effects \\nIncreased use of steroids to manage \\nside effects. No side effects from treatment. \\n1.4.5 When deciding on the radiotherapy technique for people with meningioma, take \\ninto account: \\n• the preferences of the person (for example, to minimise the number of \\nappointments or travel distance) \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 22, 'page_label': '23', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='appointments or travel distance) \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 23 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 23, 'page_label': '24', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"• tumour grade \\n• tumour location (proximity to optic nerves, optic chiasm and brainstem) \\n• tumour size. \\nFrom the suitable radiotherapy techniques, choose the one which maximises \\nthe chances of local tumour control while minimising the radiation dose to \\nnormal brain tissue. \\n1.4.6 If the multidisciplinary team thinks that radiotherapy may be appropriate, offer \\nthe person the opportunity to discuss the potential benefits and risks with an \\noncologist. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on management of \\nconfirmed meningioma following surgery, or if surgery is not possible or the person \\ndeclines surgery. \\nFull details of the evidence and the committee's discussion are in evidence review B: \\ninvestigation, management and follow-up of meningioma. \\nGenomic biomarker-based treatment for meningioma\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 23, 'page_label': '24', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Full details of the evidence and the committee's discussion are in evidence review B: \\ninvestigation, management and follow-up of meningioma. \\nGenomic biomarker-based treatment for meningioma \\nThe point at which to use genomic biomarker-based therapy in solid tumour treatment \\npathways is uncertain. See the NICE topic page on genomic biomarker-based cancer \\ntreatments. \\n1.5 Follow-up for meningioma \\n1.5.1 Offer regular clinical review for people with meningioma to assess changes in \\ntheir physical, psychological and cognitive wellbeing. \\n1.5.2 Base decisions on the timing of regular clinical reviews and follow-up imaging for \\npeople with meningioma on: \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 24 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 24, 'page_label': '25', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"• any residual tumour \\n• life expectancy \\n• the person's preferences (see table 6 for factors to discuss with them) \\n• treatments used before \\n• treatment options available \\n• tumour grade. \\nTable 6 Factors to take into account when deciding on frequency of follow-up for \\npeople with meningioma \\nPossible advantages of more frequent follow-up Possible disadvantages of more frequent follow-up \\nMay identify recurrent disease earlier \\nwhich may increase treatment options or \\nenable treatment before people become \\nsymptomatic. \\nThere is no definitive evidence that \\nidentifying recurrent disease early improves \\noutcomes. \\nMay help provide information about the \\ncourse of the illness and prognosis. \\nMay increase anxiety if changes of uncertain \\nsignificance are detected on imaging. \\nSome people can find more frequent \\nimaging and hospital contact reassuring. \\nProvides an opportunity to identify \\npatient or carer needs (such as \\npsychosocial support and late side \\neffects of treatment).\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 24, 'page_label': '25', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='imaging and hospital contact reassuring. \\nProvides an opportunity to identify \\npatient or carer needs (such as \\npsychosocial support and late side \\neffects of treatment). \\nSome people can find more frequent imaging \\nand hospital contact burdensome and \\ndisruptive – they feel their life revolves \\naround their latest scan. \\nThere may be a financial cost from taking \\ntime off work and travelling to appointments. \\n– More imaging and follow-up is resource \\nintensive for the NHS. \\n1.5.3 Consider the follow-up schedule given in table 7 for people with meningioma. \\n1.5.4 Consider standard structural MRI (defined as T2 weighted, FLAIR, DWI series and \\nT1 pre- and post-contrast volume) as part of regular clinical review for people \\nwith meningioma, to assess for progression or recurrence, unless MRI is \\ncontraindicated. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 24, 'page_label': '25', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='contraindicated. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 25 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 25, 'page_label': '26', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='1.5.5 For people with meningioma having routine imaging, be aware that having routine \\nimaging and waiting for the results may cause anxiety. \\n1.5.6 Arrange a clinical review, including appropriate imaging, for people with \\nmeningioma (including incidental meningioma) who develop new or changing \\nneurological symptoms or signs at any time. \\nTable 7 Possible regular clinical review schedule by years after end of treatment for \\npeople with meningioma depending on grade of tumour \\nGrade 1: no \\nresidual \\ntumour \\nGrade 1: \\nresidual \\ntumour \\nGrade 1: after \\nradiotherapy Grade 2 Grade 3 \\n0 to 1 years \\nScan at \\n3 months \\nScan at \\n3 months \\nScan 6 months \\nafter \\nradiotherapy \\nScan at 3 months, \\nthen 6 to 12 months \\nlater \\nEvery 3 to \\n6 months \\n1 to 2 years Annually Annually Annually Annually Every 3 to \\n6 months \\n2 to 3 years Annually Annually Annually Annually Every 6 to \\n12 months \\n3 to 4 years \\nOnce \\nevery \\n2 years \\nAnnually Once every \\n2 years Annually Every 6 to \\n12 months \\n4 to 5 years'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 25, 'page_label': '26', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='6 months \\n2 to 3 years Annually Annually Annually Annually Every 6 to \\n12 months \\n3 to 4 years \\nOnce \\nevery \\n2 years \\nAnnually Once every \\n2 years Annually Every 6 to \\n12 months \\n4 to 5 years \\nOnce \\nevery \\n2 years \\nAnnually Once every \\n2 years Annually Every 6 to \\n12 months \\n5 to 6 years \\nOnce \\nevery \\n2 years \\nOnce \\nevery \\n2 years \\nOnce every \\n2 years Once every 2 years Annually \\n6 to 7 years \\nOnce \\nevery \\n2 years \\nOnce \\nevery \\n2 years \\nOnce every \\n2 years Once every 2 years Annually \\n7 to 8 years \\nOnce \\nevery \\n2 years \\nOnce \\nevery \\n2 years \\nOnce every \\n2 years Once every 2 years Annually \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 26 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 26, 'page_label': '27', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Grade 1: no \\nresidual \\ntumour \\nGrade 1: \\nresidual \\ntumour \\nGrade 1: after \\nradiotherapy Grade 2 Grade 3 \\n8 to 9 years \\nOnce \\nevery \\n2 years \\nOnce \\nevery \\n2 years \\nOnce every \\n2 years Once every 2 years Annually \\n>9 years (for \\nthe rest of life) \\nConsider \\ndischarge \\nConsider \\ndischarge \\nConsider \\ndischarge Consider discharge Annually \\nFor asymptomatic incidental meningioma: scan at 12 months and if no change, consider \\ndischarge or scan at 5 years. \\nNote: the presence of any residual tumour can only be established after the first scan at 3 \\nmonths. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on follow up for \\nmeningioma. \\nFull details of the evidence and the committee's discussion are in evidence review B: \\ninvestigation, management and follow-up of meningioma. \\n1.6 Investigation of suspected brain metastases\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 26, 'page_label': '27', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Full details of the evidence and the committee's discussion are in evidence review B: \\ninvestigation, management and follow-up of meningioma. \\n1.6 Investigation of suspected brain metastases \\n1.6.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and \\nT1 pre- and post-contrast volume) as the initial diagnostic test for suspected \\nbrain metastases, unless MRI is contraindicated. \\n1.6.2 To help establish current disease status, offer extracranial imaging (appropriate \\nto the primary tumour type) to people with any radiologically suspected brain \\nmetastases that may be suitable for focal treatment. \\n1.6.3 Perform all intracranial and extracranial diagnostic imaging and, if appropriate, \\nbiopsy of extracranial disease, before referral to the neuro-oncology \\nmultidisciplinary team. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 26, 'page_label': '27', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='multidisciplinary team. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 27 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 27, 'page_label': '28', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on investigation of \\nsuspected brain metastases. \\nFull details of the evidence and the committee's discussion are in evidence review C: \\ninvestigation, management and follow-up of brain metastases. \\n1.7 Management of confirmed brain metastases \\n1.7.1 When choosing management options for brain metastases, take into account: \\n• extracranial disease \\n• leptomeningeal disease \\n• location of metastases \\n• resection cavity size \\n• the number and volume of metastases \\n• the person's preference (based on a discussion of the factors listed in \\ntables 8 and 9) \\n• their age \\n• their performance status \\n• the primary tumour site, type, and molecular profile. \\n1.7.2 Consider systemic anti-cancer therapy for people who have brain metastases \\nlikely to respond effectively, for example, germ cell tumours or small-cell lung \\ncancer.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 27, 'page_label': '28', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='1.7.2 Consider systemic anti-cancer therapy for people who have brain metastases \\nlikely to respond effectively, for example, germ cell tumours or small-cell lung \\ncancer. \\n1.7.3 Consider maximal local therapy with either surgery, stereotactic radiosurgery or \\nstereotactic radiotherapy for people with a single brain metastasis. \\n1.7.4 Base the choice of treatment for people with a single brain metastasis on: \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 28 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 28, 'page_label': '29', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"• comorbidities \\n• extent of oedema \\n• location of metastasis \\n• the person's preference (see table 8) \\n• tumour size. \\nTable 8 Factors to take into account when deciding between surgery and stereotactic \\nradiosurgery or radiotherapy as treatment for a single brain metastasis \\nSurgery Stereotactic radiosurgery or radiotherapy \\nOverall survival \\nNo clinically important \\ndifference. No clinically important difference. \\nRisk of needing \\nadditional treatment \\nRisk that stereotactic \\nradiosurgery or radiotherapy \\nmay be needed in any case. \\nRisk that surgery may be needed in \\nany case. However, has higher local \\ncontrol rate than surgery (meaning \\nsurgery is less likely after radiotherapy \\nthan the other way around). \\nKey benefit of \\ntreatment \\nHas more rapid control of \\nsymptoms. \\nAdditionally, surgery allows for \\nobtaining an up-to-date \\npathological diagnosis which \\nmay guide future treatment, \\nmaking it more effective. \\nHas a higher local control rate than\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 28, 'page_label': '29', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='symptoms. \\nAdditionally, surgery allows for \\nobtaining an up-to-date \\npathological diagnosis which \\nmay guide future treatment, \\nmaking it more effective. \\nHas a higher local control rate than \\nsurgery, meaning more treatment is \\nless likely to be needed. \\nAdditionally, is an outpatient treatment \\nand does not need a general \\nanaesthetic. \\nKey risks of \\ntreatment \\nSurgical procedures carry \\nknown risks that vary \\ndepending on the person and \\nthe tumour. These include \\ninfection, stroke, a prolonged \\nhospital stay and death. \\nSurgery is more painful than \\nradiotherapy during recovery. \\nRadiation carries the risk of delayed \\neffects such as radionecrosis, which \\nmight need surgical resection. \\nThere is an increased risk of seizures \\nwith this technique, although this \\nappears to mostly affect people who \\nhave pre-existing epilepsy. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 28, 'page_label': '29', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='with this technique, although this \\nappears to mostly affect people who \\nhave pre-existing epilepsy. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 29 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 29, 'page_label': '30', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Surgery Stereotactic radiosurgery or radiotherapy \\nSteroid use Early reduction in steroid \\ndose. \\nLikely to need steroids for longer, and \\nat a higher dose. Steroids have \\nsignificant side effects when used \\nlong-term, such as changes in mood, \\nheart problems and changes in body \\nfat. \\nPlanning \\ntreatment \\naround \\nimportant life \\nevents \\nThe wound from the surgery \\nmay affect the ability to carry \\nout certain activities in the \\nshort term, such as air travel \\nand sport. \\nThe cosmetic appearance of \\nthe wound from surgery may \\nbe important to some people, \\nand should be discussed. \\nSome people find the techniques used \\nin radiotherapy challenging or \\nupsetting, especially the equipment \\nwhich immobilises the head. This is \\nespecially likely to be true for people \\nwith claustrophobia. \\nOther \\nconsiderations – \\nRadiotherapy can reach some areas of \\nthe brain that surgery cannot, and \\nmight be the only appropriate \\ntechnique for certain tumour types.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 29, 'page_label': '30', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"with claustrophobia. \\nOther \\nconsiderations – \\nRadiotherapy can reach some areas of \\nthe brain that surgery cannot, and \\nmight be the only appropriate \\ntechnique for certain tumour types. \\n1.7.5 Do not offer adjuvant whole-brain radiotherapy to people with a single brain \\nmetastasis treated with stereotactic radiosurgery or radiotherapy or surgery. \\n1.7.6 See NHS England's clinical commissioning policy on stereotactic radiosurgery and \\nstereotactic radiotherapy to the surgical cavity following resection of cerebral \\nmetastases. [amended 2021] \\n1.7.7 Consider stereotactic radiosurgery or radiotherapy for people with multiple brain \\nmetastases who have controlled or controllable extracranial disease and \\nKarnofsky performance status of 70 or more. Take into account the number and \\ntotal volume of metastases. \\n1.7.8 Do not offer whole-brain radiotherapy to people with: \\n• non-small-cell lung cancer and \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 29, 'page_label': '30', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='total volume of metastases. \\n1.7.8 Do not offer whole-brain radiotherapy to people with: \\n• non-small-cell lung cancer and \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 30\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 30, 'page_label': '31', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='• brain metastases that are not suitable for surgery or stereotactic \\nradiosurgery or radiotherapy and \\n• a Karnofsky performance status of under 70. \\n1.7.9 For people with multiple brain metastases who have not had stereotactic \\nradiosurgery or radiotherapy or surgery, decide with them whether to use whole-\\nbrain radiotherapy after a discussion with them and their relatives and carers (as \\nappropriate) of the potential benefits and risks (see table 9). \\nTable 9 Potential benefits and harms of whole-brain radiotherapy for multiple \\nmetastases \\n– Whole-brain radiotherapy No whole-brain radiotherapy \\nOverall \\nsurvival No clinically important difference. No clinically important difference. \\nQuality of life Short-term deterioration in quality \\nof life because of treatment. \\nNo impact on quality of life \\nbecause of treatment, but \\ndeterioration because of the \\ndisease progression. \\nPotential \\nbenefits \\nCan stabilise or reduce the brain \\nmetastases. \\nBrain metastases may continue to \\ngrow.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 30, 'page_label': '31', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='because of treatment, but \\ndeterioration because of the \\ndisease progression. \\nPotential \\nbenefits \\nCan stabilise or reduce the brain \\nmetastases. \\nBrain metastases may continue to \\ngrow. \\nSide effects \\nTemporary hair loss and fatigue. \\nPotential for accelerated cognitive \\nloss because of radiotherapy. \\nPotential for cognitive loss \\nbecause of disease progression. \\nTime \\ncommitment Requires 5 to 10 hospital visits. No time commitment. \\nOther \\nconsiderations \\nPeople with non-small-cell lung \\ncancer will not benefit from \\ntreatment if their overall prognosis \\nis poor. \\n– \\n1.7.10 Do not offer memantine in addition to whole-brain radiotherapy to people with \\nmultiple brain metastases, unless as part of a clinical trial. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 31 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 31, 'page_label': '32', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"1.7.11 Do not offer concurrent systemic therapy to enhance the efficacy of whole-brain \\nradiotherapy to people with multiple brain metastases, unless as part of a clinical \\ntrial. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on management of \\nconfirmed brain metastases. \\nFull details of the evidence and the committee's discussion are in evidence review C: \\ninvestigation, management and follow-up of brain metastases. \\n1.8 Follow-up for brain metastases \\n1.8.1 Offer regular clinical review for people with brain metastases to assess changes \\nin their physical, psychological and cognitive wellbeing. \\n1.8.2 Base decisions on the timing of regular clinical reviews and follow-up imaging for \\npeople with brain metastases on: \\n• extracranial disease status \\n• life expectancy \\n• primary cancer \\n• the person's preferences (see table 10 for factors to discuss with them)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 31, 'page_label': '32', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"people with brain metastases on: \\n• extracranial disease status \\n• life expectancy \\n• primary cancer \\n• the person's preferences (see table 10 for factors to discuss with them) \\n• treatment options available. \\nTable 10 Factors to take into account when deciding on frequency of follow-up for \\npeople with brain metastases \\nPossible advantages of more frequent follow-up Possible disadvantages of more frequent follow-up \\nMay identify recurrent disease earlier \\nwhich may increase treatment options or \\nenable treatment before people become \\nsymptomatic. \\nThere is no definitive evidence that \\nidentifying recurrent disease early improves \\noutcomes. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 32 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 32, 'page_label': '33', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Possible advantages of more frequent follow-up Possible disadvantages of more frequent follow-up \\nMay help provide information about the \\ncourse of the illness and prognosis. \\nMay increase anxiety if changes of uncertain \\nsignificance are detected on imaging. \\nSome people can find more frequent \\nimaging and hospital contact reassuring. \\nProvides an opportunity to identify \\npatient or carer needs (such as \\npsychosocial support and late side \\neffects of treatment). \\nSome people can find more frequent imaging \\nand hospital contact burdensome and \\ndisruptive – they feel their life revolves \\naround their latest scan. \\nThere may be a financial cost from taking \\ntime off work and travelling to appointments. \\n– More imaging and follow-up is resource \\nintensive for the NHS. \\n1.8.3 Consider the follow-up schedule given in table 11 for people with brain \\nmetastases. \\n1.8.4 Consider standard structural MRI (defined as T2 weighted, FLAIR, DWI series and'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 32, 'page_label': '33', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='1.8.3 Consider the follow-up schedule given in table 11 for people with brain \\nmetastases. \\n1.8.4 Consider standard structural MRI (defined as T2 weighted, FLAIR, DWI series and \\nT1 pre- and post-contrast volume) as part of regular clinical review for people \\nwith brain metastases, to assess for progression or recurrence, unless MRI is \\ncontraindicated. \\n1.8.5 Consider advanced MRI techniques, such as MR perfusion, diffusion tensor \\nimaging and MR spectroscopy, if findings from standard imaging are unclear \\nabout whether there is recurrence and early identification is potentially clinically \\nuseful. \\n1.8.6 For people with brain metastases having routine imaging: \\n• explain to them, and their relatives and carers, that imaging can be difficult to \\ninterpret and results can be of uncertain significance and \\n• be aware that having routine imaging and waiting for the results may cause \\nanxiety. \\n1.8.7 Arrange a clinical review, including appropriate imaging, for people with brain'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 32, 'page_label': '33', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='• be aware that having routine imaging and waiting for the results may cause \\nanxiety. \\n1.8.7 Arrange a clinical review, including appropriate imaging, for people with brain \\nmetastases who develop new or changing neurological symptoms or signs at any \\ntime. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 33\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 33, 'page_label': '34', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Table 11 Possible regular clinical review \\nschedule for people with brain metastases \\nYears after end of treatment Clinical review schedule \\n0 to 1 years Every 3 months \\n1 to 2 years Every 4 to 6 months \\n2 years and onwards Annually \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on follow up for brain \\nmetastases. \\nFull details of the evidence and the committee's discussion are in evidence review C: \\ninvestigation, management and follow-up of brain metastases. \\n1.9 Care needs of people with brain tumours \\n1.9.1 Be aware that the care needs of people with brain tumours represent a unique \\nchallenge, because (in addition to physical disability) the tumour and treatment \\ncan have effects on: \\n• behaviour \\n• cognition \\n• personality. \\n1.9.2 Discuss health and social care support needs with the person with a brain tumour\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 33, 'page_label': '34', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='can have effects on: \\n• behaviour \\n• cognition \\n• personality. \\n1.9.2 Discuss health and social care support needs with the person with a brain tumour \\nand their relatives and carers (as appropriate). Take into account the complex \\nhealth and social care support needs people with any type of brain tumour and \\ntheir relatives and carers may have (for example, psychological, cognitive, \\nphysical, spiritual, emotional). \\n1.9.3 Set aside enough time to discuss the impact of the brain tumour on the person \\nand their relatives and carers (as appropriate), and to elicit and discuss their \\nhealth and social care support needs. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 34\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 34, 'page_label': '35', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='1.9.4 Health and social care professionals involved in the care of people with brain \\ntumours should address additional complex needs during or at the end of \\ntreatment and throughout follow-up. These include: \\n• changes to cognitive functioning \\n• fatigue \\n• loss of personal identity \\n• loss of independence \\n• maintaining a sense of hope \\n• potential for change in personal and sexual relationships \\n• the challenges of living with uncertainty \\n• the impact of brain tumour-associated epilepsy on wellbeing (see the NICE \\nguideline on epilepsies in children, young people and adults). \\n1.9.5 Provide a named healthcare professional with responsibility for coordinating \\nhealth and social care support for people with brain tumours and their relatives \\nand carers, for example, a key worker (often a clinical nurse specialist) as defined \\nin NICE cancer service guidance on improving outcomes for people with brain \\nand other central nervous system tumours.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 34, 'page_label': '35', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"in NICE cancer service guidance on improving outcomes for people with brain \\nand other central nervous system tumours. \\n1.9.6 Give information to the person with a brain tumour and their relatives and carers \\n(as appropriate): \\n• in a realistic and empathetic manner \\n• in suitable formats (written and spoken, with information available to take \\naway), following the principles in the NICE guideline on patient experience in \\nadult NHS services (also see NHS England's guidance on the Accessible \\nInformation Standard). \\n• at appropriate times throughout their care pathway. \\n1.9.7 Explain to the person that they have a legal obligation to notify the Driver and \\nVehicle Licensing Agency (DVLA) if they have a brain tumour, and that this may \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 35 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 35, 'page_label': '36', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"have implications for their driving. \\n1.9.8 Provide and explain clinical results, for example, imaging and pathology reports, \\nto the person with a brain tumour and their relatives and carers (as appropriate) \\nas soon as possible. \\n1.9.9 Offer supportive care to people with brain tumours and their relatives and carers \\n(as appropriate) throughout their treatment and care pathway \\n1.9.10 In people aged between 16 and 24 years old, refer to the NICE quality standard \\non cancer services for children and young people. \\n1.9.11 Discuss the potential preservation of fertility with people with brain tumours \\nwhere treatment may have an impact on their fertility (see the recommendations \\non people with cancer who wish to preserve fertility in NICE's guideline on fertility \\nproblems). \\n1.9.12 If the person with a brain tumour is likely to be in their last year of life, refer to the \\nNICE quality standards on end of life care for adults and, when appropriate, care\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 35, 'page_label': '36', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"problems). \\n1.9.12 If the person with a brain tumour is likely to be in their last year of life, refer to the \\nNICE quality standards on end of life care for adults and, when appropriate, care \\nof dying adults in the last days of life. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on care needs of \\npeople with brain tumours. \\nFull details of the evidence and the committee's discussion are in evidence review D: \\nsupporting people living with a brain tumour. \\n1.10 Neurorehabilitation needs of people with brain \\ntumours \\n1.10.1 Consider referring the person with a brain tumour for a neurological rehabilitation \\nassessment of physical, cognitive and emotional function at diagnosis and every \\nstage of follow-up. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 35, 'page_label': '36', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='stage of follow-up. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 36\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 36, 'page_label': '37', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"1.10.2 Offer people with brain tumours and their relatives and carers (as appropriate) \\ninformation on accessing neurological rehabilitation, and on what needs it can \\nhelp address. \\n1.10.3 Give people with brain tumours and their relatives and carers (as appropriate) \\ninformation on: \\n• neurological rehabilitation options in the community, as an outpatient, or an \\ninpatient and \\n• how to get a neurological rehabilitation assessment. \\nFor a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on neurorehabilitation \\nneeds of people with brain tumours. \\nFull details of the evidence and the committee's discussion are in evidence review D: \\nsupporting people living with a brain tumour. \\n1.11 Surveillance for the late-onset side effects of \\ntreatment \\n1.11.1 Be aware that people with brain tumours can develop side effects of treatment \\nmonths or years after treatment, which can include: \\n• cataracts\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 36, 'page_label': '37', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='treatment \\n1.11.1 Be aware that people with brain tumours can develop side effects of treatment \\nmonths or years after treatment, which can include: \\n• cataracts \\n• cavernoma \\n• cognitive decline \\n• epilepsy \\n• hearing loss \\n• hypopituitarism \\n• infertility \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 37 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 37, 'page_label': '38', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"• neuropathy (for example, nerve damage causing visual loss, numbness, pain \\nor weakness) \\n• radionecrosis \\n• secondary tumours \\n• SMART (stroke-like migraine attacks after radiotherapy) \\n• stroke. \\n1.11.2 Assess the person's individual risk of developing late effects when they finish \\ntreatment. Record these in their written treatment summary and explain them to \\nthe person (and their relatives and carers, as appropriate). \\n1.11.3 Encourage people who have had cranial radiotherapy to follow a healthy lifestyle, \\nincluding exercise, a healthy diet and stopping smoking (if applicable), to \\ndecrease their risk of stroke. See the NICE guidelines on overweight and obesity \\nmanagement, physical activity, and tobacco: preventing uptake, promoting \\nquitting and treating dependence. \\n1.11.4 For people who are at risk of stroke, consider checking their blood pressure, \\nHbA1c level and cholesterol profile regularly.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 37, 'page_label': '38', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='quitting and treating dependence. \\n1.11.4 For people who are at risk of stroke, consider checking their blood pressure, \\nHbA1c level and cholesterol profile regularly. \\n1.11.5 Consider ongoing neuropsychology assessment for people at risk of cognitive \\ndecline. \\n1.11.6 If a person has had a radiotherapy dose that might affect pituitary function, \\nconsider checking their endocrine function regularly after the end of treatment. \\n1.11.7 Consider referring people who are at risk of visual impairment for an \\nophthalmological assessment. \\n1.11.8 Consider referring people who are at risk of hearing loss to audiology for a \\nhearing test. \\n1.11.9 Consider referring the person to stroke services if an MRI during active \\nmonitoring identifies asymptomatic ischaemic stroke. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 38\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 38, 'page_label': '39', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made these recommendations and how \\nthey might affect practice see the rationale and impact section on surveillance for the \\nlate-onset side effects of treatment. \\nFull details of the evidence and the committee's discussion are in evidence review D: \\nsupporting people living with a brain tumour. \\nTerms used in this guideline \\nActive monitoring \\nThis is regular clinical and radiological review of a person with a brain tumour or brain \\nmetastases who are not currently having treatment for their cancer. \\nRegular clinical review \\nThis is outpatient review of the person with a brain tumour or brain metastases at a \\nplanned interval from the previous visit in order to assess symptoms and care needs, to \\nprovide support and treatment and to perform imaging when appropriate. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 38, 'page_label': '39', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Brain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 39\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 39, 'page_label': '40', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Recommendations for research \\nThe guideline committee has made the following recommendations for research. \\nKey recommendations for research \\n1 Managing glioma: management of IDH wildtype grade 2 glioma \\nDoes the addition of concurrent and adjuvant temozolomide to radiotherapy improve \\noverall survival in patients with IDH wildtype grade 2 glioma? \\nWhy this is important \\nThe World Health Organization (WHO) 2016 reclassification of brain tumours recognised \\nthat the molecular characteristics of glioma are extremely important in helping \\ndifferentiate between disease entities with very different outcomes. Although evidence \\nexists to guide management recommendations for certain molecular gliomas, such as \\ncodeleted and non-codeleted grade 3 glioma, currently no studies have investigated the \\nbest approach for the management of grade 2 glioma with IDH wildtype. The biological \\nbehaviour of these tumours is more like a high-grade glioma with a much shorter'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 39, 'page_label': '40', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='best approach for the management of grade 2 glioma with IDH wildtype. The biological \\nbehaviour of these tumours is more like a high-grade glioma with a much shorter \\nprognosis than IDH-mutated grade 2 glioma. \\nBecause of this, some clinicians have advocated treating such tumours with concurrent \\nchemoradiation recommended for grade 4 glioma (glioblastoma multiforme, GBM). \\nHowever, there is currently no research evidence to support this approach and this \\nregimen is more intensive and people experience increased acute and late side effects \\ncompared to radiotherapy alone. \\nResearch is needed to establish whether or not this approach is beneficial in terms of \\nimproved survival, and at what cost in terms of toxicity and, potentially, reduced quality of \\nlife. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 40\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 40, 'page_label': '41', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made the recommendation for research, \\nsee the rationale and impact section on managing glioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\n2 Managing glioma: supportive care clinics for low-grade glioma \\nDoes a dedicated supportive care clinic in addition to standard care improve outcomes for \\npeople with low-grade gliomas? \\nWhy this is important \\nPeople with low-grade gliomas have significant symptoms and complex healthcare needs \\nacross multiple physical, cognitive, emotional and social domains. This is often from the \\ninitial diagnosis onwards. There are indications from research literature and patient reports \\nthat these needs are currently unmet. Helping people with low-grade gliomas maintain \\ntheir quality of life and function is important, especially as there is currently no cure,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 40, 'page_label': '41', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='that these needs are currently unmet. Helping people with low-grade gliomas maintain \\ntheir quality of life and function is important, especially as there is currently no cure, \\nbecause earlier supportive care interventions and care plans may help reduce unplanned \\nor emergency contact with secondary and tertiary providers. \\nAs no research literature exists which establishes the effectiveness of a specific \\nhealthcare intervention, uncertainty exists about the most appropriate intervention to \\naddress unmet needs and improve patient-reported outcome measures (or to establish \\nwhether current healthcare provision can meet these needs). Current uncertainty is likely \\nto have led to variations in service provision across the UK. It is also possible that no \\nspecific intervention is available in some areas. \\nResearch is needed to identify whether, in addition to standard care, a specific supportive \\ncare intervention can significantly improve patient-reported outcome measures, and if so'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 40, 'page_label': '41', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Research is needed to identify whether, in addition to standard care, a specific supportive \\ncare intervention can significantly improve patient-reported outcome measures, and if so \\nto establish what this intervention should consist of. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 41 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 41, 'page_label': '42', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made the recommendation for research, \\nsee the rationale and impact section on supportive care clinics for low-grade glioma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\n3 Managing glioma: early referral to palliative care for \\nglioblastoma \\nDoes early referral to palliative care improve outcomes for people with glioblastomas in \\ncomparison with standard oncology care? \\nWhy this is important \\nPeople with grade 4 brain tumours (glioblastomas) have a poor prognosis which has not \\nimproved in over a decade. Median overall survival is 14 to 18 months even with gold-\\nstandard chemoradiation following surgery. \\nFrom initial diagnosis people experience multiple complex symptoms resulting from \\nneurological impairment. These can significantly impact on their quality of life, function and\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 41, 'page_label': '42', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"From initial diagnosis people experience multiple complex symptoms resulting from \\nneurological impairment. These can significantly impact on their quality of life, function and \\npsychological wellbeing. Their caregivers report high levels of distress and carer burden. \\nThe aim of palliative care is to relieve symptoms and improve people's quality of life and \\nfunction – not just towards the end of life but throughout the duration of illness. There is \\nsome evidence that early palliative care referral significantly improves overall survival, \\nquality of life and mood. \\nResearch in this area is important because this group of people have substantial health \\nneeds, which use significant healthcare resources. Supportive care interventions such as \\nearly palliative care may improve quality of life and function throughout the duration of \\nillness. It may also help people to manage the distress associated with a reduced life \\nexpectancy and participate in advanced care planning.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 41, 'page_label': '42', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='illness. It may also help people to manage the distress associated with a reduced life \\nexpectancy and participate in advanced care planning. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 42 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 42, 'page_label': '43', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"For a short explanation of why the committee made the recommendation for research, \\nsee the rationale and impact section on early referral to palliative care for \\nglioblastoma. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\n4 Managing glioma: early detection of recurrence after treatment \\nDoes early detection of recurrence after treatment improve overall survival and outcomes \\nin molecularly stratified glioma? \\nWhy this is important \\nPrognosis for brain tumours is inherently uncertain, and recent advances in treatment \\nmean many people with a brain tumour will live for a long time after the initial diagnosis. \\nFor these individuals, follow-up is the longest component of their treatment and it is both \\nexpensive for the NHS and (sometimes) a burden for the person. There is no high-quality \\nevidence that follow-up after treatment is beneficial, no high-quality evidence on the\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 42, 'page_label': '43', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"expensive for the NHS and (sometimes) a burden for the person. There is no high-quality \\nevidence that follow-up after treatment is beneficial, no high-quality evidence on the \\noptimal frequency of imaging, and clinical uncertainty about whether such follow-up is \\nlikely to alter outcomes of importance to people with tumours (such as overall life \\nexpectancy or quality of life). \\nResearch is needed to establish at what point the value of identifying recurrence early is \\noutweighed by the harms of increasing burden to patients. \\nFor a short explanation of why the committee made the recommendation for research, \\nsee the rationale and impact section on the early detection of recurrence after \\ntreatment. \\nFull details of the evidence and the committee's discussion are in evidence review A: \\ninvestigation, management and follow-up of glioma. \\n5 Managing meningioma: immediate versus deferred \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 42, 'page_label': '43', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='investigation, management and follow-up of glioma. \\n5 Managing meningioma: immediate versus deferred \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 43\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 43, 'page_label': '44', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='radiotherapy for incompletely excised grade 1 meningioma \\nIs immediate or deferred radiotherapy better for incompletely excised grade 1 \\nmeningioma? \\nWhy this is important \\nThere are no randomised studies on the use of radiotherapy or radiosurgery in the \\ntreatment of grade 1 meningioma. Though case series have shown that people with \\ninoperable and incompletely excised grade 1 meningioma treated with radiotherapy have \\nhigh rates of control of their tumour, treatment risks significant side effects. The side \\neffects include: neuropathy, radionecrosis, significant oedema, neuro-cognitive effects, \\nincreased risk of stroke and secondary tumours. Therefore, the timing of treatment is a \\nbalance between control of tumour and side effects. It is not known if early treatment has \\na greater or lesser chance of long-term tumour control or risk of tumour complications, or \\nif this just risks complications of treatment earlier.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 43, 'page_label': '44', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"a greater or lesser chance of long-term tumour control or risk of tumour complications, or \\nif this just risks complications of treatment earlier. \\nPeople with grade 1 meningioma have traditionally been overlooked as a priority area for \\nresearch. This is likely because of the slow nature of the disease resulting in need for long-\\nterm follow-up and the difficulty to obtain funding for radiotherapy-only studies. However, \\nthis lack of research is inequitable, hence the reason for its prioritisation by the committee. \\nA study on this topic would provide clear information to guide clinicians and people with \\nmeningiomas, hopefully leading to overall improvement in quality of life. Because of the \\nslow-growing characteristics of grade 1 meningioma, treatment decisions made early in \\nthe management pathway will have long-term effects on the person with the \\nmeningioma's overall quality of life outcomes, and potentially overall survival.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 43, 'page_label': '44', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"the management pathway will have long-term effects on the person with the \\nmeningioma's overall quality of life outcomes, and potentially overall survival. \\nFor a short explanation of why the committee made the recommendation for research, \\nsee the rationale and impact section on managing meningioma. \\nFull details of the evidence and the committee's discussion are in evidence review B: \\ninvestigation, management and follow-up of meningioma. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 44\\nof 67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 44, 'page_label': '45', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Rationale and impact \\nThese sections briefly explain why the committee made the recommendations and how \\nthey might affect practice. They link to details of the evidence and a full description of the \\ncommittee's discussion. \\nInvestigations for suspected glioma: imaging \\nRecommendations 1.1.1 to 1.1.3 \\nWhy the committee made the recommendations \\nThe evidence indicated that standard structural MRI is useful in distinguishing high-grade \\nfrom low-grade glioma. The committee noted that this knowledge will inform management. \\nBased on their experience, the committee recommended a protocol that they defined as a \\nminimum standard for imaging acquisition. \\nNo evidence was found on more advanced MRI techniques. However, the committee \\nagreed that in their experience such techniques can be useful for assessing malignant \\nfeatures of a tumour – in particular, for ensuring that high-grade tumours are not \\nmisdiagnosed as low-grade tumours, which could have serious consequences for people\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 44, 'page_label': '45', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"features of a tumour – in particular, for ensuring that high-grade tumours are not \\nmisdiagnosed as low-grade tumours, which could have serious consequences for people \\nwho receive suboptimal management as a result. However, the committee explained that a \\nspecialist multidisciplinary team would be needed to interpret features of the scan and \\ndecide management, even if advanced techniques were used. \\nHow the recommendations might affect practice \\nCurrently, various imaging strategies are used in different centres and depending on the \\nperson's circumstances. These recommendations aim to reduce variation in practice, and \\nensure that images obtained at different sites and using different equipment can be more \\naccurately compared. Some centres may need to change their imaging protocols. This \\nmight increase or reduce costs depending on the imaging protocols which are currently in \\nplace. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 44, 'page_label': '45', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='might increase or reduce costs depending on the imaging protocols which are currently in \\nplace. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 45 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 45, 'page_label': '46', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Investigations for suspected glioma: molecular \\nmarkers \\nRecommendations 1.1.4 to 1.1.6 \\nWhy the committee made the recommendations \\nMolecular markers are an emerging and important area in the treatment of brain tumours. \\nThe committee looked for evidence on these markers but did not find any. However, they \\nnoted that there are some molecular markers for which the evidence of benefit if tested is \\noverwhelming, as reported in studies identified in searches for other review questions. \\nThis applies in particular for MGMT promoter methylation and TERT promoter mutations in \\nIDH-wildtype glioma, although the committee agreed the evidence was of a higher quality \\nin the first case than the second. The committee agreed that even these markers are not \\nbeing consistently tested for and that testing should be standardised. Therefore, they \\nmade recommendations based on their knowledge and experience, highlighting the World'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 45, 'page_label': '46', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='being consistently tested for and that testing should be standardised. Therefore, they \\nmade recommendations based on their knowledge and experience, highlighting the World \\nHealth Organization (WHO) classification, to ensure that all centres follow a consistent \\nprocess for assessing and interpreting information on molecular markers. This was \\nimportant, since failure to consistently report molecular markers can mislead clinicians or \\nlimit treatment options. \\nHow the recommendations might affect practice \\nAs testing for molecular markers is relatively new, practice can vary widely and this is to be \\nexpected. In principle there should not be a major change, although the time taken to \\nimplement the new molecular tests will vary significantly between centres. \\nReturn to recommendations \\nManagement of glioma: initial surgery for low-\\ngrade glioma \\nRecommendations 1.2.1 to 1.2.5 \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 45, 'page_label': '46', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Return to recommendations \\nManagement of glioma: initial surgery for low-\\ngrade glioma \\nRecommendations 1.2.1 to 1.2.5 \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 46\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 46, 'page_label': '47', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Why the committee made the recommendations \\nThere was evidence that optimal resection of a large percentage of the tumour improved \\nsurvival for people with low-grade glioma. The committee noted that it is sometimes not \\nappropriate to offer maximal safe resection (for example, if the balance of risks and \\nbenefits favours not resecting all areas) and that a specialist surgical team should look at \\nthe value of doing an operation given its safe extent. They agreed that biopsy should be \\nconsidered in these cases, based on limited evidence showing improved overall survival \\nafter biopsy compared with active monitoring. However, the committee also concluded \\nthat some tumours were of such limited risk that the risks of surgery outweighed the \\npossible gain of biopsy or resection. \\nThe committee described how there was no evidence for immediate intervention, but that \\nintervention should not be delayed due to the probability that surgical resection would'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 46, 'page_label': '47', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='The committee described how there was no evidence for immediate intervention, but that \\nintervention should not be delayed due to the probability that surgical resection would \\nhave benefit for the person with the tumour. They therefore recommended intervention \\nwithin 6 months, to allow for time to discuss treatment options with the person with the \\ntumour. This also allows for the possibility of a second imaging sequence to be done later \\nto look for progression and to assess for symptom change, as the committee also \\nrecognised that a proportion of low-grade gliomas have unfavourable gene profiles (for \\nexample, IDH wildtype) that make them more like high-grade tumours from a prognostic \\nperspective. \\nA small number of people might have had initial treatment before it was standard practice \\nto save a tissue sample for biopsy, and these people would currently be actively \\nmonitored. Based on their experience the committee agreed that these people may not'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 46, 'page_label': '47', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='to save a tissue sample for biopsy, and these people would currently be actively \\nmonitored. Based on their experience the committee agreed that these people may not \\nneed further surgery as long as their condition is stable (that is, they are not showing \\nradiological or clinical disease progression). \\nHow the recommendations might affect practice \\nThe recommendations are likely to change practice at some centres, and remove \\nunnecessary variation. There are currently differences between centres in which molecular \\ndiagnoses are performed and in treatment of very low-risk, low-grade tumours. This is \\npartly because low-grade gliomas may be managed by non-expert surgical teams. \\nThe recommendation about the management of low-grade gliomas that have been \\nmanaged but then progress is unlikely to substantially change practice, as management \\nwould be largely unchanged. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 46, 'page_label': '47', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='managed but then progress is unlikely to substantially change practice, as management \\nwould be largely unchanged. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 47 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 47, 'page_label': '48', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Return to recommendations \\nManagement of glioma: further management of \\nlow-grade glioma \\nRecommendations 1.2.6 to 1.2.11 \\nWhy the committee made the recommendations \\nThere was evidence that PCV chemotherapy (procarbazine, CCNU [lomustine] and \\nvincristine) after radiotherapy improved overall survival and progression-free survival \\ncompared with radiotherapy alone. The committee discussed how the evidence for the \\nexact regime was complex, and used their judgement to recommend possible sequence \\nand dose. In addition, the committee noted that there are some circumstances where \\nradiotherapy and PCV might not be appropriate (particularly for the very lowest-concern \\nand highest-concern low-grade tumours) and made recommendations based on their \\nexperience in these cases. \\nThe committee included approximate age cut-offs based on evidence showing that \\ntreatment improved survival in people aged around 40 or over with or without residual'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 47, 'page_label': '48', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='experience in these cases. \\nThe committee included approximate age cut-offs based on evidence showing that \\ntreatment improved survival in people aged around 40 or over with or without residual \\ntumour, and their clinical judgement that treatment would be unlikely to be of benefit for \\npeople aged around 40 or under without residual tumour. \\nThe committee found no evidence on the treatment of IDH wildtype grade 2 glioma. They \\ndetermined that management of this type of glioma was likely to be different from other \\nlow-grade glioma, as IDH wildtype grade 2 glioma behaves more like a high-grade glioma. \\nThe committee therefore made a recommendation for research on whether treating this \\ntumour type more like a grade 2 glioma or grade 4 glioma was most beneficial. \\nHow the recommendations might affect practice \\nThese recommendations aim to standardise practice. They will probably result in the same \\namounts of chemotherapy and radiotherapy being given, but these treatments will be'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 47, 'page_label': '48', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='These recommendations aim to standardise practice. They will probably result in the same \\namounts of chemotherapy and radiotherapy being given, but these treatments will be \\nmore precisely targeted and it is possible that they will be given earlier. This would result \\nin more people requiring long-term treatment for the side effects of radiation and \\nchemotherapy. More people are likely to have active monitoring alone, which is not likely to \\ncreate a resource impact. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 48\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 48, 'page_label': '49', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Return to recommendations \\nManagement of glioma: grade 3 glioma following \\nsurgery \\nRecommendations 1.2.12 to 1.2.17 \\nWhy the committee made the recommendations \\nThe committee considered evidence for grade 3 and grade 4 glioma separately. \\nTreatments to be offered \\nBased on randomised controlled trial evidence, the committee recommended radiotherapy \\nand either PCV or temozolomide chemotherapy, depending on tumour subtype and \\nperformance status, for people with grade 3 glioma. \\nTreatments that should not be offered \\nBased on the available evidence, the committee recommended that some treatments \\nshould not be offered because they were harmful. They also agreed, based on their \\nexperience, that it would be useful for healthcare professionals to tell people with glioma \\nthat no evidence had been found to indicate that certain treatments are beneficial. \\nHow the recommendations might affect practice \\nAdjuvant PCV for treating codeleted grade 3 glioma is standard practice, but adjuvant'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 48, 'page_label': '49', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='How the recommendations might affect practice \\nAdjuvant PCV for treating codeleted grade 3 glioma is standard practice, but adjuvant \\ntemozolomide for non-codeleted grade 3 gliomas is a change in practice. However, some \\ncentres may already have started to adopt this as standard care, since the results of the \\nstudy supporting this treatment were made publicly available in 2016. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 49\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 49, 'page_label': '50', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Management of glioma: grade 4 glioma following \\nsurgery \\nRecommendations 1.2.18 to 1.2.27 \\nWhy the committee made the recommendations \\nThe committee considered evidence for grade 3 and grade 4 glioma separately. \\nTreatments to be used \\nThe committee saw some evidence demonstrating improved overall survival in some \\ngroups of people with grade 4 glioma who had radiotherapy with concurrent and adjuvant \\ntemozolomide (compared with radiotherapy alone). However, based on their clinical \\nexperience they were unsure that these results could be generalised to all people with \\ngrade 4 glioma, so suggested a range of possible treatments that can be considered for \\nother groups, depending on the exact clinical characteristics of the tumour. \\nApproximate age cut-offs for people with grade 4 glioma were specified by the committee \\nbased on evidence that a radiotherapy dose of 40 Gy did not result in lower survival in \\npeople aged around 70 or over compared with a 60 Gy dose. Therefore, a lower'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 49, 'page_label': '50', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='based on evidence that a radiotherapy dose of 40 Gy did not result in lower survival in \\npeople aged around 70 or over compared with a 60 Gy dose. Therefore, a lower \\nradiotherapy dose is likely to cause fewer side effects without compromising clinical \\neffectiveness for this group. \\nThe committee were aware that the prognosis of people with a grade 4 glioma and a low \\nperformance status was poor, and recommended palliative care be considered. However, \\nthe committee did not find any evidence on whether earlier or later palliative care was \\nmost beneficial for people who might need it. They therefore made a recommendation for \\nresearch on this topic, with the aim of finding out the point in the treatment pathway when \\nit would be most beneficial for people with this type of glioma to have palliative care. \\nTreatments that should not be used \\nBased on the available evidence, the committee recommended that certain treatments'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 49, 'page_label': '50', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Treatments that should not be used \\nBased on the available evidence, the committee recommended that certain treatments \\nshould not be offered. This included tumour treating fields (TTF) based on published \\nhealth economic evidence that they are not an efficient use of NHS resources. They also \\nagreed, based on their clinical experience, that it would be useful for healthcare \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 50 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 50, 'page_label': '51', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='professionals to tell people with glioma that no evidence had been found to suggest that \\ncertain treatments are beneficial. \\nHow the recommendations might affect practice \\nFor younger people with a grade 4 glioma and a good performance status, a course of \\nradiotherapy with concurrent and adjuvant temozolomide is standard care. However, for \\npeople aged around 70 and over, particularly those with a glioma with methylated MGMT, \\nthe use of concurrent and adjuvant temozolomide with 15 fractions of radiotherapy is a \\nchange of practice that will probably result in more people being treated. This is a \\nrelatively small group of people, and so the recommendation is unlikely to have a \\nsignificant resource impact. \\nReturn to recommendations \\nManagement of glioma: recurrent high-grade \\nglioma \\nRecommendations 1.2.28 to 1.2.35 \\nWhy the committee made the recommendations \\nTreatments to be offered \\nBased on the available evidence, the committee recommended that treatment options for'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 50, 'page_label': '51', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='glioma \\nRecommendations 1.2.28 to 1.2.35 \\nWhy the committee made the recommendations \\nTreatments to be offered \\nBased on the available evidence, the committee recommended that treatment options for \\npeople with recurrent glioma should include temozolomide, PCV and single-agent CCNU \\n(lomustine). No evidence was found to indicate which of these 3 options is likely to lead to \\nthe best outcomes, and on the basis of their clinical experience the committee concluded \\nthat the choice of treatment should take several factors into account, including the \\nindividual features of the tumour and the preferences of the person. The committee also \\nhighlighted the possibility of considering supportive care alone. \\nTreatments that should not be offered \\nBased on the available evidence, the committee recommended that certain treatments \\nshould not be offered. This included tumour treating fields (TTF) on the basis of evidence'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 50, 'page_label': '51', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Based on the available evidence, the committee recommended that certain treatments \\nshould not be offered. This included tumour treating fields (TTF) on the basis of evidence \\nof some clinical benefit but indirect published health economic evidence, in people with \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 51 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 51, 'page_label': '52', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='newly diagnosed high-grade glioma, that they are not cost effective. They also agreed, \\nbased on their clinical experience, that it would be useful for healthcare professionals to \\ntell people with glioma that no evidence had been found to suggest that certain \\ntreatments are beneficial. \\nHow the recommendations might affect practice \\nThese recommendations reflect standard treatment for recurrent high-grade glioma, and \\ntherefore should not represent a substantial change in practice. \\nReturn to recommendations \\nManagement of glioma: techniques for resection of \\nglioma \\nRecommendations 1.2.36 to 1.2.42 \\nWhy the committee made the recommendations \\nThere was evidence that 5-aminolevulinic acid (5-ALA), intraoperative MRI and diffusion \\ntensor imaging could improve either the extent or safety of resection (particularly the \\npreservation of neurological function). The committee noted that a combination of \\ntechniques might be needed to optimise both the extent and safety of resection for a'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 51, 'page_label': '52', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"preservation of neurological function). The committee noted that a combination of \\ntechniques might be needed to optimise both the extent and safety of resection for a \\nparticular surgical plan. The committee concluded that the evidence for MRI could be \\ngeneralised to intraoperative ultrasound on the basis of their clinical experience, and \\ntherefore that clinicians should be able to choose either technique depending on \\navailability. \\nThe evidence for awake craniotomy was equivocal (non-significant differences compared \\nwith surgery under general anaesthesia), therefore from the evidence it was not possible \\nto conclude that awake craniotomy would benefit all people with glioma. This is in line with \\nthe committee's clinical experience that some people benefit from the procedure (in terms \\nof preserving language, motor and visual function) but others are harmed – particularly \\nfrom psychological effects which act as a contraindication to awake craniotomy. The\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 51, 'page_label': '52', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='of preserving language, motor and visual function) but others are harmed – particularly \\nfrom psychological effects which act as a contraindication to awake craniotomy. The \\ncommittee described how better preoperative procedures could reduce the number of \\npeople distressed by the procedure. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 52 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 52, 'page_label': '53', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='How the recommendations might affect practice \\nSome techniques recommended by the committee require a very high level of \\nintraoperative skill, and this might have resource implications for hospitals recruiting \\npeople with these specialist skills. There is significant variation in the current provision of \\npsychological support for people before and during awake craniotomy, and implementing \\nthis could carry a high cost to an individual unit. \\nIf a unit does not have access to intraoperative ultrasound or MRI, the cost of acquiring \\nthis equipment could be substantial (MRI is relatively expensive, ultrasound is relatively \\ncheap). However, the committee concluded that most units should have access to one or \\nthe other already. Therefore, the only resource impact would be if a unit currently using \\nintraoperative ultrasound decided that the additional evidence for preservation of \\nneurological function in intraoperative MRI justified the cost of switching machines.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 52, 'page_label': '53', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='intraoperative ultrasound decided that the additional evidence for preservation of \\nneurological function in intraoperative MRI justified the cost of switching machines. \\nHowever, the committee thought this was unlikely to happen. \\nUsing 5-ALA is associated with a high cost, and 5-ALA-guided surgery needs a non-\\nstandard fluorescence-detecting microscope. Therefore, the resource impact of this \\nrecommendation is likely to be high in all settings, and very high in settings without access \\nto a fluorescence-detecting microscope. The anticipated resource impact of this \\nrecommendation is greater than £1 million per year. \\nReturn to recommendations \\nFollow-up for glioma \\nRecommendations 1.3.1 to 1.3.9 \\nWhy the committee made the recommendations \\nIn the absence of evidence, the committee made recommendations based on their clinical \\nexperience. They recommended regular clinical review as the only plausible way of'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 52, 'page_label': '53', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"In the absence of evidence, the committee made recommendations based on their clinical \\nexperience. They recommended regular clinical review as the only plausible way of \\nidentifying and potentially managing recurrence or changing symptoms. They also \\nrecommended the review schedule take into account all of the person's relevant \\ncharacteristics, including grade of tumour. As this is quite difficult to work out, the \\ncommittee suggested a schedule of clinical reviews that is likely to be beneficial for a \\n'typical' person, which can be amended as needed to take into account individual \\nvariation. The committee did not uncover evidence on who should do the follow-up and so \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 53 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 53, 'page_label': '54', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='did not make a recommendation on this topic as it would vary according to clinical need, \\nbut discussed how it could be – for example – the local oncologist, neuro-oncologist, \\nneurologist, neurosurgeon, clinical nurse specialist or GP. \\nAs regular clinical review should include imaging, based on their experience the committee \\nsuggested an MRI sequence which they believed would be suitable to monitor for \\nrecurrence. They discussed how advanced MRI techniques might be valuable, but as these \\ntechniques are time-consuming and difficult to interpret the committee concluded they \\nshould only be recommended under certain circumstances where extra information was \\nlikely to substantially alter treatment plans. The committee recommended that any change \\nin neurological signs or symptoms (which would include changes in behavioural, emotional \\nand psychological signs and symptoms) be treated as a sign of a potential change to the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 53, 'page_label': '54', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='in neurological signs or symptoms (which would include changes in behavioural, emotional \\nand psychological signs and symptoms) be treated as a sign of a potential change to the \\ntumour, and therefore recommended clinical review outside the usual schedule in order to \\ninvestigate this. \\nThe committee believed that a dedicated supportive care clinic could improve outcomes \\nfor people with low-grade glioma, but did not find any evidence on this. Therefore, they \\nmade a recommendation for research on improving the long-term outcomes of people with \\nlow-grade glioma. \\nHow the recommendations might affect practice \\nThe recommendations are in line with current best practice, and should standardise \\npractice. They are unlikely to cause a significant increase in resource use, but there may \\nbe some additional costs or changes in service configuration if practice differs in a \\nparticular centre. \\nThe imaging sequences are recommended on the basis of evidence for the appropriate'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 53, 'page_label': '54', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='be some additional costs or changes in service configuration if practice differs in a \\nparticular centre. \\nThe imaging sequences are recommended on the basis of evidence for the appropriate \\nsequences for initial diagnosis, and so might not be the standard sequence for follow-up in \\nall centres. As a result, adopting the recommended sequences might create some \\nadditional workload for some centres. However the recommendations for exact schedules \\nare examples based on consensus in the committee, and there is therefore flexibility for \\ncentres to adapt these to their own models, limiting resource impact. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 54 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 54, 'page_label': '55', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Investigation of suspected meningioma \\nRecommendations 1.4.1 and 1.4.2 \\nWhy the committee made the recommendations \\nEvidence indicated that standard structural MRI is useful in distinguishing high-grade from \\nlow-grade glioma, and the committee agreed that it is appropriate to extrapolate from this \\nevidence to a belief that MRI can be used to distinguish meningioma from healthy brain \\ntissue. In the committee's experience, CT scans can be more accurate than MRI for \\nassessing meningioma with bone involvement. \\nHow the recommendations might affect practice \\nCurrently, various imaging strategies are used depending on the centre and the person's \\ncircumstances. These recommendations aim to reduce variation in practice, and ensure \\nthat images obtained at different sites and using different equipment can be more \\naccurately compared. Some centres may need to change their imaging protocols as a \\nresult, but this should not require the purchase of additional equipment.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 54, 'page_label': '55', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='accurately compared. Some centres may need to change their imaging protocols as a \\nresult, but this should not require the purchase of additional equipment. \\nReturn to recommendations \\nManagement of confirmed meningioma following \\nsurgery or if surgery is not possible (or has been \\ndeclined) \\nRecommendations 1.4.3 to 1.4.6 \\nWhy the committee made the recommendations \\nBased on limited evidence and their clinical experience, the committee concluded that \\nmanagement of this group of meningiomas will depend on the type of meningioma. They \\nnoted that evidence for 1 grade of meningioma could not normally be used to suggest best \\nmanagement for another grade. Therefore, the committee made recommendations for \\neach grade of meningioma separately, using evidence if this was available and their \\njudgement if it was not. The committee identified that management could be more \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 54, 'page_label': '55', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='judgement if it was not. The committee identified that management could be more \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 55 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 55, 'page_label': '56', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='conservative if the tumour grade was lower and initial resection more complete, and \\nshould be more aggressive if the tumour grade was higher or initial resection more partial. \\nThe committee agreed that the 3 management options – further radiotherapy, surgery and \\nactive monitoring – had different balances of benefits and harms in different situations. \\nHowever, they also agreed that serious harm could be done to a person with a tumour if \\nthey were over- or under-treated given the risk profile of their tumour, and so made \\nrecommendations according to this risk. For example, for a low-grade almost completely \\nresected tumour (grade 1, Simpson 2 excision), radiotherapy or further surgery could \\nexpose the person to risk of harm for no expected clinical gain. \\nBased on limited evidence, the committee made recommendations on how to deliver \\nradiotherapy or radiosurgery where this was appropriate. They used their experience to'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 55, 'page_label': '56', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Based on limited evidence, the committee made recommendations on how to deliver \\nradiotherapy or radiosurgery where this was appropriate. They used their experience to \\nhighlight features of the tumour or preferences of the person that might help select the \\nmost appropriate radiotherapy or radiosurgery modality, and explained that the best \\nresults would come through minimising the dose of radiation delivered to healthy brain \\ntissue while maximising the chance of local control. \\nThe committee were unable to find evidence comparing different timings of radiotherapy \\nin incompletely excised grade 1 meningioma. As the disease is slow growing it can be \\ndifficult to assess the risks of immediate side effects from treatment compared to the \\nlonger-term benefits of tumour control. Therefore, the committee made a recommendation \\nfor research to investigate this topic. \\nHow the recommendations might affect practice'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 55, 'page_label': '56', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='longer-term benefits of tumour control. Therefore, the committee made a recommendation \\nfor research to investigate this topic. \\nHow the recommendations might affect practice \\nThe recommendations reflect standard practice in many centres, and should make \\ntreatment more consistent. \\nAn appointment with an oncologist for all people who may have radiotherapy is not \\ncurrently standard practice. However, for most people this is likely to mean a change in the \\ntiming of their first appointment with an oncologist, rather than many more people having \\noncologist appointments. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 56 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 56, 'page_label': '57', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Follow-up for meningioma \\nRecommendations 1.5.1 to 1.5.6 \\nWhy the committee made the recommendations \\nIn the absence of evidence, the committee made recommendations based on their clinical \\nexperience. They recommended regular clinical review as the only plausible way of \\nidentifying and potentially managing recurrence or changing symptoms. They also \\nrecommended the review schedule take into account all of the person's relevant \\ncharacteristics, including grade of tumour. As this is quite difficult to work out, the \\ncommittee suggested a schedule of clinical reviews that is likely to be beneficial for a \\n'typical' person, which can be amended as needed to take into account individual \\nvariation. The committee did not uncover evidence on who should do the follow-up and so \\ndid not make a recommendation on this topic as it would vary according to clinical need, \\nbut discussed how it could be – for example – the local oncologist, neuro-oncologist,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 56, 'page_label': '57', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='did not make a recommendation on this topic as it would vary according to clinical need, \\nbut discussed how it could be – for example – the local oncologist, neuro-oncologist, \\nneurologist, neurosurgeon, clinical nurse specialist or GP. \\nAs regular clinical review should include imaging, based on their experience the committee \\nsuggested an MRI sequence which they believed would be suitable to monitor for \\nrecurrence. They discussed how advanced MRI techniques might be valuable, but as these \\ntechniques are time-consuming and difficult to interpret the committee concluded they \\nshould only be recommended under certain circumstances where extra information was \\nlikely to substantially alter treatment plans. The committee recommended that any change \\nin neurological signs or symptoms (which would include changes in behavioural, emotional \\nand psychological signs and symptoms) be treated as a sign of a potential change to the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 56, 'page_label': '57', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='in neurological signs or symptoms (which would include changes in behavioural, emotional \\nand psychological signs and symptoms) be treated as a sign of a potential change to the \\ntumour, and therefore recommended clinical review outside the usual schedule in order to \\ninvestigate this. \\nHow the recommendations might affect practice \\nThe recommendations are in line with current best practice, and should standardise \\npractice. They are unlikely to cause a significant increase in resource use, but there may \\nbe some additional costs or changes in service configuration if practice differs in a \\nparticular centre. \\nThe imaging sequences are recommended on the basis of evidence for the appropriate \\nsequences for initial diagnosis, and so might not be the standard sequence for follow-up in \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 57 of'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 56, 'page_label': '57', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 57 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 57, 'page_label': '58', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='all centres. As a result, adopting the recommended sequences might create some \\nadditional workload for some centres. However the recommendations for exact schedules \\nare examples based on consensus in the committee, and there is therefore flexibility for \\ncentres to adapt these to their own models, limiting resource impact. \\nReturn to recommendations \\nInvestigation of suspected brain metastases \\nRecommendations 1.6.1 to 1.6.3 \\nWhy the committee made the recommendations \\nIn the absence of evidence, the committee recommended standard structural MRI based \\non their experience, because it is important to establish the exact number of metastases in \\nthe brain, which can guide further treatment. The committee described how failing to \\nestablish this could be dangerous. Extracranial imaging, biopsy of the extracranial disease \\n(where indicated) and performing all imaging before multidisciplinary team discussions'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 57, 'page_label': '58', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='establish this could be dangerous. Extracranial imaging, biopsy of the extracranial disease \\n(where indicated) and performing all imaging before multidisciplinary team discussions \\nshould ensure that all necessary information is available so that appropriate decisions are \\nmade and delays in treatment avoided. \\nHow the recommendations might affect practice \\nThe recommendations reinforce current best practice and should reduce delays to local \\nintracranial treatment. \\nReturn to recommendations \\nManagement of confirmed brain metastases \\nRecommendations 1.7.1 to 1.7.11 \\nWhy the committee made the recommendations \\nThe committee made recommendations based on the available evidence and their \\njudgement. They described how features of brain metastases, including the number and \\nvolume (which is important for establishing prognosis), should be evaluated before \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 57, 'page_label': '58', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='volume (which is important for establishing prognosis), should be evaluated before \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 58 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 58, 'page_label': '59', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"starting treatment, and decisions about treatment made on the basis of these features and \\nthe person's preferences. \\nThe committee described how systematic anti-cancer therapies were widely used in the \\nmanagement of other types of metastases, and therefore they might be expected to work \\nfor brain tumours. In the absence of evidence, the committee recommended considering \\nsystematic anti-cancer therapies on the basis of their clinical experience. Whether or not \\nthese therapies should be given depends on the type of metastasis: if it is not likely to \\nrespond then the side effects would not justify giving the therapy, whereas if the \\nmetastasis was likely to respond then the therapy was likely to be beneficial. \\nEvidence indicated that surgery, stereotactic radiosurgery and stereotactic radiotherapy \\nare effective for treating a single brain metastasis, but there was no evidence to \\nrecommend 1 technique over the other. There was some evidence that irradiation of the\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 58, 'page_label': '59', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='are effective for treating a single brain metastasis, but there was no evidence to \\nrecommend 1 technique over the other. There was some evidence that irradiation of the \\ncavity site improved local control, so the committee recommended it on the basis that \\nimproving local control should improve quality of life. \\nJanuary 2021: the recommendations on this surgical cavity radiosurgery and radiotherapy \\nhave been updated. For details see the update information. \\nFor people with multiple brain metastases, the committee described how treatment \\noptions are more variable, and that resection, stereotactic radiosurgery, stereotactic \\nradiotherapy and whole-brain radiotherapy could all be considered in certain \\ncircumstances. \\nThe committee recommended that neither memantine nor concurrent systemic therapy \\nshould be offered to enhance the efficacy of whole-brain radiotherapy, on the basis of \\nevidence of no benefit and a potential risk of harm. However, there were biological reasons'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 58, 'page_label': '59', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='should be offered to enhance the efficacy of whole-brain radiotherapy, on the basis of \\nevidence of no benefit and a potential risk of harm. However, there were biological reasons \\nto think these treatments might be beneficial in some settings, so the committee agreed \\nthese therapies could be offered in the context of a clinical trial to investigate this. \\nHow the recommendations might affect practice \\nCurrent practice varies greatly between centres. Some of the variation reflects clinically \\nrelevant factors such as expertise in a particular technique or the patient population. The \\nrecommendations should help to standardise care and prevent some harmful and wasteful \\npractices from continuing. Economic modelling identified that the recommendations will \\nlikely increase costs, but the committee believed that this was still an efficient use of NHS \\nBrain tumours (primary) and brain metastases in over 16s (NG99)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 58, 'page_label': '59', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='likely increase costs, but the committee believed that this was still an efficient use of NHS \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 59 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 59, 'page_label': '60', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"resources, as the improvement to quality of life was significant. \\nReturn to recommendations \\nFollow-up for brain metastases \\nRecommendations 1.8.1 to 1.8.7 \\nWhy the committee made the recommendations \\nIn the absence of evidence, the committee made recommendations based on their clinical \\nexperience. They recommended regular clinical review as the only plausible way of \\nidentifying and potentially managing recurrence or changing symptoms. They also \\nrecommended the review schedule take into account all of the person's relevant \\ncharacteristics, including grade of tumour. As this is quite difficult to work out, the \\ncommittee suggested a schedule of clinical reviews that is likely to be beneficial for a \\n'typical' person, which can be amended as needed to take into account individual \\nvariation. The committee did not uncover evidence on who should do the follow-up and so \\ndid not make a recommendation on this topic as it would vary according to clinical need,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 59, 'page_label': '60', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='variation. The committee did not uncover evidence on who should do the follow-up and so \\ndid not make a recommendation on this topic as it would vary according to clinical need, \\nbut discussed how it could be – for example – the local oncologist, neuro-oncologist, \\nneurologist, neurosurgeon, clinical nurse specialist or GP. \\nAs regular clinical review should include imaging, based on their experience the committee \\nsuggested an MRI sequence which they believed would be suitable to monitor for \\nrecurrence. They discussed how advanced MRI techniques might be valuable, but as these \\ntechniques are time-consuming and difficult to interpret the committee concluded they \\nshould only be recommended under certain circumstances where extra information was \\nlikely to substantially alter treatment plans. The committee recommended that any change \\nin neurological signs or symptoms (which would include changes in behavioural, emotional'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 59, 'page_label': '60', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='likely to substantially alter treatment plans. The committee recommended that any change \\nin neurological signs or symptoms (which would include changes in behavioural, emotional \\nand psychological signs and symptoms) be treated as a sign of a potential change to the \\ntumour, and therefore recommended clinical review outside the usual schedule in order to \\ninvestigate this. \\nHow the recommendations might affect practice \\nThe recommendations are in line with current best practice, and should standardise \\npractice. They are unlikely to cause a significant increase in resource use, but there may \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 60 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 60, 'page_label': '61', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='be some additional costs or changes in service configuration if practice differs in a \\nparticular centre. \\nThe imaging sequences are recommended on the basis of evidence for the appropriate \\nsequences for initial diagnosis, and so might not be the standard sequence for follow-up in \\nall centres. As a result, adopting the recommended sequences might create some \\nadditional workload for some centres. However the recommendations for exact schedules \\nare examples based on consensus in the committee, and there is therefore flexibility for \\ncentres to adapt these to their own models, limiting resource impact. \\nReturn to recommendations \\nCare needs of people with brain tumours \\nRecommendations 1.9.1 to 1.9.12 \\nWhy the committee made the recommendations \\nBased on the evidence and their own experience, the committee determined that people \\nwith brain tumours have very specific needs that are often not met. In particular, they'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 60, 'page_label': '61', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Based on the evidence and their own experience, the committee determined that people \\nwith brain tumours have very specific needs that are often not met. In particular, they \\nhighlighted ways in which the care needs of people with brain tumours differ from those of \\npeople with other types of cancer, such as the impact on the person's sense of identity \\nand legal requirements related to driving. Losing the ability or legal right to drive can have \\na profound effect on the patient's independence, employment status and self-esteem. The \\ncommittee's aim was to improve the support and information offered to people with brain \\ntumours. \\nThe committee described how the care needs of people with brain tumours were often \\nmore complex than could be considered in a single guideline. In particular, young people, \\npeople wishing to preserve their fertility, and people nearing the end of their life have \\nespecially complex needs. In order to address these needs, the committee signposted to\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 60, 'page_label': '61', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='people wishing to preserve their fertility, and people nearing the end of their life have \\nespecially complex needs. In order to address these needs, the committee signposted to \\nexisting NICE guidance in the specific area. \\nHow the recommendations might affect practice \\nThe recommendations should improve care for both people living with brain tumours and \\ntheir relatives and carers. It is likely that there will be a short-term resource impact in some \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 61 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 61, 'page_label': '62', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='areas, as supportive care for people with brain tumours is currently variable, with very little \\nsupport available in some areas. \\nReturn to recommendations \\nNeurorehabilitation needs of people with brain \\ntumours \\nRecommendations 1.10.1 to 1.10.3 \\nWhy the committee made the recommendations \\nNo evidence was found for this topic. Based on their experience, the committee agreed \\nthat neurological rehabilitation is likely to be suitable for many people with brain tumours. \\nGiven that neurological rehabilitation is time-consuming (especially if the person with a \\ntumour lives a long way from the rehabilitation centre) and sometimes not appropriate, the \\ncommittee agreed that assessment should be carried out at every stage of diagnosis and \\nfollow-up to identify which, if any, forms of rehabilitation are suitable for the person. The \\naim of the recommendations is to ensure that neurological rehabilitation is considered at \\nevery stage of treatment and follow-up.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 61, 'page_label': '62', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"aim of the recommendations is to ensure that neurological rehabilitation is considered at \\nevery stage of treatment and follow-up. \\nHow the recommendations might affect practice \\nThere is currently variation in practice in assessing whether people with a brain tumour \\nneed neurological rehabilitation. Some of this reflects the availability of neurological \\nrehabilitation services. The recommendations reinforce current best practice, and will \\nmean a change in practice in some areas, including where assessment is 'ad hoc' rather \\nthan systematic. \\nPeople with a brain tumour make up a small percentage of people referred for neurological \\nrehabilitation, so only a small increase in demand on resources is expected. There should \\nnot be any extra training needs because professionals already have the knowledge and \\nskills to provide the services. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 61, 'page_label': '62', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='skills to provide the services. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 62 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 62, 'page_label': '63', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Surveillance for the late-onset side effects of \\ntreatment \\nRecommendations 1.11.1 to 1.11.9 \\nWhy the committee made the recommendations \\nNo evidence was found for this topic. Some people experience late effects after treatment \\nfor a brain tumour. With the possible exception of stroke risk, it is unknown if these late \\neffects can be prevented, but the committee agreed that any negative impact can be \\nmanaged through clinical vigilance and referral into appropriate specialist monitoring \\npathways. The committee explained that it was important to consider referral for anyone \\nat risk of late effects – not just those at 'high' risk – but that there may be no value in such \\na referral overall in lower risk groups. \\nHow the recommendations might affect practice \\nThe recommendations should not significantly alter practice, as they reflect common \\nclinical practice. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 62, 'page_label': '63', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='The recommendations should not significantly alter practice, as they reflect common \\nclinical practice. \\nReturn to recommendations \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 63\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 63, 'page_label': '64', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='Context \\nIt is estimated there are around 10,000 new cases of primary brain tumours per year. \\nThese tumours come from the brain tissue or its coverings – the meninges. Malignant \\nhigh-grade gliomas (anaplastic gliomas and glioblastomas) and pre-malignant low-grade \\ngliomas come from the brain tissue glial cells, and make up over 60% of primary brain \\ntumours. Meningiomas make up a further 30%. Although often thought benign, \\nmeningiomas can have an acute presentation and are associated with significant long-\\nterm neurological morbidity. Because of this, they can behave in a malignant fashion in \\nterms of recurrence and impact. \\nOver 60% of people with primary brain tumours present at, and are diagnosed by, accident \\nand emergency services rather than from conventional GP or specialist referral. This \\ncauses a significant demand on these services. Although primary malignant brain tumours \\nrepresent only 3% of all cancers, they result in the most life-years lost of any cancer. There'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 63, 'page_label': '64', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='causes a significant demand on these services. Although primary malignant brain tumours \\nrepresent only 3% of all cancers, they result in the most life-years lost of any cancer. There \\nis concern that the true incidence of these tumours is rising. \\nCancers that have spread to the brain from somewhere else in the body are called \\nsecondary brain tumours, or brain metastases. Many different cancer types can spread to \\nthe brain, with lung and breast cancers being the most common. More people with \\nsystemic cancers are surviving longer and are referred to neuroscience multidisciplinary \\nteams for management of their brain metastases. The number of people needing \\nassessment for cranial treatment is now over 10,000 per year in the UK and rising. \\nThe specialist nature of neuro-imaging and the need for complex diagnostic and reductive \\nsurgery emphasises the importance of well-organised service delivery by dedicated units.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 63, 'page_label': '64', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='The specialist nature of neuro-imaging and the need for complex diagnostic and reductive \\nsurgery emphasises the importance of well-organised service delivery by dedicated units. \\nThe singular effects of brain tumours on mental performance (both psychological state \\nand cognitive decline) are a particular challenge to carers and professionals alike, \\nespecially in delivering support to people at home. The peak age of presentation of brain \\ncancer is between 65 and 69, and there are concerns that delivery of all services to these \\nolder people is suboptimal. There are also concerns that the transition from paediatric to \\nadult units could create a care gap. This would most specifically affects patients who are \\nbetween 18 and 30 years old. \\nSurvival with malignant brain tumours has remained poor despite some improvements in \\nsurgery, radiotherapy and chemotherapy, and a greater understanding of molecular'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 63, 'page_label': '64', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='between 18 and 30 years old. \\nSurvival with malignant brain tumours has remained poor despite some improvements in \\nsurgery, radiotherapy and chemotherapy, and a greater understanding of molecular \\nclassification. The management of a low-grade glioma that is likely to transform to high \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 64\\nof 67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 64, 'page_label': '65', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content='grade remains controversial, and presents issues for ongoing care. Follow-up for people \\nwith meningiomas after primary treatment is often long term, and there is variation in both \\nfollow-up and treatments for recurrence. \\nConventional whole-brain irradiation as optimal therapy for brain metastases is being \\nchallenged by concerns about its effectiveness and toxicity, as well as the availability and \\nimmediacy of surgery and stereotactic radiotherapy. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 65 of\\n67'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 65, 'page_label': '66', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Finding more information and committee \\ndetails \\nTo find NICE guidance on related topics, including guidance in development, see the NICE \\nwebpage on brain cancers. \\nFor full details of the evidence and the guideline committee's discussions, see the \\nevidence reviews. You can also find information about how the guideline was developed, \\nincluding details of the committee. \\nNICE has produced tools and resources to help you put this guideline into practice. For \\ngeneral help and advice on putting our guidelines into practice, see resources to help you \\nput NICE guidance into practice. \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 66 of\\n67\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2021-01-29T00:00:00+00:00', 'keywords': 'NG99', 'subject': 'Brain tumours (primary) and brain metastases in over 16s (NG99)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Brain tumours (primary) and brain metastases in over 16s', 'source': '../data/pdf_files/brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'total_pages': 67, 'page': 66, 'page_label': '67', 'source_file': 'brain-tumours-primary-and-brain-metastases-in-over-16s-pdf-1837763558341.pdf', 'file_type': 'pdf'}, page_content=\"Update information \\nJanuary 2021: We replaced recommendation 1.7.6 with a link to the NHS England \\ncommissioning policy on stereotactic radiosurgery and stereotactic radiotherapy to the \\nsurgical cavity after resection of brain metastases. \\nMinor changes since publication \\nMarch 2025: We updated links following publication of NICE's guideline on overweight and \\nobesity management. \\nISBN: 978-1-4731-3001-2 \\nBrain tumours (primary) and brain metastases in over 16s (NG99)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 67 of\\n67\"),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 0, 'page_label': '1', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n1\\nMalnutrition has long-term effects on \\nhealth, development and economic \\ngrowth\\nMalnutrition has short- and long-term effects on the \\nhealth, development and economic growth of individuals, \\ncommunities and nations. It is a major cause of death, \\nillness and health inequities, particularly among children \\nunder five years of age, with almost half of child deaths \\nlinked to undernutrition (1). It also creates cycles of \\npoverty by reducing workforce productivity and increasing \\nhealthcare costs. Ensuring optimal nutrition, especially \\nduring the first 1000 days from conception to two years \\nGlobal nutrition targets 2030\\nof age, is essential for long-term health and economic \\nbenefits (1). Tackling malnutrition in all its forms, \\nincluding undernutrition (wasting, stunting, underweight), \\nmicronutrient deficiencies, overweight, obesity, and'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 0, 'page_label': '1', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='benefits (1). Tackling malnutrition in all its forms, \\nincluding undernutrition (wasting, stunting, underweight), \\nmicronutrient deficiencies, overweight, obesity, and \\nresulting diet-related noncommunicable diseases, requires \\na coordinated effort from key sectors such as education, \\nfood and agriculture, health and nutrition, and social \\nprotection systems, and water, sanitation and hygiene \\n(WASH). By increasing education, transforming food \\nsystems, expanding health and nutrition services, \\nstrengthening social protection, and implementing WASH \\npolicies, we can ensure better nutrition for all, leaving no \\none behind.\\nThis brief outlines the rationale for extending the 2025 Global Nutrition Targets to 2030 and introduces \\nthe extended and new operational targets. It provides an overview of nutrition interventions that \\nshould be implemented at scale in order to drive progress in maternal, infant, and young child'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 0, 'page_label': '1', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='the extended and new operational targets. It provides an overview of nutrition interventions that \\nshould be implemented at scale in order to drive progress in maternal, infant, and young child \\nnutrition. The World Health Organization (WHO) and UNICEF have developed six content- specific \\nbriefs, each addressing a respective target in detail and outlining the actions required to achieve it. \\nTopical briefs on maternal,  \\ninfant and young child nutrition \\n1 3\\n2\\n 4\\n 5 6\\n© WHO / Ipro Media'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 1, 'page_label': '2', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n2\\nMalnutrition remains a global \\nchallenge\\nDespite the progress made in recent decades, maternal, \\ninfant, and young child malnutrition remains a global \\nissue (see Fig. 1). Conflict, climate change, poverty and \\ngender discrimination are among the major drivers of \\nmalnutrition. While the number of people facing hunger is \\non the rise due to ongoing conflicts and global economic \\nchallenges (2), at the same time, cheap ultra-processed \\nfoods that are high in energy, fats, free sugars, and salt, \\nare being aggressively marketed to children. These factors, \\ncombined with reduced levels of physical activity, are \\nfueling the obesity crisis. The nutrition transition (3) and \\nchanges in our food environments have contributed to \\none out of every eight people in the world living with \\nobesity, as of 2022 (4). To add to the complexity, many \\nlow- and middle-income countries face a double or triple'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 1, 'page_label': '2', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='one out of every eight people in the world living with \\nobesity, as of 2022 (4). To add to the complexity, many \\nlow- and middle-income countries face a double or triple \\nburden of malnutrition, with concurrent undernutrition, \\nmicronutrient deficiencies and rising obesity rates (4, 5). \\nMalnutrition is not confined to low-income countries; \\nhigh-income countries also grapple with increasing obesity \\nrates and micronutrient deficiencies (2).\\nProgress and gaps are evident\\nNotable successes in addressing malnutrition can be \\ncited. The global rate of exclusive breastfeeding amongst \\ninfants less than six months of age increased from 37% in \\n2012 to 48% in 2024 and is expected to reach the target \\nof 50% by 2025 (6), while the prevalence of overweight \\nin children under five years of age have remained stable, \\nindicating that the 2025 target is close to being met. (5). \\nThese achievements should be celebrated, and the lessons \\nlearned applied to scaling up other proven interventions.'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 1, 'page_label': '2', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='indicating that the 2025 target is close to being met. (5). \\nThese achievements should be celebrated, and the lessons \\nlearned applied to scaling up other proven interventions. \\nDespite some progress, however, we are unlikely to meet \\nall the 2025 Global Nutrition Targets. While there has \\nbeen a notable decline in stunting and to a lesser extent \\nin wasting among children under five years of age, this is \\ninsufficient to meet the 2025 goals (5). No progress has \\nbeen made in reducing the prevalence of low birth weight, \\nwhich remains stagnant at nearly 15% (2). As of 2023, the \\nprevalence of anaemia in women 15-49 years of age has \\nalso remained stagnant at 30.7% compared to the 2012 \\nbaseline of 27.6%.\\nThe economic benefits of scaling up nutrition investments \\nfar outweigh the costs and offer substantial returns on \\ninvestment. The World Bank’s 2024 Investment framework \\nestimates that every dollar spent on early nutrition \\ninterventions can yield US$ 23 in return, contributing'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 1, 'page_label': '2', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='investment. The World Bank’s 2024 Investment framework \\nestimates that every dollar spent on early nutrition \\ninterventions can yield US$ 23 in return, contributing \\nup to US$ 2.4 trillion in economic benefits (8). However, \\nsignificant investments are needed, with an additional  \\nUS$ 128 billion required over the next decade to scale up \\nthe needed nutrition interventions.\\nFig 1. Maternal, infant and young child malnutrition is a global issue \\nSource: numbers are taken from (5-7)\\nIn 2024, \\n35.5 million \\nchildr\\nen under the age of \\n5 years were overweight\\nIn 2023, \\n604.8 million \\nw\\nomen 15-49 years of age were \\naffected by anaemia\\nIn 2020, \\n19.8 million \\nb\\nabies were born  \\nwith low birth weight\\nIn 2024, \\n42.8 million \\nchildren were wasted (too \\nthin for their height)\\nIn 2024, \\n150.2 million \\nchildren were stunted \\n(too short for their age)\\nIn 2024, \\n48% of infants \\nunder six months w\\nere \\nexclusively breastfed'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 2, 'page_label': '3', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n3\\nExtending the targets to 2030\\nIn 2019, UNICEF and WHO published a discussion paper on \\nextending the timeline of the targets to align with the 2030 \\nSustainable Development Goals (9). To further build on this \\ndiscussion WHO conducted an online public consultation \\nin 2024 suggesting new targets and proposing the \\nintroduction of a number of process-related operational \\ntargets (10). During the 78th World Health Assembly in \\n2025, WHO’s Member States passed a resolution to extend \\nthe target for five more years to 2030, during which \\ntime actors can intensify attention to, investment in, \\nand actions to address the targets (11). For targets that \\nare close to being reached, such as those for exclusive \\nbreastfeeding and overweight in children under five years \\nof age, the focus has shifted to accelerating progress, \\naiming to increase exclusive breastfeeding amongst infants'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 2, 'page_label': '3', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='breastfeeding and overweight in children under five years \\nof age, the focus has shifted to accelerating progress, \\naiming to increase exclusive breastfeeding amongst infants \\nunder six months of age to 60% and reduce overweight to \\nless than 5% in children under five years of age by 2030\\n. \\nTo increase efforts and measure progress, WHO \\nrecommends adopting operational targets to measure \\nkey indicators that are proximally linked to the 2030 \\nNutrition Targets. The relationships between these \\nprocess indicators and the nutritional outcome targets are \\nillustrated in Fig. 2. Details for each of the indicators are \\nprovided in Table 1. \\nThe extended global nutrition targets to be achieved by \\n2030 are:\\n1   A 40% r eduction in the number of children under five \\nyears of age who are stunted, compared to the 2012 \\nbaseline.\\n2   A 50% r eduction in anaemia in women of reproductive \\nage, compared to the 2012 baseline.\\n3  A 30% r eduction in low birth weight, compared to the \\n2012 baseline.'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 2, 'page_label': '3', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='baseline.\\n2   A 50% r eduction in anaemia in women of reproductive \\nage, compared to the 2012 baseline.\\n3  A 30% r eduction in low birth weight, compared to the \\n2012 baseline.\\n4  R educe and maintain overweight in children under \\nfive years of age to less than 5%.\\n5  Incr ease the rate of exclusive breastfeeding in the first \\nsix months up to at least 60%.\\n6   Reduce and maintain wasting in children under five \\nyears of age to less than 5%.\\nTable 1. Operational 2030 targets for maternal, infant and young child nutrition\\nProcess indicator Baseline data source Baseline coverage/ \\nprevalence\\n2030 operational \\ntarget\\n% of children aged 6 to 23 months consuming minimum dietary \\ndiversity\\nUNICEF IYCF database 34.3% (2016-2022) Increase by 20%\\n*\\n% of women consuming at least 90 iron-containing supplements \\nduring pregnancy\\nDemographic and Health Surveys 36.4% (2015-2022) Increase by 50%*'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 2, 'page_label': '3', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='*\\n% of women consuming at least 90 iron-containing supplements \\nduring pregnancy\\nDemographic and Health Surveys 36.4% (2015-2022) Increase by 50%*\\n% of women consuming minimum dietary diversity Global Diet Quality Project 65.8% (2021-2023) Increase by 30%**\\n% of children aged 6 to 23 months consuming sweet beverages \\non the previous day\\na\\nDemographic and Health Surveys 31.6% (2021-2023) Decrease by 25%**\\n% of newborns being put to the breast in the first hour after birth UNICEF IYCF database 45.8% (2016-2022) Increase by 25%*\\n% of caregivers counselled on infant and young child feedinga UNICEF Nutridash survey 39.3% (2022) Increase by 65%**\\na  No t a global estimate (i.e. population coverage is below 50%)\\n*  Based on projected coverage at the best performing quintile of past progress\\n**  Based on best perf orming quintile of coverage\\nFig 2. Linking process indicators to 2030 Nutrition Targets\\n1\\n2\\n4\\n5\\n6\\n1  Stunting\\n2  Anaemia\\n3  Low birth weight\\n4  Overweight\\n5  Breastfeeding'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 2, 'page_label': '3', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='**  Based on best perf orming quintile of coverage\\nFig 2. Linking process indicators to 2030 Nutrition Targets\\n1\\n2\\n4\\n5\\n6\\n1  Stunting\\n2  Anaemia\\n3  Low birth weight\\n4  Overweight\\n5  Breastfeeding\\n6  Wasting\\nIron-containing \\nsupplements\\nMinimum dietary \\ndiversity for women\\nMinimum dietary \\ndiversity for children\\nSweetened  \\nbeverages\\nEarly initiation of \\nbreastfeeding\\nCounselling on infant \\nand young child feeding\\n3'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 3, 'page_label': '4', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n4\\nGlobal efforts are in place to tackle \\nmalnutrition\\nSince the launch of the Comprehensive implementation \\nplan on maternal, infant and young child nutrition (12), \\nthere have been numerous impactful global efforts to \\ncombat malnutrition:\\n·\\t The Nutrition for Growth (N4G) (13) summits have \\nraised billions of dollars and mobilized hundreds of \\npolicy and programmatic commitments to reduce \\nmalnutrition.\\n·\\t The Second International Conference on Nutrition \\n(ICN2) (14) established a Framework for Action in 2014 \\nthat was endorsed by over 170 governments, setting \\na global agenda for food systems and nutrition for the \\nensuing decade.\\n·\\t New financing mechanisms for nutrition were \\nlaunched, including the Global Financing Facility, \\nPower of Nutrition, UNITLIFE, Nutrition impact bonds, \\nand more recently the Child Nutrition Fund.\\n·\\t The UN Decade of Action on Nutrition (2016-2030)'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 3, 'page_label': '4', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Power of Nutrition, UNITLIFE, Nutrition impact bonds, \\nand more recently the Child Nutrition Fund.\\n·\\t The UN Decade of Action on Nutrition (2016-2030) \\n(15) co-led by the Food and Agriculture Organization of \\nthe United Nations (FAO) and WHO, the Decade calls \\nfor multisectoral efforts to achieve the global nutrition \\ntargets by 2030 across six action areas:\\n– sus tainable, resilient food systems for healthy diets;\\n– aligned he alth systems providing universal coverage \\nof essential nutrition actions;\\n– social pr otection and nutrition education;\\n– tr ade and investment for improved nutrition; \\n– saf e and supportive environments for nutrition at \\nall ages; and\\n– s trengthened governance and accountability for \\nnutrition.\\n·\\t The UN Food Systems Summit (UNFSS) (16) held in \\n2021 brought together diverse global stakeholders \\nto advance progress towards the Sustainable \\nDevelopment Goals, focusing on sustainable food \\naccess, consumption, and production. UNFSS conducts'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 3, 'page_label': '4', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='2021 brought together diverse global stakeholders \\nto advance progress towards the Sustainable \\nDevelopment Goals, focusing on sustainable food \\naccess, consumption, and production. UNFSS conducts \\na stocktaking moment every two years to review \\nprogress on the commitments made. \\n·\\t The Committee on World Food Security (17) holds \\nannual sessions to develop policies for eliminating \\nhunger and malnutrition, with the 2024-2027 strategy \\nfocusing on resilient livelihoods, food security, \\nenvironmental sustainability, and gender equality.\\n·\\t The Scaling Up Nutrition Movement (SUN) (18) \\nbrings together civil society, donors, UN agencies, \\nbusinesses and researchers aims to support country-\\nled, multisectoral strategies to address all forms of \\nmalnutrition. \\n·\\t Three alliances were formed by WHO, UNICEF and \\npartners.\\n– The Global Breastfeeding Collective (19) equips \\npartners with tools ranging from communication \\nresources, advocacy briefs, and implementation'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 3, 'page_label': '4', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='partners.\\n– The Global Breastfeeding Collective (19) equips \\npartners with tools ranging from communication \\nresources, advocacy briefs, and implementation \\nguidance to strengthen regional and local advocacy \\non breastfeeding.\\n– The Global Complementary Feeding Collective (20)  \\ncalls on governments, policymakers and civil \\nsociety to take concrete, coordinated and \\nsynergistic actions to accelerate access to \\nnutritious, safe and diverse diets during the \\ncomplementary feeding period. \\n– The Anaemia Ac tion Alliance (21). Under the \\nleadership of WHO and UNICEF, the Alliance was \\ncreated to foster accelerated and coordinated \\nefforts among all actors and stakeholders. The \\nAlliance focuses on workstreams for national \\nintegrated action, programme implementation, \\ninvestment, and research.\\n·\\t Two global action plans were formed.\\n– The Global Action Plan (GAP) on Child Wasting (22), \\nled by FAO, UNHCR, UNICEF, WFP and WHO aims to \\nstimulate and accelerate progress towards reducing'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 3, 'page_label': '4', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='·\\t Two global action plans were formed.\\n– The Global Action Plan (GAP) on Child Wasting (22), \\nled by FAO, UNHCR, UNICEF, WFP and WHO aims to \\nstimulate and accelerate progress towards reducing \\nchild wasting.\\n– The WHO acceleration plan to stop obesity (23) \\npromotes the development of comprehensive \\npolicies on infant and young child feeding, healthy \\ndiets, physical activity, and health promoting \\nschools, and calls for integrating obesity prevention \\nand treatment into primary health care services and \\nschool health programmes. \\n© WHO / Antoine Tardy'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 4, 'page_label': '5', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n5\\nEnding malnutrition in all its forms \\nrequires a multisectoral approach \\nEnding malnutrition in all its forms requires integrating \\nnutrition into all sectors, including education, food and \\nagriculture, health and nutrition, and social protection \\nsystems, and WASH. Food systems must be transformed in \\norder to offer affordable, safe, nutritious, and sustainable \\ndiets (24, 25, 26). Nutrition services should be fully \\nintegrated into health systems to improve maternal, child, \\nadolescent and adult health (24, 27, 28). By redesigning \\ncash and food transfers to promote healthy diets and \\npreventive care, social safety nets can help break the cycle \\nof poverty and malnutrition. Strong WASH policies reduce \\nchild malnutrition and prevent diseases such as diarrhoea \\n(24). Recognizing that the six Global Nutrition Targets are \\ninterlinked (see Fig. 2), many of the priority interventions'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 4, 'page_label': '5', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='child malnutrition and prevent diseases such as diarrhoea \\n(24). Recognizing that the six Global Nutrition Targets are \\ninterlinked (see Fig. 2), many of the priority interventions \\ndescribed in each of the briefs can advance multiple \\ntargets. Key interventions to implement across sectors are \\nhighlighted in Table 2. \\nTable 2. Overview of key nutrition policy and interventions across sectors\\nFood systems Health systems Social protection and WASH\\n·\\t Improve household food security, food \\ndiversity and food safety (24).\\n·\\t Develop fiscal policies to promote \\nhealthy and safe diets (25). \\n·\\t Implement regulations on nutrition \\nlabelling and marketing restrictions  \\n(29, 30, 31). \\n·\\t Procure and serve nutritious and safe \\nfoods in schools (32).\\n·\\t Fortify staple foods with vitamins and \\nminerals (33, 34).\\n·\\t Adopt and monitor the International \\nCode of Marketing of Breast-milk \\nSubstitutes (35). \\n·\\t Reformulate food and beverage \\nproducts for healthier diets (36).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 4, 'page_label': '5', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='minerals (33, 34).\\n·\\t Adopt and monitor the International \\nCode of Marketing of Breast-milk \\nSubstitutes (35). \\n·\\t Reformulate food and beverage \\nproducts for healthier diets (36).\\n·\\t Provide nutritional care to pregnant and \\npostpartum women (37). \\n·\\t Deliver quality counselling on healthy \\ndiets, nutrition and physical activity  \\n(38, 39, 40).\\n·\\t Provide multiple micronutrient powders \\nor supplements to children as needed \\n(41).\\n·\\t Provide iron and folic acid containing \\nsupplements during antenatal care  \\n(42, 43).\\n·\\t Implement the ‘Ten Steps to Successful \\nBreastfeeding’ in maternity facilities \\n(38).\\n·\\t Routinely monitor child growth (27).\\n·\\t Prevent and manage child wasting in \\nprimary health services (44). \\n·\\t Provide nutritional support in \\nemergencies (44). \\n·\\t Integrate nutrition objectives into social \\nsafety net programmes (45). \\n·\\t Provide nutritious foods in food \\nassistance or cash transfer programmes \\n(44, 45).\\n·\\t Integrate behaviour change'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 4, 'page_label': '5', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='·\\t Integrate nutrition objectives into social \\nsafety net programmes (45). \\n·\\t Provide nutritious foods in food \\nassistance or cash transfer programmes \\n(44, 45).\\n·\\t Integrate behaviour change \\ncommunication in social protection \\nservices (46).\\n·\\t Promote hygiene education (24, 46).\\n·\\t Ensure access to safe, clean and potable \\nwater, sanitation and hygiene services \\n(24, 46).\\n·\\t Enact paid maternity leave and family-\\nfriendly workplace policies (47, 48). \\nData, monitoring and evaluation\\n·\\t Strengthen national data systems to monitor food environments, diets and malnutrition using standardized indicators and data \\ncollection methods (24, 49, 50, 51). \\n·\\t Regularly collect data on the WHA global nutrition and operational 2030 targets for maternal, infant and young child nutrition  \\n(\\ntable 1) (49).\\nHuman capacity building \\n·\\t Build capacity of the national workforce to deliver nutrition policies and programmes (12, 24).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 4, 'page_label': '5', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='(\\ntable 1) (49).\\nHuman capacity building \\n·\\t Build capacity of the national workforce to deliver nutrition policies and programmes (12, 24).\\n·\\t Implement nutrition education in the health, agriculture and social protection services, and community interventions (24). \\nFinancial resources\\n·\\t Allocate domestic funding to support the inclusion of comprehensive nutrition interventions in national health plans (24, 28).   \\n·\\t Establish a budget line and national financial targets for nutrition policies, programmes and services across sectors (24). \\nTo integrate policies and programmes across sectors, \\ngovernments and their are encouraged to: \\n·\\t Ensure policies and programmes include nutrition.\\n·\\t Set clear SMART targets (Specific, Measurable, \\nAchievable, Relevant, and Time-bound).\\n·\\t Mobilize resources, both domestically and \\ninternationally.\\n·\\t Foster partnerships for financial and policy support.\\n·\\t Scale up implementation of recommended \\ninterventions.'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 4, 'page_label': '5', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='·\\t Mobilize resources, both domestically and \\ninternationally.\\n·\\t Foster partnerships for financial and policy support.\\n·\\t Scale up implementation of recommended \\ninterventions. \\n·\\t Develop and implement suitable monitoring and \\nevaluation mechanisms.'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 5, 'page_label': '6', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n6\\n© World Health Organization and the United Nations Children’s Fund (UNICEF), 2025. Some rights reserved. This work is available \\nunder the CC BY-NC-SA 3.0 IGO licence. \\nSuggested citation. Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition. Geneva: World Health \\nOrganization and the United Nations Children’s Fund (UNICEF); 2025. https://doi.org/10.2471/B09485\\nAcknowledgements\\nThis brief was prepared by the Department of Nutrition and Food Safety (NFS) of the World Health Organization (WHO) \\nunder the overall leadership of Francesco Branca and Luz Maria De-Regil, and the coordination of Laurence Grummer-\\nStrawn. This brief was prepared by Jørgen Torgerstuen Johnsen (NFS) with valuable inputs from Jaden Bendabenda (NFS), \\nRimu Byadya (NFS), Nina Chad (NFS), Maria Nieves Garcia-Casal (NFS), Lisa Rogers (NFS), and Zita Weise (NFS). WHO is'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 5, 'page_label': '6', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Rimu Byadya (NFS), Nina Chad (NFS), Maria Nieves Garcia-Casal (NFS), Lisa Rogers (NFS), and Zita Weise (NFS). WHO is \\ngrateful for the contributions and reviews from (in alphabetical order): Mauro Brero (UNICEF), Angela De Silva (Regional \\nadvisor for nutrition and physical activity SEARO), Katrin Engelhardt (NFS), Andreas Hasman (UNICEF), Leendert Nederveen \\n(Regional advisor for nutrition PAHO/AMRO), Grainne Moloney (UNICEF), Fatmata Fatima Sesay (UNICEF), Linda Shaker \\n(UNICEF) and Vilma Tyler (UNICEF).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 6, 'page_label': '7', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n7\\nReferences\\n1. Malnutrition [w ebsite]. World Health Organization. 2021 \\n(https://www.who.int/news-room/fact-sheets/detail/\\nmalnutrition, accessed 23 March 2025). \\n2. The S tate of Food Security and Nutrition in the World 2024 \\n– Financing to end hunger, food insecurity and malnutrition \\nin all its forms. 2024. FAO, IFAD, UNICEF, WFP and WHO. 2024 \\n(https://openknowledge.fao.org/items/ebe19244-9611-443c-\\na2a6-25cec697b361, accessed 23 March 2025). \\n3. P opkin BM, Adair LS, Ng SW. Global nutrition transition and \\nthe pandemic of obesity in developing countries. Nutr Rev. \\n2012 Jan;70(1):3-21. DOI: 10.1111/j.1753-4887.2011.00456.x \\n4. Phelps, N.H., Single ton, R.K., Zhou, B., Heap, R.A., Mishra, \\nA., Bennett, J.E., et al., Worldwide trends in underweight \\nand obesity from 1990 to 2022: a pooled analysis of 3663 \\npopulation-representative studies with 222 million children,'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 6, 'page_label': '7', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='A., Bennett, J.E., et al., Worldwide trends in underweight \\nand obesity from 1990 to 2022: a pooled analysis of 3663 \\npopulation-representative studies with 222 million children, \\nadolescents, and adults. The Lancet, 2024. 403(10431):  \\np. 1027-1050. DOI:  10.1016/S0140-6736(23)02750-2\\n5. Unit ed Nations Children’s Fund (UNICEF), World Health \\nOrganization, International Bank for Reconstruction and \\nDevelopment/The World Bank. Levels and trends in child \\nmalnutrition: Key Findings of the 2025 Edition of the \\nJoint Child Malnutrition Estimates. Geneva: World Health \\nOrganization; 2025 (https://www.who.int/teams/nutrition-\\nand-food-safety/monitoring-nutritional-status-and-food-\\nsafety-and-events/joint-child-malnutrition-estimates/latest-\\nestimates, accessed 27 August 2025).\\n6. Glob al breastfeeding scorecard 2024, Meeting the global \\ntarget for breastfeeding requires bold commitments and \\naccelerated action by governments and donors. Global'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 6, 'page_label': '7', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='6. Glob al breastfeeding scorecard 2024, Meeting the global \\ntarget for breastfeeding requires bold commitments and \\naccelerated action by governments and donors. Global \\nbreastfeeding collective, UNICEF, World Health Organization; \\n2025 (https://www.globalbreastfeedingcollective.org/\\nmedia/2856/file, accessed 09 April 2025). \\n7. WHO Glob al Anaemia estimates, 2025 Edition. World Health \\nOrganization; 2025 (https://www.who.int/data/gho/data/\\nthemes/topics/anaemia_in_women_and_children, accessed \\n27 August 2025). \\n8. Inv estment Framework for Nutrition 2024. The World Bank. \\nWashington, DC. 2024 (https://openknowledge.worldbank.\\norg/entities/publication/2c0b8b5e-0f67-47fe-9eae-\\nd4707d9ed195, accessed 23 March 2025). \\n9. Discussion p aper. The extension of the 2025 maternal, infant \\nand young child nutrition targets to 2030. World health \\nOrganization and UNICEF. 2019 (https://data.unicef.org/\\nresources/who-unicef-discussion-paper-nutrition-targets/, \\naccessed 23 March 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 6, 'page_label': '7', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='and young child nutrition targets to 2030. World health \\nOrganization and UNICEF. 2019 (https://data.unicef.org/\\nresources/who-unicef-discussion-paper-nutrition-targets/, \\naccessed 23 March 2025). \\n10. 2025-2030 World He alth Assembly global maternal, infant \\nand young child nutrition targets and proposal for process \\nindicators. Results of the online consultation and way \\nforward. World Health Organization. 2024 (https://www.who.\\nint/news-room/articles-detail/online-consultation-2025-\\n2030-world-health-assembly-global-maternal-infant-and-\\nyoung-child-nutrition-targets-and-proposal-for-process-\\nindicators, accessed 23 March 2025). \\n11. Compr ehensive implementation plan on maternal, infant and \\nyoung child nutrition 2012–2025: extension. Seventy-eighth \\nWorld Health Assembly. World Health Organization; 2025 \\n(https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R24-\\nen.pdf, accessed 24 June 2025).\\n12. Compr ehensive implementation plan on maternal, infant'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 6, 'page_label': '7', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='(https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R24-\\nen.pdf, accessed 24 June 2025).\\n12. Compr ehensive implementation plan on maternal, infant \\nand young child nutrition. World Health Organization. 2014 \\n(https://www.who.int/publications/i/item/WHO-NMH-\\nNHD-14.1, accessed 23 March 2025). \\n13. Nutrition f or growth. Working to end malnutrition by \\n2030 [website]. Nutrition for Growth. n.d. (https://\\nnutritionforgrowth.org/, accessed 26 February 2025). \\n14. F AO/WHO Second International Conference on Nutrition \\n(ICN2) [website]. World Health Organization; 2014 (https://\\nwww.who.int/news-room/events/detail/2014/11/19/default-\\ncalendar/fao-who-second-international-conference-on-\\nnutrition-(icn2), accessed 23 March 2025). \\n15. Unit ed Nations Decade of Action on Nutrition 2016-2025 \\n[website]. United Nations. n.d (https://www.un.org/\\nnutrition/, accessed 23 March 2025). \\n16. The F ood Systems Summit [website]. United Nations. n.d \\n(https://www.un.org/en/food-systems-summit, accessed'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 6, 'page_label': '7', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='nutrition/, accessed 23 March 2025). \\n16. The F ood Systems Summit [website]. United Nations. n.d \\n(https://www.un.org/en/food-systems-summit, accessed  \\n23 March 2025). \\n17. Commit tee on World Food Security [website]. FAO. n.d \\n(https://www.fao.org/cfs/en/, accessed 23 March 2025). \\n18. About . What we do [website]. Scaling Up Nutrition. n.d \\n(https://scalingupnutrition.org/about/what-we-do, accessed \\n26 February 2025). \\n19. About the Collec tive. Because no one breastfeeds alone \\n[website]. Global breastfeeding collective. n.d. (https://www.\\nglobalbreastfeedingcollective.org/, accessed 26 February \\n2025). \\n20. The Glob al Complementary Feeding Collective [website]. \\nUNICEF and World Health Organization. n.d (https://www.\\ncomplementaryfeedingcollective.org/, accessed 27 August \\n2025). \\n21. Anaemia ac tion alliance [website]. World Health Organization. \\nn.d (https://www.who.int/teams/nutrition-and-food-safety/\\nanaemia-action-alliance, accessed 01 May 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 6, 'page_label': '7', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='2025). \\n21. Anaemia ac tion alliance [website]. World Health Organization. \\nn.d (https://www.who.int/teams/nutrition-and-food-safety/\\nanaemia-action-alliance, accessed 01 May 2025). \\n22. Glob al action plan on child wasting: a framework for action to \\naccelerate progress in preventing and managing child wasting \\nand the achievement of the Sustainable Development Goals. \\nFood and Agriculture Organization, UNHCFR, UNICEF, World \\nFood Programme, World Health Organization; 2021 (https:// \\nwww.childwasting.org/media/1126/file/GAP-Framework-All- \\nFINAL-2021-11-15.pdf,  accessed 28 February 2025). \\n23. WHO ac celeration plan to stop obesity. World Health \\nOrganization; 2023 (https://www.who.int/publications/i/\\nitem/9789240075634, accessed 27 February 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 7, 'page_label': '8', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n8\\n24. S trengthening nutrition action. A resource guide for countries \\nbased on the policy recommendations of the Second \\nInternational Conference on Nutrition (ICN2). Food and \\nAgriculture Organization of the United Nations World Health \\nOrganization; 2018 (https://www.who.int/publications/i/\\nitem/9789241550253, accessed 28 August 2025). \\n25. Fisc al policies to promote healthy diets: WHO guideline. \\nWorld Health Organization. 2024 (https://www.who.int/\\npublications/i/item/9789240091016, accessed 23 March \\n2025). \\n26. F ood systems for health: information brief. World Health \\nOrganization. 2021 (https://www.who.int/publications/i/\\nitem/9789240035263, accessed 23 March 2025). \\n27. Essential nutrition ac tions: mainstreaming nutrition through \\nthe life-course. World Health Organization. 2019 (https://\\nwww.who.int/publications/i/item/9789241515856, accessed \\n23 March 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 7, 'page_label': '8', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='27. Essential nutrition ac tions: mainstreaming nutrition through \\nthe life-course. World Health Organization. 2019 (https://\\nwww.who.int/publications/i/item/9789241515856, accessed \\n23 March 2025). \\n28. Mobilizing ambitious and imp actful commitments for \\nmainstreaming nutrition in health systems: nutrition \\nin universal health coverage – global nutrition summit. \\nWorld Health Organization. 2020 (https://www.who.int/\\npublications/i/item/9789240004252, accessed 23 March \\n2025).\\n29. P olicies to protect children from the harmful impact of \\nfood marketing: WHO guideline. Geneva: World Health \\nOrganization. 2023. (https://www.who.int/publications/i/\\nitem/9789240075412, accessed 27 August 2025).\\n30. Implementing nutrition labelling policies: a r eview of \\ncontextual factors. Geneva: World Health Organization. 2021. \\n(https://www.who.int/publications/i/item/9789240035089, \\naccessed 27 August 2025).\\n31. Nutrition labelling: polic y brief. World Health'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 7, 'page_label': '8', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='contextual factors. Geneva: World Health Organization. 2021. \\n(https://www.who.int/publications/i/item/9789240035089, \\naccessed 27 August 2025).\\n31. Nutrition labelling: polic y brief. World Health \\nOrganization. 2022. (https://www.who.int/publications/i/\\nitem/9789240051324, accessed 27 August 2025).\\n32. Ac tion framework for developing and implementing public \\nfood procurement and service policies for a healthy diet. \\nGeneva: World Health Organization. 2021. (https://www.who.\\nint/publications/i/item/9789240018341, accessed 27 August \\n2025).\\n33. Guideline: f ortification of wheat flour with vitamins and \\nminerals as a public health strategy. Geneva: World Health \\nOrganization; 2022. (https://www.who.int/publications/i/\\nitem/9789240043398, accessed 27 August 2025). \\n34. Guideline: f ortification of rice with vitamins and minerals \\nas a public health strategy. Geneva: World Health \\nOrganization; 2018. (https://www.who.int/publications/i/\\nitem/9789241550291, accessed 27 August 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 7, 'page_label': '8', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='as a public health strategy. Geneva: World Health \\nOrganization; 2018. (https://www.who.int/publications/i/\\nitem/9789241550291, accessed 27 August 2025). \\n35. Int ernational Code of Marketing of Breast-milk Substitutes. \\nWorld Health Assembly. 1981. (https://iris.who.int/\\nhandle/10665/156596, accessed 26 February 2025).\\n36. R eformulation of food and beverage products for healthier \\ndiets: policy brief. World Health Organization; 2022 (https://\\nwww.who.int/publications/i/item/9789240039919, accessed \\n27 August 2025).\\n37. WHO r ecommendations on antenatal care for a positive \\npregnancy experience. World Health Organization; 2016. \\n(https://www.who.int/publications/i/item/9789241549912, \\naccessed 27 August 2025). \\n38. Implement ation guidance: protecting, promoting, and \\nsupporting breastfeeding in facilities providing maternity \\nand newborn services: the revised Baby-friendly Hospital \\nInitiative 2018. World Health Organization; 2018 (https://'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 7, 'page_label': '8', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='supporting breastfeeding in facilities providing maternity \\nand newborn services: the revised Baby-friendly Hospital \\nInitiative 2018. World Health Organization; 2018 (https://\\nwww.who.int/publications/i/item/9789241513807, accessed \\n26 February 2025).\\n39. WHO Guideline f or complementary feeding of infants \\nand young children 6–23 months of age. World Health \\nOrganization; 2023 (https://iris.who.int/bitstream/hand\\nle/10665/373358/9789240081864-eng.pdf?sequence=1, \\naccessed 27 August, 2025).\\n40. WHO guidelines on physic al activity and sedentary behaviour. \\nWorld Health Organization. 2020 (https://www.who.int/\\npublications/i/item/9789240015128, accessed 27 August \\n2025).\\n41. WHO guideline: U se of multiple micronutrient powders for \\npoint-of-use fortification of foods consumed by infants and \\nyoung children aged 6–23 months and children aged 2–12 \\nyears. Geneva: World Health Organization; 2016. (https://\\nwww.who.int/publications/i/item/9789241549943, accessed \\n27 August 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 7, 'page_label': '8', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='young children aged 6–23 months and children aged 2–12 \\nyears. Geneva: World Health Organization; 2016. (https://\\nwww.who.int/publications/i/item/9789241549943, accessed \\n27 August 2025). \\n42. Guideline: int ermittent iron and folic acid supplementation \\nin menstruating women. World Health Organization; 2011 \\n(https://iris.who.int/handle/10665/44649, accessed 27 August \\n2025).\\n43. WHO Guideline: U se of multiple micronutrient powders for \\npoint-of-use fortification of foods consumed by pregnant \\nwomen. Geneva: World Health Organization; 2016. (https://\\nwww.who.int/publications/i/item/9789241549516, accessed \\n27 August 2025). \\n44. WHO guideline on the pr evention and management of \\nwasting and nutritional oedema (acute malnutrition) in \\ninfants and children under 5 years. Geneva: World Health \\nOrganization; 2023. (https://www.who.int/publications/i/\\nitem/9789240082830, accessed 27 August 2025).\\n45. L everaging Nutrition and Social Protection Programming to'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 7, 'page_label': '8', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Organization; 2023. (https://www.who.int/publications/i/\\nitem/9789240082830, accessed 27 August 2025).\\n45. L everaging Nutrition and Social Protection Programming to \\naddress Malnutrition and Poverty, including in Fragile and \\nHumanitarian Contexts. New York: United Nations Children’s \\nFund (UNICEF). 2023. (https://www.unicef.org/documents/\\nleveraging-nutrition-and-social-protection-programming, \\naccessed 27 August 2025).\\n46. Impr oving nutrition outcomes with better water, sanitation \\nand hygiene: practical solutions for policies and programmes. \\nUNICEF, USAID and World Health Organization. 2015. (https://\\nwww.who.int/publications/i/item/9789241565103, accessed \\n27 August 2025). \\n47. R191 - Ma ternity Protection Recommendation, 2000 (No. 191). \\nInternational Labour Organization; n.d. (https://normlex.ilo.\\norg/dyn/nrmlx_en/f?p=NORMLEXPUB:12100:0::NO::P12100_\\nILO_CODE:R191, accessed 26 February 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 8, 'page_label': '9', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n9\\n48. F amily-friendly policies: Redesigning the workplace of the \\nfuture. A policy brief. UNICEF; 2019 (https://www.unicef.org/\\ndocuments/family-friendly-policies-redesigning-workplace-\\nfuture, accessed 26 February 2025).\\n49. Glob al nutrition monitoring framework: operational guidance \\nfor tracking progress in meeting targets for 2025. UNICEF \\nand World Health Organization; 2017 (https://www.who.int/\\npublications/i/item/9789241513609, accessed 18 September \\n2025).\\n50. Indic ators for assessing infant and young child feeding \\npractices: definitions and measurement methods. UNICEF \\nand World Health Organization; 2021 (https://www.who.int/\\npublications/i/item/9789240018389, accessed 18 September \\n2025).\\n51. Micr onutrient survey manual. Centers for Disease Control \\nand Prevention, World Health Organization, Nutrition \\nInternational and UNICEF; 2020 (https://www.who.int/'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 8, 'page_label': '9', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='2025).\\n51. Micr onutrient survey manual. Centers for Disease Control \\nand Prevention, World Health Organization, Nutrition \\nInternational and UNICEF; 2020 (https://www.who.int/\\npublications/i/item/9789240012691, accessed 18 September \\n2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 9, 'page_label': '10', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n10\\nAnnex: Development of this brief\\nThe methodology for developing this brief involved synthesizing the initial updated Global Nutrition Target briefs and an initial  \\nliterature review of previously published WHO guidelines and WHO and UNICEF recommendations. Such documents were selected  \\nfrom the WHO and UNICEF databases based on their applicability, importance and impact to maternal, infant and young child \\nmalnutrition. Key references include: Comprehensive implementation plan on maternal, infant and young child nutrition (1); 2025-2030 \\nWorld Health Assembly global maternal, infant and young child nutrition targets and proposal for process indicators. Results of the \\nonline consultation and way forward (2); Essential nutrition actions: mainstreaming nutrition through the life-course (3); \\nThe UNICEF'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 9, 'page_label': '10', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='online consultation and way forward (2); Essential nutrition actions: mainstreaming nutrition through the life-course (3); \\nThe UNICEF \\nNutrition Strategy 2020–2030: Nutrition, for Every Child (4); Strengthening nutrition action. A resource guide for countries based on the \\npolicy recommendations of the Second International Conference on Nutrition (ICN2) (5); and Global nutrition targets 2025: policy brief \\nseries (6). \\nThe brief was drafted by the WHO Department of Nutrition and Food Safety working collaboratively with other relevant WHO and UNICEF \\noffices and regional teams. Table 2 is a synthesis of the priority interventions in the six global nutrition target briefs and latest guidelines \\nand recommendations. In addition, this brief builds on the review from public comments received during the online consultation that \\nwas held between May and June 2024. This consultation aimed to solicit feedback from Member States, private sector, civil society,'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 9, 'page_label': '10', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='was held between May and June 2024. This consultation aimed to solicit feedback from Member States, private sector, civil society, \\nacademia and interested individuals on the proposal for the 2025-2030 outcome and process indicators and targets. WHO and UNICEF \\nexperts in public health nutrition and programme management reviewed the draft and provided feedback on its clarity and content. This \\nthorough process ensured that the final publication was comprehensive and embodied a broad spectrum of expert perspectives.\\n1. Compr ehensive implementation plan on maternal, infant and young child nutrition. World Health Organization; 2014 ( https://www.\\nwho.int/publications/i/item/WHO-NMH-NHD-14.1, accessed 07 April 2025).\\n2. 2025-2030 World He alth Assembly global maternal, infant and young child nutrition targets and proposal for process indicators. \\nResults of the online consultation and way forward. World Health Organization; 2024 (https://cdn.who.int/media/docs/default-'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 9, 'page_label': '10', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Results of the online consultation and way forward. World Health Organization; 2024 (https://cdn.who.int/media/docs/default-\\nsource/breastfeeding/online-consultation-cip-discussion-paper-responses-2024.pdf?sfvrsn=f0fa14e7_3, accessed 07 April 2025). \\n3. Essential nutrition ac tions: mainstreaming nutrition through the life-course. Geneva: World Health Organization; 2019 (https://www.\\nwho.int/publications/i/item/9789241515856, accessed 07 April 2025). \\n4. Nutrition, f or Every Child: UNICEF Nutrition Strategy 2020–2030. UNICEF; 2020 (https://www.unicef.org/reports/nutrition-\\nstrategy-2020-2030, accessed 07 April 2025). \\n5.  S trengthening nutrition action. A resource guide for countries based on the policy recommendations of the Second International \\nConference on Nutrition (ICN2). Food and Agriculture Organization of the United Nations World Health Organization; 2018 (https://\\nwww.who.int/publications/i/item/9789241550253, accessed 28 August 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 9, 'page_label': '10', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='www.who.int/publications/i/item/9789241550253, accessed 28 August 2025).\\n6. Glob al nutrition targets 2025: policy brief series. World Health Organization; 2014 ( https://www.who.int/publications/i/item/WHO-\\nNMH-NHD-14.2, accessed 07 April 2025).'),\n",
       " Document(metadata={'producer': 'Adobe PDF Library 17.0', 'creator': 'Adobe InDesign 18.1 (Macintosh)', 'creationdate': '2025-10-08T14:08:44+02:00', 'moddate': '2025-10-15T15:16:02+02:00', 'trapped': '/False', 'source': '../data/pdf_files/malnutrition.pdf', 'total_pages': 11, 'page': 10, 'page_label': '11', 'source_file': 'malnutrition.pdf', 'file_type': 'pdf'}, page_content='Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition\\n11\\nFor more information, please contact:\\nDepartment of Nutrition and Food Safety \\nWorld Health Organization\\nAvenue Appia 20 1211 Geneva 27 Switzerland\\nEmail: nfs@who.int\\nhttps://www.who.int/teams/nutrition-and-food-safety'),\n",
       " Document(metadata={'producer': 'Matplotlib pdf backend v3.6.3', 'creator': 'Matplotlib v3.6.3, https://matplotlib.org', 'creationdate': '2025-10-26T11:16:30+00:00', 'source': '../data/pdf_files/nice_hypertension_guideline_summary.pdf', 'total_pages': 3, 'page': 0, 'page_label': '1', 'source_file': 'nice_hypertension_guideline_summary.pdf', 'file_type': 'pdf'}, page_content='NICE Hypertension in Adults: Educational Summary (RAG Demo)\\nScope This document is a condensed, educational summary inspired by UK guidance on\\nhypertension for technical testing. It is NOT an official guideline. For clinical\\ndecisions, consult the latest NICE guidance.  Definition (Clinic/BP) - Hypertension is\\nbroadly defined by sustained elevated blood pressure measurements. - Home or ambulatory\\nmeasurements are recommended to confirm diagnosis when available.  Initial Assessment -\\nConfirm blood pressure with repeated measurements and appropriate cuff size. - Evaluate\\ncardiovascular risk (e.g., QRISK), lifestyle factors, and secondary causes when indicated.\\n- Baseline labs may include renal function, electrolytes, HbA1c, lipids, and urinalysis.'),\n",
       " Document(metadata={'producer': 'Matplotlib pdf backend v3.6.3', 'creator': 'Matplotlib v3.6.3, https://matplotlib.org', 'creationdate': '2025-10-26T11:16:30+00:00', 'source': '../data/pdf_files/nice_hypertension_guideline_summary.pdf', 'total_pages': 3, 'page': 1, 'page_label': '2', 'source_file': 'nice_hypertension_guideline_summary.pdf', 'file_type': 'pdf'}, page_content='Management Principles (Simplified)\\nLifestyle Measures (all stages) - Weight optimisation, regular physical activity, reduced\\nsalt intake, moderation of alcohol. - Dietary patterns rich in vegetables, fruits, and\\nwhole grains.  Pharmacological Strategy (typical adult pathway, simplified for demo) -\\nFirst-line options depend on age, ethnicity, and comorbidities. - Common classes include:\\nACE inhibitors/ARBs, calcium channel blockers, thiazide-like diuretics. - Escalation: add\\na second/third agent if targets are not met; consider resistant hypertension workup.\\nT argets (illustrative, not exhaustive) - Clinic and home targets can differ; use validated\\ndevices and consistent methodology. - Tighter targets may be considered for certain high-\\nrisk groups under specialist guidance.'),\n",
       " Document(metadata={'producer': 'Matplotlib pdf backend v3.6.3', 'creator': 'Matplotlib v3.6.3, https://matplotlib.org', 'creationdate': '2025-10-26T11:16:30+00:00', 'source': '../data/pdf_files/nice_hypertension_guideline_summary.pdf', 'total_pages': 3, 'page': 2, 'page_label': '3', 'source_file': 'nice_hypertension_guideline_summary.pdf', 'file_type': 'pdf'}, page_content='Monitoring, Safety, and Follow-up\\nMonitoring - Reassess blood pressure after medication changes. - Monitor electrolytes and\\nrenal function when using ACE inhibitors/ARBs or diuretics.  Safety - Watch for adverse\\neffects (e.g., cough with ACE inhibitors, hyperkalaemia with RAAS blockers, ankle oedema\\nwith CCBs).  Special Considerations - Pregnancy, diabetes, CKD, and older adults may\\nrequire tailored targets and drug choices.  Disclaimer This is an educational, non-\\nofficial summary for software testing of RAG pipelines. Refer to the latest NICE guidance\\nfor clinical use.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 0, 'page_label': '1', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='Parkinson’s disease in \\nadults \\nNICE guideline \\nPublished: 19 July 2017 \\nwww.nice.org.uk/guidance/ng71 \\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 1, 'page_label': '2', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='Your responsibility \\nThe recommendations in this guideline represent the view of NICE, arrived at after careful \\nconsideration of the evidence available. When exercising their judgement, professionals \\nand practitioners are expected to take this guideline fully into account, alongside the \\nindividual needs, preferences and values of their patients or the people using their service. \\nIt is not mandatory to apply the recommendations, and the guideline does not override the \\nresponsibility to make decisions appropriate to the circumstances of the individual, in \\nconsultation with them and their families and carers or guardian. \\nAll problems (adverse events) related to a medicine or medical device used for treatment \\nor in a procedure should be reported to the Medicines and Healthcare products Regulatory \\nAgency using the Yellow Card Scheme. \\nLocal commissioners and providers of healthcare have a responsibility to enable the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 1, 'page_label': '2', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='Agency using the Yellow Card Scheme. \\nLocal commissioners and providers of healthcare have a responsibility to enable the \\nguideline to be applied when individual professionals and people using services wish to \\nuse it. They should do so in the context of local and national priorities for funding and \\ndeveloping services, and in light of their duties to have due regard to the need to eliminate \\nunlawful discrimination, to advance equality of opportunity and to reduce health \\ninequalities. Nothing in this guideline should be interpreted in a way that would be \\ninconsistent with complying with those duties. \\nCommissioners and providers have a responsibility to promote an environmentally \\nsustainable health and care system and should assess and reduce the environmental \\nimpact of implementing NICE recommendations wherever possible. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 1, 'page_label': '2', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='impact of implementing NICE recommendations wherever possible. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 2 of\\n31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 2, 'page_label': '3', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Contents \\nOverview ...................................................................................................................................... 4 \\nWho is it for? .......................................................................................................................................... 4 \\nRecommendations ....................................................................................................................... 5 \\n1.1 Communication with people with Parkinson's disease and their carers .................................... 5 \\n1.2 Diagnosing Parkinson's disease ..................................................................................................... 6 \\n1.3 Pharmacological management of motor symptoms .................................................................... 8 \\n1.4 Managing and monitoring impulse control disorders as an adverse effect of dopaminergic\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 2, 'page_label': '3', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.4 Managing and monitoring impulse control disorders as an adverse effect of dopaminergic \\ntherapy ................................................................................................................................................... 12 \\n1.5 Pharmacological management of non-motor symptoms ............................................................ 14 \\n1.6 Pharmacological neuroprotective therapy .................................................................................... 19 \\n1.7 Non-pharmacological management of motor and non-motor symptoms ................................. 20 \\n1.8 Treating advanced Parkinson's disease ........................................................................................ 22 \\n1.9 Palliative care ................................................................................................................................... 23\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 2, 'page_label': '3', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.9 Palliative care ................................................................................................................................... 23 \\nRecommendations for research ................................................................................................. 25 \\n1 Combination treatment for Parkinson's disease dementia ............................................................. 25 \\n2 Orthostatic hypotension treatment .................................................................................................. 25 \\n3 Psychotic symptoms (hallucinations and delusions) ...................................................................... 26 \\n4 Rapid eye movement sleep behaviour disorder treatment ............................................................ 27 \\n5 Physiotherapy ..................................................................................................................................... 27\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 2, 'page_label': '3', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='5 Physiotherapy ..................................................................................................................................... 27 \\nContext ......................................................................................................................................... 28 \\nFinding more information and committee details .....................................................................29 \\nUpdate information .....................................................................................................................30 \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 3 of\\n31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 3, 'page_label': '4', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"This guideline replaces ESUOM48, ESUOM15, ES6 and ES9. \\nThis guideline is the basis of QS164. \\nOverview \\nThis guideline covers diagnosing and managing Parkinson's disease in people aged 18 and \\nover. It aims to improve care from the time of diagnosis, including monitoring and \\nmanaging symptoms, providing information and support, and palliative care. \\nWho is it for? \\n• Healthcare professionals \\n• Commissioners and providers \\n• Adults with Parkinson's disease and their families and carers \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 4 of\\n31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 4, 'page_label': '5', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Recommendations \\nPeople have the right to be involved in discussions and make informed decisions \\nabout their care, as described in making decisions about your care. \\nMaking decisions using NICE guidelines explains how we use words to show the \\nstrength (or certainty) of our recommendations, and has information about \\nprescribing medicines (including off-label use), professional guidelines, standards \\nand laws (including on consent and mental capacity), and safeguarding. \\n1.1 Communication with people with Parkinson's \\ndisease and their carers \\n1.1.1 Communication with people with Parkinson's disease should aim towards \\nempowering them to participate in judgements and choices about their own care. \\n[2006] \\n1.1.2 In discussions, aim to achieve a balance between providing honest, realistic \\ninformation about the condition and promoting a feeling of optimism. [2006] \\n1.1.3 Because people with Parkinson's disease may develop impaired cognitive ability,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 4, 'page_label': '5', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"information about the condition and promoting a feeling of optimism. [2006] \\n1.1.3 Because people with Parkinson's disease may develop impaired cognitive ability, \\ncommunication problems and/or depression, provide them with: \\n• both oral and written communication throughout the course of the disease, \\nwhich should be individually tailored and reinforced as necessary \\n• consistent communication from the professionals involved. [2006] \\n1.1.4 Advise family members and carers about their right to carer assessment, and \\nassessment for respite care and other support. \\nSee the NICE guideline on supporting adult carers for recommendations on \\nidentifying, assessing and meeting the caring, physical and mental health needs \\nof families and carers. [2006] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 5 of\\n31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 5, 'page_label': '6', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.1.5 People with Parkinson's disease should have a comprehensive care plan agreed \\nbetween the person, their family members and carers (as appropriate), and \\nspecialist and secondary healthcare providers. [2006] \\n1.1.6 Offer people with Parkinson's disease an accessible point of contact with \\nspecialist services. This could be provided by a Parkinson's disease nurse \\nspecialist. [2006] \\n1.1.7 Advise people with Parkinson's disease who drive that they should inform the \\nDriver and Vehicle Licensing Agency (DVLA) and their car insurer of their \\ncondition when Parkinson's disease is diagnosed. [2006] \\n1.2 Diagnosing Parkinson's disease \\nDefinition and differential diagnosis \\n1.2.1 Suspect Parkinson's disease in people presenting with tremor, stiffness, \\nslowness, balance problems and/or gait disorders. [2006] \\n1.2.2 If Parkinson's disease is suspected, refer people quickly and untreated to a \\nspecialist with expertise in the differential diagnosis of this condition. [2006,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 5, 'page_label': '6', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.2.2 If Parkinson's disease is suspected, refer people quickly and untreated to a \\nspecialist with expertise in the differential diagnosis of this condition. [2006, \\namended 2017] \\nClinical and post-mortem diagnosis \\n1.2.3 Diagnose Parkinson's disease clinically, based on the UK Parkinson's Disease \\nSociety Brain Bank Clinical Diagnostic Criteria. [2006] \\n1.2.4 Encourage healthcare professionals to discuss with people with Parkinson's \\ndisease the possibility of donating tissue to a brain bank for diagnostic \\nconfirmation and research. [2006] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 6 of\\n31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 6, 'page_label': '7', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Review of diagnosis \\n1.2.5 Review the diagnosis of Parkinson's disease regularly, and reconsider it if atypical \\nclinical features develop. (People diagnosed with Parkinson's disease should be \\nseen at regular intervals of 6 to 12 months to review their diagnosis.) [2006] \\nSingle photon emission computed tomography \\n1.2.6 Consider 123\\nI-FP-CIT single photon emission computed tomography (SPECT) for \\npeople with tremor if essential tremor cannot be clinically differentiated from \\nparkinsonism. [2006, amended 2017] \\n1.2.7 123\\nI-FP-CIT SPECT should be available to specialists with expertise in its use and \\ninterpretation. [2006] \\nPositron emission tomography \\n1.2.8 Do not use positron emission tomography (PET) in the differential diagnosis of \\nparkinsonian syndromes, except in the context of clinical trials. [2006, amended \\n2017] \\nStructural MRI \\n1.2.9 Do not use structural MRI to diagnose Parkinson's disease. [2006, amended \\n2017]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 6, 'page_label': '7', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"parkinsonian syndromes, except in the context of clinical trials. [2006, amended \\n2017] \\nStructural MRI \\n1.2.9 Do not use structural MRI to diagnose Parkinson's disease. [2006, amended \\n2017] \\n1.2.10 Structural MRI may be considered in the differential diagnosis of other \\nparkinsonian syndromes. [2006] \\nMagnetic resonance volumetry \\n1.2.11 Do not use magnetic resonance volumetry in the differential diagnosis of \\nparkinsonian syndromes, except in the context of clinical trials. [2006, amended \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 7 of\\n31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 7, 'page_label': '8', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"2017] \\nMagnetic resonance spectroscopy \\n1.2.12 Do not use magnetic resonance spectroscopy in the differential diagnosis of \\nparkinsonian syndromes. [2006, amended 2017] \\nAcute levodopa and apomorphine challenge tests \\n1.2.13 Do not use acute levodopa and apomorphine challenge tests in the differential \\ndiagnosis of parkinsonian syndromes. [2006, amended 2017] \\nObjective smell testing \\n1.2.14 Do not use objective smell testing in the differential diagnosis of parkinsonian \\nsyndromes, except in the context of clinical trials. [2006, amended 2017] \\n1.3 Pharmacological management of motor \\nsymptoms \\n1.3.1 Before starting treatment for people with Parkinson's disease, discuss: \\n• the person's individual clinical circumstances, for example, their symptoms, \\ncomorbidities and risks from polypharmacy \\n• the person's individual lifestyle circumstances, preferences, needs and goals \\n• the potential benefits and harms of the different drug classes (see table 1). \\n[2017]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 7, 'page_label': '8', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"• the person's individual lifestyle circumstances, preferences, needs and goals \\n• the potential benefits and harms of the different drug classes (see table 1). \\n[2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 8 of\\n31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 8, 'page_label': '9', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='Table 1 Potential benefits and harms of dopamine agonists, levodopa and MAO-B \\ninhibitors \\n- Levodopa Dopamine agonists Monoamine oxidase-B (MAO-B) \\ninhibitors \\nMotor \\nsymptoms \\nMore improvement in \\nmotor symptoms \\nLess improvement in \\nmotor symptoms \\nLess improvement in \\nmotor symptoms \\nActivities of \\ndaily living \\nMore improvement in \\nactivities of daily living \\nLess improvement in \\nactivities of daily living \\nLess improvement in \\nactivities of daily living \\nMotor \\ncomplications \\nMore motor \\ncomplications \\nFewer motor \\ncomplications \\nFewer motor \\ncomplications \\nAdverse \\nevents \\nFewer specified adverse \\nevents \\nMore specified adverse \\nevents \\nFewer specified adverse \\nevents \\n1.3.2 Antiparkinsonian medicines should not be withdrawn abruptly or allowed to fail \\nsuddenly due to poor absorption (for example, gastroenteritis, abdominal \\nsurgery) to avoid the potential for acute akinesia or neuroleptic malignant \\nsyndrome. [2006]'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 8, 'page_label': '9', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"suddenly due to poor absorption (for example, gastroenteritis, abdominal \\nsurgery) to avoid the potential for acute akinesia or neuroleptic malignant \\nsyndrome. [2006] \\n1.3.3 The practice of withdrawing people from their antiparkinsonian drugs (so called \\n'drug holidays') to reduce motor complications should not be undertaken because \\nof the risk of neuroleptic malignant syndrome. [2006] \\n1.3.4 In view of the risks of sudden changes in antiparkinsonian medicines, people with \\nParkinson's disease who are admitted to hospital or care homes should have their \\nmedicines: \\n• given at the appropriate times, which in some cases may mean allowing self-\\nmedication \\n• adjusted by, or adjusted only after discussion with, a specialist in the \\nmanagement of Parkinson's disease. [2006] \\nFirst-line treatment \\n1.3.5 Offer levodopa to people in the early stages of Parkinson's disease whose motor \\nsymptoms impact on their quality of life. [2017] \\nParkinson’s disease in adults (NG71)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 8, 'page_label': '9', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"First-line treatment \\n1.3.5 Offer levodopa to people in the early stages of Parkinson's disease whose motor \\nsymptoms impact on their quality of life. [2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 9 of\\n31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 9, 'page_label': '10', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.3.6 Consider a choice of dopamine agonists, levodopa or monoamine oxidase B \\n(MAO-B) inhibitors for people in the early stages of Parkinson's disease whose \\nmotor symptoms do not impact on their quality of life. [2017] \\n1.3.7 Do not offer ergot-derived dopamine agonists as first-line treatment for \\nParkinson's disease. [2017] \\nFollow the Medicines and Healthcare products Regulatory Agency guidance on \\nthe warnings and contraindications for ergot-derived dopamine agonists. \\nInformation and support \\n1.3.8 When starting treatment for people with Parkinson's disease, give people and \\ntheir family members and carers (as appropriate) oral and written information \\nabout the following risks, and record that the discussion has taken place: \\n• Impulse control disorders with all dopaminergic therapy (and the increased \\nrisk with dopamine agonists). Also see recommendations in the section on \\nmanaging and monitoring impulse control disorders as an adverse effect of \\ndopaminergic therapy\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 9, 'page_label': '10', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"risk with dopamine agonists). Also see recommendations in the section on \\nmanaging and monitoring impulse control disorders as an adverse effect of \\ndopaminergic therapy \\n• Excessive sleepiness and sudden onset of sleep with dopamine agonists. \\nAlso see recommendations on daytime sleepiness in the section on \\npharmacological management of non-motor symptoms \\n• Psychotic symptoms (hallucinations and delusions) with all Parkinson's \\ndisease treatments (and the higher risk with dopamine agonists). Also see \\nthe recommendations on psychotic symptoms (hallucinations and delusions) \\nin the section on pharmacological management of non-motor symptoms. \\n[2017] \\nAdjuvant treatment of motor symptoms \\n1.3.9 If a person with Parkinson's disease has developed dyskinesia and/or motor \\nfluctuations, including medicines 'wearing off', seek advice from a healthcare \\nprofessional with specialist expertise in Parkinson's disease before modifying \\nParkinson’s disease in adults (NG71)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 9, 'page_label': '10', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"fluctuations, including medicines 'wearing off', seek advice from a healthcare \\nprofessional with specialist expertise in Parkinson's disease before modifying \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 10\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 10, 'page_label': '11', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"therapy. [2017] \\n1.3.10 Offer a choice of dopamine agonists, MAO-B inhibitors or catechol-O-methyl \\ntransferase (COMT) inhibitors as an adjunct to levodopa for people with \\nParkinson's disease who have developed dyskinesia or motor fluctuations despite \\noptimal levodopa therapy, after discussing: \\n• the person's individual clinical circumstances, for example, their Parkinson's \\ndisease symptoms, comorbidities and risks from polypharmacy \\n• the person's individual lifestyle circumstances, preferences, needs and goals \\n• the potential benefits and harms of the different drug classes (see table 2). \\n[2017] \\nTable 2 Potential benefits and harms of dopamine agonists, MAO-B inhibitors, COMT \\ninhibitors and amantadine \\n- Dopamine agonists Monoamine oxidase-\\nB (MAO-B) inhibitors \\nCatechol-O-methyl \\ntransferase (COMT) \\ninhibitors \\nAmantadine \\nMotor \\nsymptoms \\nImprovement \\nin motor \\nsymptoms \\nImprovement \\nin motor \\nsymptoms \\nImprovement \\nin motor \\nsymptoms \\nNo evidence of \\nimprovement in\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 10, 'page_label': '11', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='transferase (COMT) \\ninhibitors \\nAmantadine \\nMotor \\nsymptoms \\nImprovement \\nin motor \\nsymptoms \\nImprovement \\nin motor \\nsymptoms \\nImprovement \\nin motor \\nsymptoms \\nNo evidence of \\nimprovement in \\nmotor symptoms \\nActivities of \\ndaily living \\nImprovement \\nin activities of \\ndaily living \\nImprovement \\nin activities of \\ndaily living \\nImprovement \\nin activities of \\ndaily living \\nNo evidence of \\nimprovement in \\nactivities of daily \\nliving \\nOff time More off-time \\nreduction \\nOff-time \\nreduction \\nOff-time \\nreduction \\nNo studies reporting \\nthis outcome \\nAdverse \\nevents \\nIntermediate \\nrisk of adverse \\nevents \\nFewer adverse \\nevents \\nMore adverse \\nevents \\nNo studies reporting \\nthis outcome \\nHallucinations More risk of \\nhallucinations \\nLower risk of \\nhallucinations \\nLower risk of \\nhallucinations \\nNo studies reporting \\nthis outcome \\n1.3.11 Choose a non-ergot-derived dopamine agonist in most cases, because of the \\nmonitoring that is needed with ergot-derived dopamine agonists. [2017]'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 10, 'page_label': '11', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='No studies reporting \\nthis outcome \\n1.3.11 Choose a non-ergot-derived dopamine agonist in most cases, because of the \\nmonitoring that is needed with ergot-derived dopamine agonists. [2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 11 of\\n31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 11, 'page_label': '12', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Follow the Medicines and Healthcare products Regulatory Agency guidance on \\nthe warnings and contraindications for ergot-derived dopamine agonists. \\n1.3.12 Only consider an ergot-derived dopamine agonist as an adjunct to levodopa for \\npeople with Parkinson's disease: \\n• who have developed dyskinesia or motor fluctuations despite optimal \\nlevodopa therapy and \\n• whose symptoms are not adequately controlled with a non-ergot-derived \\ndopamine agonist. [2017] \\nFollow the Medicines and Healthcare products Regulatory Agency guidance \\non the warnings and contraindications for ergot-derived dopamine agonists. \\n1.3.13 If dyskinesia is not adequately managed by modifying existing therapy, consider \\namantadine. [2017] \\n1.3.14 Do not offer anticholinergics to people with Parkinson's disease who have \\ndeveloped dyskinesia and/or motor fluctuations. [2017] \\n1.4 Managing and monitoring impulse control \\ndisorders as an adverse effect of dopaminergic \\ntherapy\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 11, 'page_label': '12', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"developed dyskinesia and/or motor fluctuations. [2017] \\n1.4 Managing and monitoring impulse control \\ndisorders as an adverse effect of dopaminergic \\ntherapy \\nPredictors for the development of impulse control disorders \\n1.4.1 Recognise that impulse control disorders can develop in a person with \\nParkinson's disease who is on any dopaminergic therapy at any stage in the \\ndisease course. [2017] \\n1.4.2 Recognise that the following are associated with an increased risk of developing \\nimpulse control disorders: \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 12\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 12, 'page_label': '13', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='• Dopamine agonist therapy. \\n• A history of previous impulsive behaviours. \\n• A history of alcohol consumption and/or smoking. [2017] \\nInformation and support \\n1.4.3 When starting dopamine agonist therapy, give people and their family members \\nand carers (as appropriate) oral and written information about the following, and \\nrecord that the discussion has taken place: \\n• The increased risk of developing impulse control disorders when taking \\ndopamine agonist therapy, and that these may be concealed by the person \\naffected. \\n• The different types of impulse control disorders (for example, compulsive \\ngambling, hypersexuality, binge eating and obsessive shopping). \\n• Who to contact if impulse control disorders develop. \\n• The possibility that if problematic impulse control disorders develop, \\ndopamine agonist therapy will be reviewed and may be reduced or stopped. \\n[2017] \\n1.4.4 Discuss potential impulse control disorders at review appointments, particularly'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 12, 'page_label': '13', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"dopamine agonist therapy will be reviewed and may be reduced or stopped. \\n[2017] \\n1.4.4 Discuss potential impulse control disorders at review appointments, particularly \\nwhen modifying therapy, and record that the discussion has taken place. [2017] \\n1.4.5 Be aware that impulse control disorders can also develop while taking \\ndopaminergic therapies other than dopamine agonists. [2017] \\nManaging dopaminergic therapy in people who have developed an \\nimpulse control disorder \\n1.4.6 If a person with Parkinson's disease has developed a problematic impulse control \\ndisorder, seek advice from a healthcare professional with specialist expertise in \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 13\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 13, 'page_label': '14', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Parkinson's disease before modifying dopaminergic therapy. [2017] \\n1.4.7 Discuss the following with the person and their family members and carers (as \\nappropriate): \\n• How the impulse control disorder is affecting their life. \\n• Possible treatments, such as reducing or stopping dopaminergic therapy. \\n• The benefits and disadvantages of reducing or stopping dopaminergic \\ntherapy. [2017] \\n1.4.8 When managing impulse control disorders, modify dopaminergic therapy by first \\ngradually reducing any dopamine agonist. Monitor whether the impulse control \\ndisorder improves and whether the person has any symptoms of dopamine \\nagonist withdrawal. [2017] \\n1.4.9 Offer specialist cognitive behavioural therapy targeted at impulse control \\ndisorders if modifying dopaminergic therapy is not effective. [2017] \\n1.5 Pharmacological management of non-motor \\nsymptoms \\nDaytime sleepiness \\n1.5.1 Advise people with Parkinson's disease who have daytime sleepiness and/or\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 13, 'page_label': '14', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.5 Pharmacological management of non-motor \\nsymptoms \\nDaytime sleepiness \\n1.5.1 Advise people with Parkinson's disease who have daytime sleepiness and/or \\nsudden onset of sleep not to drive (and to inform the DVLA of their symptoms) \\nand to think about any occupation hazards. Adjust their medicines to reduce its \\noccurrence, having first sought advice from a healthcare professional with \\nspecialist expertise in Parkinson's disease. [2017] \\n1.5.2 Consider modafinil to treat excessive daytime sleepiness in people with \\nParkinson's disease, only if a detailed sleep history has excluded reversible \\npharmacological and physical causes. [2017] \\nWomen who are pregnant or who are planning a pregnancy should not take \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 14\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 14, 'page_label': '15', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"modafinil, in line with the MHRA safety advice on modafinil. \\n1.5.3 At least every 12 months, a healthcare professional with specialist expertise in \\nParkinson's disease should review people with Parkinson's disease who are \\ntaking modafinil. [2017] \\nWomen who are pregnant or who are planning a pregnancy should not take \\nmodafinil, in line with the MHRA safety advice on modafinil. \\nRestless leg syndrome and rapid eye movement sleep behaviour \\ndisorder \\n1.5.4 Take care to identify and manage restless leg syndrome and rapid eye movement \\nsleep behaviour disorder in people with Parkinson's disease and sleep \\ndisturbance. [2017] \\n1.5.5 Consider clonazepam or melatonin to treat rapid eye movement sleep behaviour \\ndisorder if a medicines review has addressed possible pharmacological causes. \\n[2017] \\nFor guidance on safe prescribing of benzodiazapines (such as clonazepam) and \\nmanaging withdrawal, see NICE's guideline on medicines associated with \\ndependence or withdrawal symptoms.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 14, 'page_label': '15', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"[2017] \\nFor guidance on safe prescribing of benzodiazapines (such as clonazepam) and \\nmanaging withdrawal, see NICE's guideline on medicines associated with \\ndependence or withdrawal symptoms. \\nIn July 2017, this was an off-label use of clonazepam and melatonin. See NICE's \\ninformation on prescribing medicines. \\nNocturnal akinesia \\n1.5.6 Consider levodopa or oral dopamine agonists to treat nocturnal akinesia in people \\nwith Parkinson's disease. If the selected option is not effective or not tolerated, \\noffer the other instead. [2017] \\n1.5.7 Consider rotigotine if levodopa and/or oral dopamine agonists are not effective in \\ntreating nocturnal akinesia. [2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 15\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 15, 'page_label': '16', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Orthostatic hypotension \\n1.5.8 If a person with Parkinson's disease has developed orthostatic hypotension, \\nreview the person's existing medicines to address possible pharmacological \\ncauses, including: \\n• antihypertensives (including diuretics) \\n• dopaminergics \\n• anticholinergics \\n• antidepressants. [2017] \\n1.5.9 Consider midodrine for people with Parkinson's disease and orthostatic \\nhypotension, taking into account the contraindications and monitoring \\nrequirements (including monitoring for supine hypertension). [2017] \\n1.5.10 If midodrine is contraindicated, not tolerated or not effective, consider \\nfludrocortisone (taking into account its safety profile, in particular its cardiac risk \\nand potential interactions with other medicines). [2017] \\nIn July 2017, this was an off-label use of fludrocortisone. See NICE's information \\non prescribing medicines. \\nDepression \\n1.5.11 For guidance on identifying, treating and managing depression in people with\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 15, 'page_label': '16', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"on prescribing medicines. \\nDepression \\n1.5.11 For guidance on identifying, treating and managing depression in people with \\nParkinson's disease, see the NICE guideline on depression in adults with a \\nchronic physical health problem. [2017] \\nPsychotic symptoms (hallucinations and delusions) \\nIn July 2017, the use of quetiapine in recommendations 1.5.16 and 1.5.18 was off-label. \\nSee NICE's information on prescribing medicines. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 16\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 16, 'page_label': '17', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.5.12 At review appointments and following medicines changes, ask people with \\nParkinson's disease and their family members and carers (as appropriate) if the \\nperson is experiencing hallucinations (particularly visual) or delusions. [2017] \\n1.5.13 Perform a general medical evaluation for people with hallucinations or delusions, \\nand offer treatment for any conditions that might have triggered them. [2017] \\n1.5.14 Do not treat hallucinations and delusions if they are well tolerated by the person \\nwith Parkinson's disease and their family members and carers (as appropriate). \\n[2017] \\n1.5.15 Reduce the dosage of any Parkinson's disease medicines that might have \\ntriggered hallucinations or delusions, taking into account the severity of \\nsymptoms and possible withdrawal effects. Seek advice from a healthcare \\nprofessional with specialist expertise in Parkinson's disease before modifying \\ntherapy. [2017] \\n1.5.16 Consider quetiapine to treat hallucinations and delusions in people with\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 16, 'page_label': '17', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"professional with specialist expertise in Parkinson's disease before modifying \\ntherapy. [2017] \\n1.5.16 Consider quetiapine to treat hallucinations and delusions in people with \\nParkinson's disease who have no cognitive impairment. [2017] \\n1.5.17 If standard treatment is not effective, offer clozapine to treat hallucinations and \\ndelusions in people with Parkinson's disease. Be aware that registration with a \\npatient monitoring service is needed. [2017] \\n1.5.18 Be aware that lower doses of quetiapine and clozapine are needed for people \\nwith Parkinson's disease than in other indications. [2017] \\n1.5.19 Do not offer olanzapine to treat hallucinations and delusions in people with \\nParkinson's disease. [2017] \\n1.5.20 Recognise that other antipsychotic medicines (such as phenothiazines and \\nbutyrophenones) can worsen the motor features of Parkinson's disease. [2017] \\n1.5.21 For guidance on hallucinations and delusions in people with dementia, see the\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 16, 'page_label': '17', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"butyrophenones) can worsen the motor features of Parkinson's disease. [2017] \\n1.5.21 For guidance on hallucinations and delusions in people with dementia, see the \\nsection on managing non-cognitive symptoms in the NICE guideline on dementia. \\n[2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 17\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 17, 'page_label': '18', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Parkinson's disease dementia \\n1.5.22 Offer a cholinesterase inhibitor for people with mild or moderate Parkinson's \\ndisease dementia. [2017] \\nIn July 2017, rivastigmine capsules are the only treatment with a UK marketing \\nauthorisation for this indication. Use of donepezil, galantamine and rivastigmine \\npatches was off-label. See NICE's information on prescribing medicines. \\n1.5.23 Consider a cholinesterase inhibitor for people with severe Parkinson's disease \\ndementia. [2017] \\nIn July 2017, this was an off-label use of cholinesterase inhibitors. See NICE's \\ninformation on prescribing medicines. \\n1.5.24 Consider memantine for people with Parkinson's disease dementia, only if \\ncholinesterase inhibitors are not tolerated or are contraindicated. [2017] \\nIn July 2017, this was an off-label use of memantine. See NICE's information on \\nprescribing medicines. \\n1.5.25 For guidance on assessing and managing dementia, and supporting people living\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 17, 'page_label': '18', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"In July 2017, this was an off-label use of memantine. See NICE's information on \\nprescribing medicines. \\n1.5.25 For guidance on assessing and managing dementia, and supporting people living \\nwith dementia, see the NICE guideline on dementia. [2017] \\nDrooling of saliva \\n1.5.26 Consider pharmacological management for drooling of saliva in people with \\nParkinson's disease if non-pharmacological management (for example, speech \\nand language therapy; see recommendation 1.7.8) is not available or has not been \\neffective. [2017] \\n1.5.27 Consider glycopyrronium bromide to manage drooling of saliva in people with \\nParkinson's disease. [2017] \\nIn July 2017, this was an off-label use of glycopyrronium bromide. See NICE's \\ninformation on prescribing medicines. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 18\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 18, 'page_label': '19', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.5.28 Consider referral to a specialist service for botulinum toxin A. [2017] \\nXeomin (botulinum neurotoxin type A) is recommended as an option in NICE \\ntechnology appraisal guidance for treating chronic sialorrhoea caused by \\nneurological conditions in adults. For full details, see the guidance on Xeomin \\n(botulinum neurotoxin type A), TA605 (2019). \\n1.5.29 Only consider anticholinergic medicines other than glycopyrronium bromide to \\nmanage drooling of saliva in people with Parkinson's disease if their risk of \\ncognitive adverse effects is thought to be minimal. Use topical preparations if \\npossible (for example, atropine) to reduce the risk of adverse events. [2017] \\n1.6 Pharmacological neuroprotective therapy \\n1.6.1 Do not use vitamin E as a neuroprotective therapy for people with Parkinson's \\ndisease. [2006, amended 2017] \\n1.6.2 Do not use co-enzyme Q10 as a neuroprotective therapy for people with \\nParkinson's disease, except in the context of clinical trials. [2006, amended\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 18, 'page_label': '19', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"disease. [2006, amended 2017] \\n1.6.2 Do not use co-enzyme Q10 as a neuroprotective therapy for people with \\nParkinson's disease, except in the context of clinical trials. [2006, amended \\n2017] \\n1.6.3 Do not use dopamine agonists as neuroprotective therapies for people with \\nParkinson's disease, except in the context of clinical trials. [2006, amended \\n2017] \\n1.6.4 Do not use MAO-B inhibitors as neuroprotective therapies for people with \\nParkinson's disease, except in the context of clinical trials. [2006, amended \\n2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 19\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 19, 'page_label': '20', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.7 Non-pharmacological management of motor and \\nnon-motor symptoms \\nParkinson's disease nurse specialist interventions \\n1.7.1 People with Parkinson's disease should have regular access to: \\n• clinical monitoring and medicines adjustment \\n• a continuing point of contact for support, including home visits when \\nappropriate \\n• a reliable source of information about clinical and social matters of concern to \\npeople with Parkinson's disease and their family members and their carers \\n(as appropriate), \\nwhich may be provided by a Parkinson's disease nurse specialist. [2006] \\nPhysiotherapy and physical activity \\n1.7.2 Consider referring people who are in the early stages of Parkinson's disease to a \\nphysiotherapist with experience of Parkinson's disease for assessment, \\neducation and advice, including information about physical activity. [2017] \\n1.7.3 Offer Parkinson's disease-specific physiotherapy for people who are experiencing \\nbalance or motor function problems. [2017]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 19, 'page_label': '20', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.7.3 Offer Parkinson's disease-specific physiotherapy for people who are experiencing \\nbalance or motor function problems. [2017] \\n1.7.4 Consider the Alexander Technique for people with Parkinson's disease who are \\nexperiencing balance or motor function problems. [2017] \\nOccupational therapy \\n1.7.5 Consider referring people who are in the early stages of Parkinson's disease to an \\noccupational therapist with experience of Parkinson's disease for assessment, \\neducation and advice on motor and non-motor symptoms. [2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 20\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 20, 'page_label': '21', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.7.6 Offer Parkinson's disease-specific occupational therapy for people who are \\nhaving difficulties with activities of daily living. [2017] \\nSpeech and language therapy \\n1.7.7 Consider referring people who are in the early stages of Parkinson's disease to a \\nspeech and language therapist with experience of Parkinson's disease for \\nassessment, education and advice. [2017] \\n1.7.8 Offer speech and language therapy for people with Parkinson's disease who are \\nexperiencing problems with communication, swallowing or saliva. This should \\ninclude: \\n• strategies to improve the safety and efficiency of swallowing to minimise the \\nrisk of aspiration, such as expiratory muscle strength training (EMST) \\n• strategies to improve speech and communication, such as attention to effort \\ntherapies. [2017] \\n1.7.9 Consider referring people for alternative and augmentative communication \\nequipment that meets their communication needs as Parkinson's disease \\nprogresses and their needs change. [2017]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 20, 'page_label': '21', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.7.9 Consider referring people for alternative and augmentative communication \\nequipment that meets their communication needs as Parkinson's disease \\nprogresses and their needs change. [2017] \\nNutrition \\n1.7.10 Consider referring people with Parkinson's disease to a dietitian for specialist \\nadvice. [2017] \\n1.7.11 Discuss a diet in which most of the protein is eaten in the final main meal of the \\nday (a protein redistribution diet) for people with Parkinson's disease on levodopa \\nwho experience motor fluctuations. [2017] \\n1.7.12 Advise people with Parkinson's disease to avoid a reduction in their total daily \\nprotein consumption. [2017] \\n1.7.13 Advise people with Parkinson's disease to take a vitamin D supplement. See the \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 21\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 21, 'page_label': '22', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"NICE guideline on vitamin D for recommendations on vitamin D testing, and the \\nNICE guidelines on falls in older people and osteoporosis. [2017] \\n1.7.14 Do not offer creatine supplements to people with Parkinson's disease. [2017] \\n1.7.15 Advise people with Parkinson's disease not to take over-the-counter dietary \\nsupplements without first consulting their pharmacist or other healthcare \\nprofessional. [2017] \\n1.8 Treating advanced Parkinson's disease \\n1.8.1 Offer people with advanced Parkinson's disease best medical therapy, which may \\ninclude intermittent apomorphine injection and/or continuous subcutaneous \\napomorphine infusion. [2017] \\n1.8.2 Do not offer deep brain stimulation to people with Parkinson's disease whose \\nsymptoms are adequately controlled by best medical therapy. [2017] \\n1.8.3 Consider deep brain stimulation for people with advanced Parkinson's disease \\nwhose symptoms are not adequately controlled by best medical therapy. [2017]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 21, 'page_label': '22', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.8.3 Consider deep brain stimulation for people with advanced Parkinson's disease \\nwhose symptoms are not adequately controlled by best medical therapy. [2017] \\n1.8.4 Foslevodopa–foscarbidopa is recommended as an option in NICE technology \\nappraisal guidance for treating advanced levodopa-responsive Parkinson's \\ndisease in adults whose symptoms include severe motor fluctuations and \\nhyperkinesia or dyskinesia when available medicines are not working well enough \\nand they cannot have apomorphine or deep brain stimulation, or these treatments \\nno longer control symptoms. For full details, see the guidance on \\nfoslevodopa–foscarbidopa (TA934, 2023). \\nSee also NHS England's clinical commissioning policy on levodopa–carbidopa intestinal gel \\nfor details about the use of this treatment. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 22\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 22, 'page_label': '23', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"1.9 Palliative care \\nInformation and support \\n1.9.1 Offer people with Parkinson's disease and their family members and carers (as \\nappropriate) opportunities to discuss the prognosis of their condition. These \\ndiscussions should promote people's priorities, shared decision-making and \\npatient-centred care. [2017] \\n1.9.2 Offer people with Parkinson's disease and their family members and carers (as \\nappropriate) oral and written information about the following, and record that the \\ndiscussion has taken place: \\n• Progression of Parkinson's disease. \\n• Possible future adverse effects of Parkinson's disease medicines in advanced \\nParkinson's disease. \\n• Advance care planning, including Advance Decisions to Refuse Treatment \\n(ADRT) and Do Not Attempt Resuscitation (DNACPR) orders, and Lasting \\nPower of Attorney for finance and/or health and social care. \\n• Options for future management. \\n• What could happen at the end of life.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 22, 'page_label': '23', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Power of Attorney for finance and/or health and social care. \\n• Options for future management. \\n• What could happen at the end of life. \\n• Available support services, for example, personal care, equipment and \\npractical support, financial support and advice, care at home and respite \\ncare. [2017] \\n1.9.3 When discussing palliative care, recognise that family members and carers may \\nhave different information needs from the person with Parkinson's disease. \\n[2017] \\nReferral \\n1.9.4 Consider referring people at any stage of Parkinson's disease to the palliative \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 23\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 23, 'page_label': '24', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='care team to give them and their family members or carers (as appropriate) the \\nopportunity to discuss palliative care and care at the end of life. [2017] \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 24\\nof 31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 24, 'page_label': '25', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Recommendations for research \\nThe guideline committee has made the following recommendations for research. The \\ncommittee's full set of research recommendations is detailed in the full guideline. \\n1 Combination treatment for Parkinson's disease \\ndementia \\nWhat is the effectiveness of combination treatment with a cholinesterase inhibitor and \\nmemantine for people with Parkinson's disease dementia if treatment with a \\ncholinesterase inhibitor alone is not effective or no longer effective? \\nWhy this is important \\nThe guideline committee felt that cholinesterase inhibitors, memantine and combination \\ntherapy with both treatments are all reasonable clinical options, but noted that some \\npeople do not tolerate cholinesterase inhibitors well due to side effects. The evidence \\nbase for memantine was considerably weaker than for cholinesterase inhibitors, and \\ntherefore there would be value in either additional trials of memantine compared with\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 24, 'page_label': '25', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"base for memantine was considerably weaker than for cholinesterase inhibitors, and \\ntherefore there would be value in either additional trials of memantine compared with \\nplacebo (in people for whom cholinesterase inhibitors are not an option), or non-inferiority \\nstudies compared with cholinesterase inhibitors. \\nIn clinical practice, memantine is often added to a cholinesterase inhibitor when it is no \\nlonger proving effective, but there is no evidence base for this and randomised trials to \\nestablish whether there is additional benefit would be valuable. Both of these questions \\ncould potentially be answered in a single study with 3 arms of memantine monotherapy, \\ncholinesterase inhibitor monotherapy and combination treatment. \\n2 Orthostatic hypotension treatment \\nFor people with Parkinson's disease, what is the most effective pharmacological treatment \\nfor orthostatic hypotension? \\nParticular interventions and comparisons of interest are: \\nParkinson’s disease in adults (NG71)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 24, 'page_label': '25', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='for orthostatic hypotension? \\nParticular interventions and comparisons of interest are: \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 25\\nof 31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 25, 'page_label': '26', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"• midodrine compared with fludrocortisone (primary comparison) \\n• pyridostigmine \\n• ephedrine \\n• pseudoephedrine. \\nWhy this is important \\nThe guideline committee felt that orthostatic hypotension was an important practical \\nproblem, common in people with Parkinson's disease and a contributor to falls and injuries. \\nThe current best pharmacological treatment is not yet established and research in this \\narea would help to determine this. The randomised controlled trials that have previously \\nbeen undertaken have only provided low-quality evidence (because of both small sample \\nsizes and weaknesses in the trial designs) and cover only a subset of the comparisons of \\ninterest, making future research in this area of value. \\n3 Psychotic symptoms (hallucinations and \\ndelusions) \\nWhat is the effectiveness of rivastigmine compared with atypical antipsychotic drugs for \\ntreating psychotic symptoms (particularly hallucinations and delusions) associated with \\nParkinson's disease?\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 25, 'page_label': '26', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"treating psychotic symptoms (particularly hallucinations and delusions) associated with \\nParkinson's disease? \\nWhy this is important \\nRivastigmine is commonly used to treat Parkinson's disease psychosis because it has \\nshown some effectiveness in improving behavioural symptoms in people with Parkinson's \\ndisease dementia. At present, no evidence exists to support the efficacy of rivastigmine in \\ntreating people with Parkinson's disease whose symptoms are predominantly psychotic. It \\nwould be beneficial to undertake primary research in this area to determine the most \\neffective treatment options for managing Parkinson's disease psychosis. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 26\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 26, 'page_label': '27', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"4 Rapid eye movement sleep behaviour disorder \\ntreatment \\nWhat is the best first-line treatment for rapid eye movement sleep behaviour disorder \\n(RBD) in people with Parkinson's disease? \\nWhy this is important \\nThe guideline committee highlighted the importance of minimising RBD, for both people \\nwith Parkinson's disease and their carers, particularly because of potential safety \\nconcerns. Only 1 paper was found to address optimal management, and this involved \\npeople in whom first-line treatment had failed. With multiple possible treatment options \\nand no current evidence on what the most effective first-line treatment is, research (in the \\nform of randomised controlled trials) in this area would be beneficial. \\n5 Physiotherapy \\nDoes physiotherapy started early in the course of Parkinson's disease, as opposed to after \\nmotor symptom onset, confer benefits in terms of delaying symptom onset and/or \\nreducing severity? \\nWhy this is important\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 26, 'page_label': '27', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"motor symptom onset, confer benefits in terms of delaying symptom onset and/or \\nreducing severity? \\nWhy this is important \\nThe guideline committee felt that physiotherapy was beneficial for those earlier in the \\ncourse of the disease as it may delay or lessen problems associated with symptoms, as \\nwell as for those who have developed symptoms and problems. At present, no substantial \\nevidence exists to support the efficacy of physiotherapy as an early intervention to \\nprevent the onset or reduce severity of motor symptoms, because most of the trials have \\nbeen conducted in people who have already developed motor symptoms. \\nIf physiotherapy were shown to have a beneficial effect in either delaying the onset or \\ndecreasing the severity of symptoms, this would have a substantial beneficial impact on \\nthe quality of life of people with Parkinson's disease and their family and carers. Relevant \\ntrials would not compare physiotherapy with no physiotherapy, but rather early\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 26, 'page_label': '27', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"the quality of life of people with Parkinson's disease and their family and carers. Relevant \\ntrials would not compare physiotherapy with no physiotherapy, but rather early \\nphysiotherapy (at the time of diagnosis) with physiotherapy offered at the current \\nstandard times in the UK. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 27\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 27, 'page_label': '28', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Context \\nParkinson's disease is a progressive neurodegenerative condition resulting from the death \\nof dopamine-containing cells of the substantia nigra in the brain. There is no consistently \\nreliable test that can distinguish Parkinson's disease from other conditions that have a \\nsimilar clinical presentation. The diagnosis is primarily based on a clinical history and \\nexamination. \\nParkinson's disease is one of the most common neurological conditions. It is estimated to \\naffect up to 160 people per 100,000, with an annual incidence in the UK of 15 to 20 \\nper 100,000. \\nPeople with Parkinson's disease classically present with the symptoms and signs \\ndescribed as 'parkinsonism': these include bradykinesia (slow movements), rigidity, rest \\ntremor (shaking) and postural instability (loss of balance). \\nThe symptoms of parkinsonism are not always a result of Parkinson's disease. Other \\ncauses include side effects of medicines, vascular disease, and less common degenerative\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 27, 'page_label': '28', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"The symptoms of parkinsonism are not always a result of Parkinson's disease. Other \\ncauses include side effects of medicines, vascular disease, and less common degenerative \\nconditions such as progressive supranuclear palsy and multiple system atrophy. \\nParkinson's disease has historically been recognised as a primary movement disorder; \\nhowever, other symptoms may be prominent, such as depression, cognitive impairment \\nand dementia. In the later stages of the disease, people may develop pain and autonomic \\ndisturbances (such as dizziness and fainting, and problems with sweating, heart rate, \\ndigestion, vision and sexual function). These other symptoms are sometimes described as \\nthe 'non-motor' manifestations of Parkinson's disease. The condition may progress to \\ncause significant impairments, adversely affecting quality of life and, indirectly, the quality \\nof life of family and carers. \\nParkinson’s disease in adults (NG71)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 27, 'page_label': '28', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='cause significant impairments, adversely affecting quality of life and, indirectly, the quality \\nof life of family and carers. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 28\\nof 31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 28, 'page_label': '29', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Finding more information and committee \\ndetails \\nTo find NICE guidance on related topics, including guidance in development, see the NICE \\ntopic page on neurological conditions. \\nFor full details of the guideline committee's discussion and the evidence reviews, see the \\nfull guideline. You can also find information about how the guideline was developed, \\nincluding details of the committee. \\nNICE has produced tools and resources to help you put this guideline into practice. For \\ngeneral help and advice on putting our guidelines into practice, see resources to help you \\nput NICE guidance into practice. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 29\\nof 31\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 29, 'page_label': '30', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"Update information \\nJuly 2017: We have reviewed the evidence and made new recommendations on treating \\nParkinson's disease symptoms, deep brain stimulation, monitoring and managing impulse \\ncontrol disorders, and palliative care. These recommendations are marked [2017]. \\nWe have also made some changes without an evidence review: \\n• changes made to clarify the action of a recommendation \\n• the timeframe for referral was removed because it was not evidence based. \\nThese recommendations are marked [2006, amended 2017]. \\nRecommendations marked [2006] last had an evidence review in 2006. In some cases \\nminor changes have been made to the wording to bring the language and style up to date, \\nwithout changing the meaning. \\nMinor changes since publication \\nFebruary 2025: We removed recommendation 1.8.5 on the availability of \\nlevodopa–carbidopa intestinal gel and replaced it with a link to NHS England \\ncommissioning policy on the use of this treatment.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 29, 'page_label': '30', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content=\"levodopa–carbidopa intestinal gel and replaced it with a link to NHS England \\ncommissioning policy on the use of this treatment. \\nDecember 2024: We added links to relevant technology appraisal guidance in the sections \\non drooling of saliva and treating advanced Parkinson's disease. \\nMay 2022: We added a link to NICE's guideline on medicines associated with dependence \\nor withdrawal symptoms in section 1.5. \\nMarch 2022: The heading above recommendations 1.5.4 and 1.5.5 was amended to clarify \\nthat this section covers both restless leg syndrome and rapid eye movement sleep \\nbehaviour disorder, and the abbreviation RBD was written out in full for clarity. \\nDecember 2020: We added advice for women who are pregnant or who are planning a \\npregnancy to recommendations 1.5.2 and 1.5.3, in line with the MHRA safety advice on \\nmodafinil. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 29, 'page_label': '30', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='modafinil. \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 30\\nof 31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '', 'keywords': 'NG71', 'subject': 'Parkinson’s disease in adults (NG71)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Parkinson’s disease in adults', 'source': '../data/pdf_files/parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'total_pages': 31, 'page': 30, 'page_label': '31', 'source_file': 'parkinsons-disease-in-adults-pdf-1837629189061.pdf', 'file_type': 'pdf'}, page_content='September 2020: We linked to the NICE guideline on supporting adult carers in \\nrecommendation 1.1.4 and incorporated footnotes into the recommendations in line with \\naccessibility requirements. \\nOctober 2019: Information was added to reflect a change in marketing authorisation \\nstatus for botulinum neurotoxin type A preparations. \\nISBN: 978-1-4731-2530-8 \\nParkinson’s disease in adults (NG71)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 31\\nof 31'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 0, 'page_label': '1', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Motor neurone disease: \\nassessment and \\nmanagement \\nNICE guideline \\nPublished: 24 February 2016 \\nLast updated: 23 July 2019 \\nwww.nice.org.uk/guidance/ng42 \\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 1, 'page_label': '2', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Your responsibility \\nThe recommendations in this guideline represent the view of NICE, arrived at after careful \\nconsideration of the evidence available. When exercising their judgement, professionals \\nand practitioners are expected to take this guideline fully into account, alongside the \\nindividual needs, preferences and values of their patients or the people using their service. \\nIt is not mandatory to apply the recommendations, and the guideline does not override the \\nresponsibility to make decisions appropriate to the circumstances of the individual, in \\nconsultation with them and their families and carers or guardian. \\nAll problems (adverse events) related to a medicine or medical device used for treatment \\nor in a procedure should be reported to the Medicines and Healthcare products Regulatory \\nAgency using the Yellow Card Scheme. \\nLocal commissioners and providers of healthcare have a responsibility to enable the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 1, 'page_label': '2', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Agency using the Yellow Card Scheme. \\nLocal commissioners and providers of healthcare have a responsibility to enable the \\nguideline to be applied when individual professionals and people using services wish to \\nuse it. They should do so in the context of local and national priorities for funding and \\ndeveloping services, and in light of their duties to have due regard to the need to eliminate \\nunlawful discrimination, to advance equality of opportunity and to reduce health \\ninequalities. Nothing in this guideline should be interpreted in a way that would be \\ninconsistent with complying with those duties. \\nCommissioners and providers have a responsibility to promote an environmentally \\nsustainable health and care system and should assess and reduce the environmental \\nimpact of implementing NICE recommendations wherever possible. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 1, 'page_label': '2', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Motor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 2 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 2, 'page_label': '3', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Contents \\nOverview .................................................................................................................................... 5 \\nWho is it for? ......................................................................................................................................... 5 \\nRecommendations ..................................................................................................................... 6 \\n1.1 Recognition and referral ................................................................................................................. 6 \\n1.2 Information and support at diagnosis .......................................................................................... 7 \\n1.3 Cognitive assessments .................................................................................................................. 10'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 2, 'page_label': '3', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.3 Cognitive assessments .................................................................................................................. 10 \\n1.4 Prognostic factors .......................................................................................................................... 10 \\n1.5 Organisation of care ....................................................................................................................... 11 \\n1.6 Psychological and social care support ......................................................................................... 14 \\n1.7 Planning for end of life ................................................................................................................... 16 \\n1.8 Managing symptoms ...................................................................................................................... 18'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 2, 'page_label': '3', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.8 Managing symptoms ...................................................................................................................... 18 \\n1.9 Disease-modifying treatment ........................................................................................................ 21 \\n1.10 Equipment and adaptations to aid activities of daily living and mobility ................................. 21 \\n1.11 Nutrition and gastrostomy ............................................................................................................ 22 \\n1.12 Communication ............................................................................................................................. 24 \\n1.13 Respiratory function and respiratory symptoms ....................................................................... 25 \\n1.14 Cough effectiveness ..................................................................................................................... 26'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 2, 'page_label': '3', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.14 Cough effectiveness ..................................................................................................................... 26 \\n1.15 Non-invasive ventilation ............................................................................................................... 26 \\nContext ....................................................................................................................................... 38 \\nRecommendations for research ............................................................................................... 40 \\n1 Organisation of care .......................................................................................................................... 40 \\n2 Cognitive assessment ...................................................................................................................... 40'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 2, 'page_label': '3', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='2 Cognitive assessment ...................................................................................................................... 40 \\n3 Prognostic tools ................................................................................................................................ 41 \\n4 Saliva .................................................................................................................................................. 41 \\n5 Nutrition ............................................................................................................................................. 42 \\n6 Augmentative and alternative communication ............................................................................... 42 \\nFinding more information and committee details ................................................................... 43 \\nMotor neurone disease: assessment and management (NG42)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 2, 'page_label': '3', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Finding more information and committee details ................................................................... 43 \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 3 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 3, 'page_label': '4', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Update information ................................................................................................................... 44 \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 4 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 4, 'page_label': '5', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='This guideline replaces CG105. \\nThis guideline is the basis of QS126. \\nOverview \\nThis guideline covers assessing and managing motor neurone disease (MND). It aims to \\nimprove care from the time of diagnosis, and covers information and support, organisation \\nof care, managing symptoms and preparing for end of life care. \\nMHRA advice on gabapentin: In July 2019 we linked to new MHRA safety advice on \\nprescribing gabapentin. As of 1 April 2019, because of a risk of abuse and dependence \\ngabapentin is controlled under the Misuse of Drugs Act 1971 as a class C substance and is \\nscheduled under the Misuse of Drugs Regulations 2001 as schedule 3. \\nWho is it for? \\n• Healthcare professionals and social care practitioners caring for and supporting adults \\nwith MND \\n• Commissioners and providers of MND health and social care services \\n• Adults with MND, their families and carers \\nMotor neurone disease: assessment and management (NG42)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 4, 'page_label': '5', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='with MND \\n• Commissioners and providers of MND health and social care services \\n• Adults with MND, their families and carers \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 5 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 5, 'page_label': '6', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Recommendations \\nPeople have the right to be involved in discussions and make informed decisions \\nabout their care, as described in making decisions about your care. \\nMaking decisions using NICE guidelines explains how we use words to show the \\nstrength (or certainty) or our recommendations, and has information about \\nprescribing medicines (including off-label use), professional guidelines, standards \\nand laws (including on consent and mental capacity), and safeguarding. \\n1.1 Recognition and referral \\n1.1.1 Ensure that robust protocols and pathways are in place to: \\n• inform healthcare professionals about motor neurone disease (MND) and how \\nit may present \\n• inform healthcare professionals in all settings about local referral \\narrangements \\n• ensure continued and integrated care for people with MND across all care \\nsettings. [2016] \\n1.1.2 Be aware that MND causes progressive muscular weakness that may first present \\nas isolated and unexplained symptoms. These symptoms may include:'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 5, 'page_label': '6', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='settings. [2016] \\n1.1.2 Be aware that MND causes progressive muscular weakness that may first present \\nas isolated and unexplained symptoms. These symptoms may include: \\n• functional effects of muscle weakness, such as loss of dexterity, falls or trips \\n• speech or swallowing problems, or tongue fasciculations (this is known as \\nbulbar presentation) \\n• muscle problems, such as weakness, wasting, twitching, cramps and \\nstiffness \\n• breathing problems, such as shortness of breath on exertion or respiratory \\nsymptoms that are hard to explain \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 6 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 6, 'page_label': '7', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• effects of reduced respiratory function, such as excessive daytime \\nsleepiness, fatigue, early morning headache or shortness of breath when \\nlying down. [2016] \\n1.1.3 Be aware that MND may first present with cognitive features, which may include: \\n• behavioural changes \\n• emotional lability (not related to dementia) \\n• frontotemporal dementia. [2016] \\n1.1.4 If you suspect MND, refer the person without delay and specify the possible \\ndiagnosis in the referral letter. Contact the consultant neurologist directly if you \\nthink the person needs to be seen urgently. [2016] \\n1.1.5 Provide information and support for people and their family members and/or \\ncarers (as appropriate) throughout the diagnostic process, particularly during \\nperiods of diagnostic uncertainty or delay. [2016] \\n1.2 Information and support at diagnosis \\nPlease also refer to the recommendations in the NICE guideline on patient experience in'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 6, 'page_label': '7', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='periods of diagnostic uncertainty or delay. [2016] \\n1.2 Information and support at diagnosis \\nPlease also refer to the recommendations in the NICE guideline on patient experience in \\nadult NHS services, which includes recommendations on communication, information and \\ncoordination of care. \\n1.2.1 Information about the diagnosis, prognosis and management of MND should be \\ngiven by a consultant neurologist with up-to-date knowledge and experience of \\ntreating people with MND unless it is clinically necessary to give the diagnosis in \\nan urgent situation. The neurologist should have knowledge and expertise in the \\nfollowing: \\n• Symptoms of MND. \\n• Types and possible causes of MND. \\n• Treatment options. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 7 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 7, 'page_label': '8', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• How MND may progress (including cognitive and behavioural changes) and \\nhow progression may affect the treatments offered. \\n• Crisis prevention (for example, if there is an acute hospital admission or a \\nbreakdown in care arrangements). \\n• Opportunities for people with MND to be involved in research. \\n• Likely needs and concerns of people with MND and their family members \\nand/or carers (as appropriate). \\n• Advance care planning. [2016] \\n1.2.2 Ask people about how much information they wish to receive about MND, and \\nabout their preferences for involving their family members and/or carers (as \\nappropriate). [2016] \\n1.2.3 Ensure people are provided with information about MND and support at diagnosis \\nor when they ask for it. If the person agrees, share the information with their \\nfamily members and/or carers (as appropriate). Information should be oral and \\nwritten, and may include the following: \\n• What MND is. \\n• Types and possible causes.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 7, 'page_label': '8', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"family members and/or carers (as appropriate). Information should be oral and \\nwritten, and may include the following: \\n• What MND is. \\n• Types and possible causes. \\n• Likely symptoms and how they can be managed. \\n• How MND may progress. \\n• Treatment options. \\n• Where the person's appointments will take place. \\n• Which healthcare professionals and social care practitioners will undertake \\nthe person's care. \\n• Expected waiting times for consultations, investigations and treatments. \\n• Local services (including social care and specialist palliative care services) \\nand how to get in touch with them. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 8 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 8, 'page_label': '9', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• Local support groups, online forums and national charities, and how to get in \\ntouch with them. \\n• Legal rights, including social care support, employment rights and benefits. \\n• Requirements for disclosure, such as notifying the Driver and Vehicle \\nLicensing Agency (DVLA). \\n• Opportunities for advance care planning. [2016] \\n1.2.4 When MND is diagnosed, provide people with a single point of contact for the \\nspecialist MND multidisciplinary team (see section 1.5). Provide information about \\nwhat to do if there are any concerns between assessments or appointments, \\nduring 'out-of-hours' or in an emergency, or if there is a problem with equipment. \\n[2016] \\n1.2.5 Offer the person with MND a face-to-face, follow-up appointment with a \\nhealthcare professional from the multidisciplinary team, to take place within \\n4 weeks of diagnosis. [2016] \\n1.2.6 When MND is suspected or confirmed, inform the person's GP without delay and \\nprovide information about the likely prognosis. [2016]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 8, 'page_label': '9', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"4 weeks of diagnosis. [2016] \\n1.2.6 When MND is suspected or confirmed, inform the person's GP without delay and \\nprovide information about the likely prognosis. [2016] \\n1.2.7 Set aside enough time to discuss the person's concerns and questions, which \\nmay include the following: \\n• What will happen to me? \\n• Are there any treatments available? \\n• Is there a cure? \\n• How long will I live? \\n• What will the impact on my day-to-day life be? \\n• What will happen next with my healthcare? \\n• Will my children get MND? \\n• How do I tell my family and friends? \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 9 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 9, 'page_label': '10', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• How will I die? [2016] \\n1.2.8 If the person has any social care needs, refer them to social services for an \\nassessment. Be aware that some people with MND may not have informal care \\navailable, and may live alone or care for someone else. [2016] \\n1.2.9 Advise carers about their right to carer assessment, and assessment for respite \\ncare and other support (see the NICE guideline on supporting adult carers for \\nrecommendations on identifying, assessing and meeting the caring, physical and \\nmental health needs of families and carers). [2016] \\n1.3 Cognitive assessments \\nPlease also refer to the recommendations in the NICE guideline on patient experience in \\nadult NHS services. \\n1.3.1 Be aware that people with MND and frontotemporal dementia may lack mental \\ncapacity. Care should be provided in line with the Mental Capacity Act 2005. \\n[2016] \\n1.3.2 At diagnosis, and if there is concern about cognition and behaviour, explore any'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 9, 'page_label': '10', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"capacity. Care should be provided in line with the Mental Capacity Act 2005. \\n[2016] \\n1.3.2 At diagnosis, and if there is concern about cognition and behaviour, explore any \\ncognitive or behavioural changes with the person and their family members and/\\nor carers as appropriate. If needed, refer the person for a formal assessment in \\nline with the NICE guideline on dementia. [2016] \\n1.3.3 Tailor all discussions to the person's needs, taking into account their \\ncommunication ability, cognitive status and mental capacity. [2016] \\n1.4 Prognostic factors \\n1.4.1 When planning care take into account the following prognostic factors, which are \\nassociated with shorter survival if they are present at diagnosis: \\n• Speech and swallowing problems (bulbar presentation). \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 10 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 10, 'page_label': '11', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• Weight loss. \\n• Poor respiratory function. \\n• Older age. \\n• Lower Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS or \\nALSFRS-R) score. \\n• Shorter time from first developing symptoms to time of diagnosis. [2016] \\n1.5 Organisation of care \\n1.5.1 Provide coordinated care for people with MND, using a clinic-based, specialist \\nMND multidisciplinary team approach. The clinic may be community or hospital \\nbased. [2016] \\n1.5.2 The multidisciplinary team should: \\n• include healthcare professionals and social care practitioners with expertise \\nin MND, and staff who see people in their home \\n• ensure effective communication and coordination between all healthcare \\nprofessionals and social care practitioners involved in the person's care and \\ntheir family members and/or carers (as appropriate) \\n• carry out regular, coordinated assessments at the multidisciplinary team \\nclinic (usually every 2 to 3 months) to assess people's symptoms and needs\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 10, 'page_label': '11', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• carry out regular, coordinated assessments at the multidisciplinary team \\nclinic (usually every 2 to 3 months) to assess people's symptoms and needs \\n• provide coordinated care for people who cannot attend the clinic, according \\nto the person's needs. [2016] \\n1.5.3 The multidisciplinary team should assess, manage and review the following areas, \\nincluding the person's response to treatment: \\n• Weight, diet, nutritional intake and fluid intake, feeding and swallowing (see \\nsection 1.11). \\n• Muscle problems, such as weakness, stiffness and cramps (see \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 11 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 11, 'page_label': '12', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='recommendations 1.8.1 to 1.8.9). \\n• Physical function, including mobility and activities of daily living (see section \\n1.10). \\n• Saliva problems, such as drooling of saliva (sialorrhoea) and thick, tenacious \\nsaliva (see recommendations 1.8.10 to 1.8.15). \\n• Speech and communication (see section 1.12). \\n• Cough effectiveness (see section 1.14). \\n• Respiratory function, respiratory symptoms and non-invasive ventilation (see \\nsection 1.13 and section 1.15). \\n• Pain and other symptoms, such as constipation. \\n• Cognition and behaviour (see section 1.3). \\n• Psychological support needs (see recommendations 1.6.1 to 1.6.4). \\n• Social care needs (see recommendations 1.6.5 and 1.6.6). \\n• End of life care needs (see section 1.7). \\n• Information and support needs for the person and their family members and/\\nor carers (as appropriate) (see section 1.2). [2016] \\n1.5.4 The core multidisciplinary team should consist of healthcare professionals and'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 11, 'page_label': '12', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='or carers (as appropriate) (see section 1.2). [2016] \\n1.5.4 The core multidisciplinary team should consist of healthcare professionals and \\nother professionals with expertise in MND, and should include the following: \\n• Neurologist. \\n• Specialist nurse. \\n• Dietitian. \\n• Physiotherapist. \\n• Occupational therapist. \\n• Respiratory physiologist or a healthcare professional who can assess \\nrespiratory function. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 12 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 12, 'page_label': '13', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• Speech and language therapist. \\n• A healthcare professional with expertise in palliative care (MND palliative care \\nexpertise may be provided by the neurologist or nurse in the multidisciplinary \\nteam, or by a specialist palliative care professional). [2016] \\n1.5.5 The multidisciplinary team should have established relationships with, and \\nprompt access to, the following: \\n• Clinical psychology and neuropsychology. \\n• Social care. \\n• Counselling. \\n• Respiratory ventilation services. \\n• Specialist palliative care. \\n• Gastroenterology. \\n• Orthotics. \\n• Wheelchair services. \\n• Assistive technology services. \\n• Alternative and augmentative communication (AAC) services. \\n• Community neurological care teams. [2016] \\n1.5.6 Tailor the frequency of the multidisciplinary team assessments to the person's \\nsymptoms and needs, with more or less frequent assessments as needed. [2016] \\n1.5.7 Ensure arrangements are in place to trigger an earlier multidisciplinary team\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 12, 'page_label': '13', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"symptoms and needs, with more or less frequent assessments as needed. [2016] \\n1.5.7 Ensure arrangements are in place to trigger an earlier multidisciplinary team \\nassessment if there is a significant change in symptoms identified by the person, \\nfamily members and/or carers (as appropriate), or healthcare professionals. \\n[2016] \\n1.5.8 Tailor the multidisciplinary team assessment to the person's needs, for example, \\nadjust the format if the person has cognitive or behaviour changes or difficulties \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 13 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 13, 'page_label': '14', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"with communication. [2016] \\n1.5.9 Inform all healthcare professionals and social care practitioners involved in the \\nperson's care about key decisions reached with the person and their family \\nmembers and/or carers (as appropriate). [2016] \\n1.5.10 Ensure that all healthcare professionals and social care practitioners involved in \\nthe person's care are aware that MND symptoms may get worse quickly, and that \\npeople with MND will need repeated, ongoing assessments. Priority should be \\ngiven to ensuring continuity of care and avoiding untimely case closure. [2016] \\n1.5.11 Consider referral to a specialist palliative care team for people with current or \\nanticipated significant or complex needs, for example, psychological or social \\ndistress, troublesome or rapidly progressing symptoms and complex future care \\nplanning needs. [2016] \\n1.6 Psychological and social care support \\n1.6.1 During multidisciplinary team assessments and other appointments, discuss the\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 13, 'page_label': '14', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='planning needs. [2016] \\n1.6 Psychological and social care support \\n1.6.1 During multidisciplinary team assessments and other appointments, discuss the \\npsychological and emotional impact of MND with the person and ask whether \\nthey have any psychological or support care needs. Topics to discuss may \\ninclude the following: \\n• Their understanding of MND and how it affects daily living. \\n• Accepting and coping with the diagnosis and prognosis, including concerns \\nand fears about dying. \\n• Their ability to continue with current work and usual activities. \\n• Adjusting to changes in their life and their perception of self. \\n• Changes in relationships, familial roles and family dynamics. \\n• Sexuality and intimacy. \\n• Concerns about their family members and/or carers. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 14 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 14, 'page_label': '15', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• Decision-making. [2016] \\n1.6.2 Offer the person information about sources of emotional and psychological \\nsupport, including support groups and online forums. If needed, refer the person \\nto counselling or psychology services for a specialist assessment and support. \\n[2016] \\n1.6.3 During multidisciplinary team assessments and other appointments, discuss the \\npsychological and emotional impact of MND with family members and/or carers \\n(as appropriate), and ask whether they have any psychological or social care \\nsupport needs. Topics to discuss may include the following: \\n• Their understanding of MND and how it affects daily living. \\n• Accepting and coping with the diagnosis and prognosis, including concerns \\nand fears about the person with MND dying. \\n• Adjusting to changes in their life. \\n• Changes in relationships, familial roles and family dynamics, including their \\nchange to a carer role (if appropriate). \\n• Sexuality and intimacy. \\n• Involvement in decision-making.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 14, 'page_label': '15', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• Changes in relationships, familial roles and family dynamics, including their \\nchange to a carer role (if appropriate). \\n• Sexuality and intimacy. \\n• Involvement in decision-making. \\n• Impact on other family members and/or carers. \\n• Their ability and willingness to provide personal care and operate equipment. \\nSee the NICE guideline on supporting adult carers for recommendations on \\nidentifying, assessing and meeting the caring, physical and mental health \\nneeds of families and carers. [2016] \\n1.6.4 Offer family members and/or carers (as appropriate) information about respite \\ncare and sources of emotional and psychological support, including support \\ngroups, online forums and counselling or psychology services. [2016] \\n1.6.5 A social care practitioner with knowledge of MND or rapidly progressive complex \\ndisabilities should discuss the person's needs and preferences for social care, \\nMotor neurone disease: assessment and management (NG42)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 14, 'page_label': '15', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"disabilities should discuss the person's needs and preferences for social care, \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 15 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 15, 'page_label': '16', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"and provide information and support for them to access the following: \\n• Personal care, ensuring there is continuity of care with familiar workers, so \\nthat wherever possible, personal care and support is carried out by workers \\nknown to the person and their family members and/or carers (as \\nappropriate). \\n• Equipment and practical support (see section 1.10). \\n• Financial support and advice (for example, money management, how to \\naccess carers' and disability benefits and grants, continuing healthcare \\nfunding and funeral expenses). \\n• Support to engage in work, social activities and hobbies, such as access to \\nsocial media and physical access to activities outside their home. \\n• Respite care. [2016] \\n1.6.6 Be aware that as MND progresses, people may develop communication problems \\nand have difficulty accessing support or services. For example, they may be \\nunable to access a call centre. Ensure people are given different ways of getting\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 15, 'page_label': '16', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"and have difficulty accessing support or services. For example, they may be \\nunable to access a call centre. Ensure people are given different ways of getting \\nin touch with support or services, and a designated contact if possible. [2016] \\n1.7 Planning for end of life \\n1.7.1 Offer the person with MND the opportunity to discuss their preferences and \\nconcerns about care at the end of life at trigger points such as: at diagnosis, if \\nthere is a significant change in respiratory function, or if interventions such as \\ngastrostomy or non-invasive ventilation are needed. Be sensitive about the timing \\nof discussions and take into account the person's current communication ability, \\ncognitive status and mental capacity. [2016] \\n1.7.2 Be prepared to discuss end of life issues whenever people wish to do so. [2016] \\n1.7.3 Provide support and advice on advance care planning for end of life. Topics to \\ndiscuss may include:\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 15, 'page_label': '16', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.7.2 Be prepared to discuss end of life issues whenever people wish to do so. [2016] \\n1.7.3 Provide support and advice on advance care planning for end of life. Topics to \\ndiscuss may include: \\n• What could happen at the end of life, for example, how death may occur. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 16 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 16, 'page_label': '17', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• Providing anticipatory medicines in the home. \\n• Advance care planning, including Advance Decisions to Refuse Treatment \\n(ADRT) and Do Not Attempt Resuscitation (DNACPR) orders, and Lasting \\nPower of Attorney. \\n• How to ensure advance care plans will be available when needed, for \\nexample, including the information on the person's Summary Care Record. \\n• When to involve specialist palliative care. \\n• Areas that people might wish to plan for, such as: \\n－ what they want to happen (for example, their preferred place of death) \\n－ what they do not want to happen (for example, being admitted to \\nhospital) \\n－ who will represent their decisions, if necessary \\n－ what should happen if they develop an intercurrent illness. [2016] \\n1.7.4 Think about discussing advance care planning with people at an earlier \\nopportunity if you expect their communication ability, cognitive status or mental \\ncapacity to get worse. [2016]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 16, 'page_label': '17', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"1.7.4 Think about discussing advance care planning with people at an earlier \\nopportunity if you expect their communication ability, cognitive status or mental \\ncapacity to get worse. [2016] \\n1.7.5 Offer people the opportunity to talk about, and review any existing, ADRT, \\nDNACPR orders and Lasting Power of Attorney when interventions such as \\ngastrostomy and non-invasive ventilation are planned. [2016] \\n1.7.6 Provide additional support as the end of life approaches, for example, additional \\nsocial or nursing care to enable informal carers and family to reduce their carer \\nresponsibilities and spend time with the person with MND. [2016] \\n1.7.7 Towards the end of life, ensure there is prompt access to the following, if not \\nalready provided: \\n• A method of communication that meets the person's needs, such as an AAC \\nsystem. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 16, 'page_label': '17', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='system. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 17 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 17, 'page_label': '18', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• Specialist palliative care. \\n• Equipment, if needed, such as syringe drivers, suction machines, \\nriser–recliner chair, hospital bed, commode and hoist. \\n• Anticipatory medicines, including opioids and benzodiazepines to treat \\nbreathlessness, and antimuscarinic medicines to treat problematic saliva and \\nrespiratory secretions. [2016] \\n1.7.8 Offer bereavement support to family members and/or carers (as appropriate). \\n[2016] \\n1.8 Managing symptoms \\nPharmacological treatments for muscle problems \\n1.8.1 Discuss the available treatment options for muscle problems. Take into account \\nthe person's needs and preferences, and whether they have any difficulties \\ntaking medicine (for example, if they have problems swallowing). [2016] \\n1.8.2 Consider quinine as first-line treatment for muscle cramps in people with MND. If \\nquinine is not effective, not tolerated or contraindicated, consider baclofen \\ninstead as second-line treatment. If baclofen is not effective, not tolerated or\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 17, 'page_label': '18', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"quinine is not effective, not tolerated or contraindicated, consider baclofen \\ninstead as second-line treatment. If baclofen is not effective, not tolerated or \\ncontraindicated, consider tizanidine, dantrolene or gabapentin. \\nIn February 2016 this was an off-label use of quinine, baclofen, tizanidine, and \\ndantrolene. See NICE's information on prescribing medicines and the MHRA \\nsafety advice on prescribing gabapentin. [2016] \\n1.8.3 Consider baclofen, tizanidine, dantrolene or gabapentin to treat muscle stiffness, \\nspasticity or increased tone in people with MND. If these treatments are not \\neffective, not tolerated or contraindicated, consider referral to a specialist service \\nfor the treatment of severe spasticity. \\nIn February 2016 this was an off-label use of dantrolene. See NICE's information \\non prescribing medicines and the MHRA safety advice on prescribing gabapentin. \\nMotor neurone disease: assessment and management (NG42)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 17, 'page_label': '18', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='on prescribing medicines and the MHRA safety advice on prescribing gabapentin. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 18 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 18, 'page_label': '19', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"[2016] \\n1.8.4 Review the treatments for muscle problems during multidisciplinary team \\nassessments, ask about how the person is finding the treatment, whether it is \\nworking and whether they have any adverse side effects. [2016] \\nExercise programmes \\n1.8.5 Consider an exercise programme for people with MND to: \\n• maintain joint range of movement \\n• prevent contractures \\n• reduce stiffness and discomfort \\n• optimise function and quality of life. [2016] \\n1.8.6 Choose a programme that is appropriate to the person's level of function and \\ntailored to their needs, abilities and preferences. Take into account factors such \\nas postural needs and fatigue. The programme might be a resistance programme, \\nan active-assisted programme or a passive programme. [2016] \\n1.8.7 Check that family members and/or carers (as appropriate) are willing and able to \\nhelp with exercise programmes. [2016] \\n1.8.8 Give advice to the person and their family members and/or carers (as\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 18, 'page_label': '19', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='help with exercise programmes. [2016] \\n1.8.8 Give advice to the person and their family members and/or carers (as \\nappropriate) about safe manual handling. [2016] \\n1.8.9 If a person needs orthoses to help with muscle problems, they should be referred \\nto orthotics services without delay, and the orthoses should be provided without \\ndelay. [2016] \\nSaliva problems \\n1.8.10 If a person with MND has problems with saliva, assess the volume and viscosity \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 19 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 19, 'page_label': '20', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"of the saliva and the person's respiratory function, swallowing, diet, posture and \\noral care. [2016] \\n1.8.11 If a person with MND has problems with drooling of saliva (sialorrhoea), provide \\nadvice on swallowing, diet, posture, positioning, oral care and suctioning. [2016] \\n1.8.12 Consider a trial of an antimuscarinic medicine as a first-line treatment for \\nsialorrhoea in people with MND. \\nIn February 2016 this was an off-label use of antimuscarinic medicines. See \\nNICE's information on prescribing medicines. [2016] \\n1.8.13 Consider glycopyrronium bromide as a first-line treatment for sialorrhoea in \\npeople with MND who have cognitive impairment, because it has fewer central \\nnervous system side effects. \\nIn February 2016 this was an off-label use of glycopyrronium bromide. See NICE's \\ninformation on prescribing medicines. [2016] \\n1.8.14 Consider referral to a specialist service for botulinum toxin A for first- or second-\\nline treatment. [2016, amended 2024]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 19, 'page_label': '20', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='information on prescribing medicines. [2016] \\n1.8.14 Consider referral to a specialist service for botulinum toxin A for first- or second-\\nline treatment. [2016, amended 2024] \\nXeomin (botulinum neurotoxin type A) is recommended as an option in NICE \\ntechnology appraisal guidance for treating chronic sialorrhoea caused by \\nneurological conditions in adults. For full details, see the guidance on Xeomin \\n(TA605, 2019). \\n1.8.15 If a person with MND has thick, tenacious saliva: \\n• review all current medicines, especially any treatments for sialorrhoea \\n• provide advice on swallowing, diet, posture, positioning, oral care, suctioning \\nand hydration \\n• consider treatment with humidification, nebulisers and carbocisteine. [2016] \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 20 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 20, 'page_label': '21', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"1.9 Disease-modifying treatment \\n1.9.1 Riluzole is recommended as an option in NICE technology appraisal guidance for \\npeople with the amyotrophic lateral sclerosis form of MND. For full details, see the \\nguidance on riluzole (TA20, 2001). [2016] \\n1.10 Equipment and adaptations to aid activities of \\ndaily living and mobility \\n1.10.1 Healthcare professionals and social care practitioners, which will include \\nphysiotherapists and occupational therapists, should assess and anticipate \\nchanges in the person's daily living needs, taking into account the following: \\n• Activities of daily living, including personal care, dressing and bathing, \\nhousework, shopping, food preparation, eating and drinking, and ability to \\ncontinue with current work and usual activities. \\n• Mobility and avoiding falls and problems from loss of dexterity. \\n• The home environment and the need for adaptations. \\n• The need for assistive technology, such as environmental control systems. \\n[2016]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 20, 'page_label': '21', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• The home environment and the need for adaptations. \\n• The need for assistive technology, such as environmental control systems. \\n[2016] \\n1.10.2 Provide equipment and adaptations that meet the person's needs without delay, \\nso that people can participate in activities of daily living and maintain their quality \\nof life as much as possible. [2016] \\n1.10.3 Refer people to specialist services without delay if assistive technology such as \\nenvironmental control systems is needed. People should be assessed and \\nassistive technology provided without delay. [2016] \\n1.10.4 Refer people to wheelchair services without delay if needed. Wheelchair needs \\nshould be assessed and a manual and/or powered wheelchair that meets the \\nperson's needs should be provided without delay. [2016] \\n1.10.5 Ensure that equipment, adaptations, daily living aids, assistive technology and \\nMotor neurone disease: assessment and management (NG42)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 20, 'page_label': '21', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.10.5 Ensure that equipment, adaptations, daily living aids, assistive technology and \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 21 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 21, 'page_label': '22', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"wheelchairs meet the changing needs of the person and their family and/or \\ncarers (as appropriate) to maximise mobility and participation in activities of daily \\nliving. [2016] \\n1.10.6 Ensure regular, ongoing monitoring of the person's mobility and daily life needs \\nand abilities as MND progresses. Regularly review their ability to use equipment \\nand to adapt equipment as necessary. [2016] \\n1.10.7 Healthcare professionals, social care practitioners and other services providing \\nequipment should liaise to ensure that all equipment provided can be integrated, \\nfor example, integrating AAC aids and devices and environmental control systems \\nwith wheelchairs. [2016] \\n1.10.8 Enable prompt access and assessment for funding for home adaptation. If the \\nperson is not eligible for funding, continue to offer information and support in \\narranging home environment adaptations. [2016] \\n1.11 Nutrition and gastrostomy\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 21, 'page_label': '22', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"person is not eligible for funding, continue to offer information and support in \\narranging home environment adaptations. [2016] \\n1.11 Nutrition and gastrostomy \\nPlease also refer to the recommendations in the NICE guideline on nutrition support for \\nadults. \\n1.11.1 At diagnosis and at multidisciplinary team assessments, or if there are any \\nconcerns about weight, nutrition or swallowing, assess the person's weight, diet, \\nnutritional intake, fluid intake, hydration, oral health, feeding, drinking and \\nswallowing, and offer support, advice and interventions as needed. [2016] \\n1.11.2 Assess the person's diet, hydration, nutritional intake and fluid intake by taking \\ninto account: \\n• fluids and food intake versus nutritional and hydration needs \\n• nutritional supplements, if needed \\n• appetite and thirst \\n• gastrointestinal symptoms, such as nausea or constipation \\nMotor neurone disease: assessment and management (NG42)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 21, 'page_label': '22', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• nutritional supplements, if needed \\n• appetite and thirst \\n• gastrointestinal symptoms, such as nausea or constipation \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 22 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 22, 'page_label': '23', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• causes of reduced oral intake (for example, swallowing difficulties, limb \\nweakness or the possibility of low mood or depression causing loss of \\nappetite). [2016] \\n1.11.3 Assess the person's ability to eat and drink by taking into account: \\n• the need for eating and drinking aids and altered utensils to help them take \\nfood from the plate to their mouth \\n• the need for help with food and drink preparation \\n• advice and aids for positioning, seating and posture while eating and drinking \\n• dealing with social situations (for example, eating out). [2016] \\n1.11.4 Arrange for a clinical swallowing assessment if swallowing problems are \\nsuspected. [2016] \\n1.11.5 Assess and manage factors that may contribute to problems with swallowing, \\nsuch as: \\n• positioning \\n• seating \\n• the need to modify food and drink consistency and palatability \\n• respiratory symptoms and risk of aspiration and/or choking \\n• fear of choking and psychological considerations (for example, wanting to eat\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 22, 'page_label': '23', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• respiratory symptoms and risk of aspiration and/or choking \\n• fear of choking and psychological considerations (for example, wanting to eat \\nand drink without assistance in social situations). [2016] \\n1.11.6 Discuss gastrostomy at an early stage, and at regular intervals as MND \\nprogresses, taking into account the person's preferences and issues, such as \\nability to swallow, weight loss, respiratory function, effort of feeding and drinking \\nand risk of choking. Be aware that some people will not want to have a \\ngastrostomy. [2016] \\n1.11.7 Explain the benefits of early placement of a gastrostomy, and the possible risks \\nof a late gastrostomy (for example, low critical body mass, respiratory \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 23 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 23, 'page_label': '24', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"complications, risk of dehydration, different methods of insertion, and a higher \\nrisk of mortality and procedural complications). [2016] \\n1.11.8 If a person is referred for a gastrostomy, it should take place without unnecessary \\ndelay. [2016] \\n1.11.9 Pay particular attention to the nutritional and hydration needs of people with \\nMND who have frontotemporal dementia and who lack mental capacity. The \\nmultidisciplinary team assessment should include the support they need from \\ncarers, and their ability to understand the risks of swallowing difficulties. [2016] \\n1.11.10 Before a decision is made on the use of gastrostomy for a person with MND who \\nhas frontotemporal dementia, the neurologist from the multidisciplinary team \\nshould assess the following: \\n• The person's ability to make decisions and to give consent (see Mental \\nCapacity Act 2005). \\n• The severity of frontotemporal dementia and cognitive problems. \\n• Whether the person is likely to accept and cope with treatment.\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 23, 'page_label': '24', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"Capacity Act 2005). \\n• The severity of frontotemporal dementia and cognitive problems. \\n• Whether the person is likely to accept and cope with treatment. \\nDiscuss with the person's family members and/or carers (as appropriate; with \\nthe person's consent if they have the ability to give it). [2016] \\n1.12 Communication \\n1.12.1 When assessing speech and communication needs during multidisciplinary team \\nassessments and other appointments, discuss face-to-face and remote \\ncommunication, for example, using the telephone, email, the Internet and social \\nmedia. Ensure that the assessment and review is carried out by a speech and \\nlanguage therapist without delay. [2016] \\n1.12.2 Provide AAC equipment that meets the needs of the person without delay to \\nmaximise participation in activities of daily living and maintain quality of life. The \\nuse of both low-level technologies, for example, alphabet, word or picture boards\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 23, 'page_label': '24', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='maximise participation in activities of daily living and maintain quality of life. The \\nuse of both low-level technologies, for example, alphabet, word or picture boards \\nand high-level technologies, for example, PC or tablet-based voice output \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 24 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 24, 'page_label': '25', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"communication aids may be helpful. Review the person's communication needs \\nduring multidisciplinary team assessments. [2016] \\n1.12.3 Liaise with, or refer the person with MND to, a specialised NHS AAC hub if \\ncomplex high technology AAC equipment (for example, eye gaze access) is \\nneeded or is likely to be needed. [2016] \\n1.12.4 Involve other healthcare professionals, such as occupational therapists, to ensure \\nthat AAC equipment is integrated with other assistive technologies, such as \\nenvironmental control systems and personal computers or tablets. [2016] \\n1.12.5 Ensure regular, ongoing monitoring of the person's communication needs and \\nabilities as MND progresses, and review their ability to use AAC equipment. \\nReassess and liaise with a specialised NHS AAC hub if needed. [2016] \\n1.12.6 Provide ongoing support and training for the person with MND, and their family \\nmembers and/or carers (as appropriate), in using AAC equipment and other \\ncommunication strategies. [2016]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 24, 'page_label': '25', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"1.12.6 Provide ongoing support and training for the person with MND, and their family \\nmembers and/or carers (as appropriate), in using AAC equipment and other \\ncommunication strategies. [2016] \\n1.13 Respiratory function and respiratory symptoms \\n1.13.1 Assess and monitor the person's respiratory function and symptoms. Treat \\npeople with MND and worsening respiratory impairment for reversible causes (for \\nexample, respiratory tract infections or secretion problems) before considering \\nother treatments. [2016] \\n1.13.2 Offer non-invasive ventilation as treatment for people with respiratory impairment \\n(see section 1.15). Decisions to offer non-invasive ventilation should be made by \\nthe multidisciplinary team in conjunction with the respiratory ventilation service, \\nand the person (see recommendations 1.5.1 to 1.5.5). [2016] \\n1.13.3 Consider urgent introduction of non-invasive ventilation for people with MND who\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 24, 'page_label': '25', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='and the person (see recommendations 1.5.1 to 1.5.5). [2016] \\n1.13.3 Consider urgent introduction of non-invasive ventilation for people with MND who \\ndevelop worsening respiratory impairment and are not already using non-invasive \\nventilation. [2016] \\n1.13.4 Consider opioids as an option to relieve symptoms of breathlessness. Take into \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 25 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 25, 'page_label': '26', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"account the route of administration and acquisition cost of medicines. \\nIn February 2016 this was an off-label use of opioids. See NICE's information on \\nprescribing medicines for more information. [2016] \\n1.13.5 Consider benzodiazepines to manage breathlessness that is exacerbated by \\nanxiety. Take into account the route of administration and acquisition cost of \\nmedicines. \\nIn February 2016 this was an off-label use of benzodiazepines. See NICE's \\ninformation on prescribing medicines. [2016] \\n1.14 Cough effectiveness \\n1.14.1 Offer cough augmentation techniques such as manual assisted cough to people \\nwith MND who cannot cough effectively. [2016] \\n1.14.2 Consider unassisted breath stacking and/or manual assisted cough as the \\nfirst-line treatment for people with MND who have an ineffective cough. [2016] \\n1.14.3 For people with bulbar dysfunction, or whose cough is ineffective with unassisted \\nbreath stacking, consider assisted breath stacking (for example, using a lung\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 25, 'page_label': '26', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.14.3 For people with bulbar dysfunction, or whose cough is ineffective with unassisted \\nbreath stacking, consider assisted breath stacking (for example, using a lung \\nvolume recruitment bag). [2016] \\n1.14.4 Consider a mechanical cough assist device if assisted breath stacking is not \\neffective, and/or during a respiratory tract infection. [2016] \\n1.15 Non-invasive ventilation \\nInformation and support about non-invasive ventilation \\n1.15.1 Offer to discuss the possible use of non-invasive ventilation with the person and \\n(if the person agrees) their family and carers, at an appropriate time and in a \\nsensitive manner. This may be at one or more of the following times: \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 26 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 26, 'page_label': '27', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• soon after MND is first diagnosed \\n• when monitoring respiratory function \\n• when respiratory function deteriorates \\n• if the person asks for information. [2010] \\n1.15.2 Discussions about non-invasive ventilation should be appropriate to the stage of \\nthe person's illness, carried out in a sensitive manner and include information on: \\n• the possible symptoms and signs of respiratory impairment (see table 1) \\n• the purpose, nature and timing of respiratory function tests, and explanations \\nof the test results \\n• how non-invasive ventilation (as a treatment option) can improve symptoms \\nassociated with respiratory impairment and can be life prolonging, but does \\nnot stop progression of the underlying disease. [2010, amended 2016] \\n1.15.3 When discussing non-invasive ventilation, explain the different ways that people \\ncan manage their breathlessness symptoms. This should include: \\n• non-invasive ventilation, and its advantages and disadvantages\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 26, 'page_label': '27', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"can manage their breathlessness symptoms. This should include: \\n• non-invasive ventilation, and its advantages and disadvantages \\n• using non-invasive ventilation at different points in the course of the person's \\nlifetime \\n• the possibility of the person becoming dependent on non-invasive ventilation \\n• options for treating any infections \\n• support and information on how to recognise and cope with a distressing \\nsituation \\n• the role of medication for breathing problems \\n• psychological techniques and support. [2016] \\n1.15.4 Check that the person thinking about non-invasive ventilation: \\n• understands what non-invasive ventilation is and what it can achieve \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 27 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 27, 'page_label': '28', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• recognises the need for regular review \\n• has enough information about non-invasive ventilation and other options for \\nbreathing problems to make decisions about how and when to use it. \\n• understands possible problems with compatibility with other equipment, for \\nexample, eye gaze access systems. [2016] \\n1.15.5 Explain that non-invasive ventilation can be stopped at any time. Reassure people \\nthat they can ask for help and advice if they need it, especially if they are \\ndependent on non-invasive ventilation for 24 hours a day, or become distressed \\nwhen attempting to stop it. Inform people that medicines can be used to alleviate \\nsymptoms (see recommendation 1.15.29). [2016] \\n1.15.6 Ensure that families and carers: \\n• have an initial assessment if the person they care for decides to use \\nnon-invasive ventilation, which should include: \\n－ their ability and willingness to assist in providing non-invasive ventilation \\n－ their training needs'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 27, 'page_label': '28', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='non-invasive ventilation, which should include: \\n－ their ability and willingness to assist in providing non-invasive ventilation \\n－ their training needs \\n• have the opportunity to discuss any concerns they may have with members \\nof the multidisciplinary team, the respiratory ventilation service and/or other \\nhealthcare professionals. [2010] \\nIdentification and assessment of respiratory impairment \\nSymptoms and signs \\n1.15.7 Monitor the symptoms and signs listed in table 1 to detect potential respiratory \\nimpairment. [2010, amended 2016] \\nTable 1 Symptoms and signs of potential respiratory impairment \\nSymptoms Signs \\nBreathlessness Increased respiratory rate \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 28 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 28, 'page_label': '29', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"Symptoms Signs \\nOrthopnoea Shallow breathing \\nRecurrent chest infections Weak cough \\nDisturbed sleep Weak sniff \\nNon-refreshing sleep Abdominal paradox (inward movement of the abdomen \\nduring inspiration) \\nNightmares Use of accessory muscles of respiration \\nDaytime sleepiness Reduced chest expansion on maximal inspiration \\nPoor concentration and/or \\nmemory – \\nConfusion – \\nHallucinations – \\nMorning headaches – \\nFatigue – \\nPoor appetite – \\nWeak cough could be assessed by measuring peak cough flow. \\nRespiratory function tests \\n1.15.8 As part of the initial assessment to diagnose MND, or soon after diagnosis, a \\nhealthcare professional from the multidisciplinary team who has appropriate \\ncompetencies should perform the following tests (or arrange for them to be \\nperformed) to establish the person's baseline respiratory function: \\n• oxygen saturation measured by pulse oximetry (SpO2): \\n－ this should be a single measurement of SpO2 with the person at rest and \\nbreathing room air\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 28, 'page_label': '29', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• oxygen saturation measured by pulse oximetry (SpO2): \\n－ this should be a single measurement of SpO2 with the person at rest and \\nbreathing room air \\n－ if it is not possible to perform pulse oximetry locally, refer the person to a \\nrespiratory ventilation service. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 29 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 29, 'page_label': '30', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Then one or both of the following: \\n• forced vital capacity (FVC) or vital capacity (VC) \\n• sniff nasal inspiratory pressure (SNIP) and/or maximal inspiratory pressure \\n(MIP). [2010] \\nBe aware that some pulse oximeters can underestimate or overestimate \\noxygen saturation levels, especially if the saturation level is borderline. \\nOverestimation has been reported in people with dark skin. See also the NHS \\nEngland Patient Safety Alert on the risk of harm from inappropriate \\nplacement of pulse oximeter probes. \\n1.15.9 If the person has severe bulbar impairment or severe cognitive problems that may \\nbe related to respiratory impairment: \\n• ensure that SpO2 is measured (at rest and breathing room air) \\n• do not perform the other respiratory function tests (FVC, VC, SNIP and MIP) if \\ninterfaces are not suitable for the person. [2010] \\n1.15.10 A healthcare professional with appropriate competencies should perform the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 29, 'page_label': '30', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"interfaces are not suitable for the person. [2010] \\n1.15.10 A healthcare professional with appropriate competencies should perform the \\nrespiratory function tests every 2 to 3 months, although tests may be performed \\nmore or less often depending on: \\n• whether there are any symptoms and signs of respiratory impairment (see \\ntable 1) \\n• the rate of progression of MND \\n• the person's preference and circumstances. [2010, amended 2016] \\n1.15.11 Perform arterial or capillary blood gas analysis if the person's SpO2 (measured at \\nrest and breathing room air): \\n• is less than or equal to 92% if they have known lung disease \\n• is less than or equal to 94% if they do not have lung disease. \\nIf it is not possible to perform arterial or capillary blood gas analysis locally, \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 30 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 30, 'page_label': '31', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"refer the person to a respiratory ventilation service. [2010] \\n1.15.12 If the person's SpO2 (measured at rest and breathing room air) is greater than \\n94%, or 92% for those with lung disease, but they have sleep-related respiratory \\nsymptoms: \\n• consider referring them to a respiratory ventilation service for continuous \\nnocturnal (overnight) oximetry and/or a limited sleep study and \\n• discuss both the impact of respiratory impairment and treatment options with \\nthe patient and (if the person agrees) their family and carers. [2010] \\n1.15.13 If the person's arterial partial pressure of carbon dioxide (PaCO2) is greater than \\n6 kPa: \\n• refer them urgently to a respiratory ventilation service (to be seen within \\n1 week) and \\n• explain the reasons for and implications of the urgent referral to the person \\nand (if the person agrees) their family and carers. [2010] \\n1.15.14 If the person's PaCO2 is less than or equal to 6 kPa but they have any symptoms\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 30, 'page_label': '31', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"and (if the person agrees) their family and carers. [2010] \\n1.15.14 If the person's PaCO2 is less than or equal to 6 kPa but they have any symptoms \\nor signs of respiratory impairment, particularly orthopnoea (see recommendation \\n1.15.15): \\n• refer them to a respiratory ventilation service for nocturnal (overnight) \\noximetry and/or a limited sleep study and \\n• discuss both the impact of respiratory impairment and treatment options with \\nthe person and (if the person agrees) their family and/or carers (as \\nappropriate). [2010] \\n1.15.15 If any of the results listed in table 2 is obtained, discuss with the person and (if \\nappropriate) their family and carers: \\n• their respiratory impairment \\n• their treatment options \\n• possible referral to a respiratory ventilation service for further assessment \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 30, 'page_label': '31', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Motor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 31 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 31, 'page_label': '32', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='based on discussion with the person, and their wishes. [2010, amended \\n2016] \\nTable 2 Results of respiratory function tests \\nForced vital capacity (FVC) or vital capacity (VC) Sniff nasal inspiratory pressure (SNIP) and/or maximal \\ninspiratory pressure (MIP) \\nFVC or VC less than 50% of predicted \\nvalue SNIP or MIP less than 40 cmH2O \\nFVC or VC less than 80% of predicted \\nvalue plus any symptoms or signs of \\nrespiratory impairment (see \\nrecommendation 1.15.7), particularly \\northopnoea \\nSNIP or MIP less than 65 cmH2O for men or \\n55 cmH2O for women plus any symptoms or \\nsigns of respiratory impairment (see \\nrecommendation 1.15.7), particularly \\northopnoea \\n– \\nRepeated regular tests show a rate of \\ndecrease of SNIP or MIP of more than \\n10 cm H2O per 3 months \\nPeople with a diagnosis of frontotemporal dementia \\n1.15.16 Base decisions on respiratory function tests for a person with a diagnosis of \\nfrontotemporal dementia on considerations specific to their needs and \\ncircumstances, such as:'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 31, 'page_label': '32', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.15.16 Base decisions on respiratory function tests for a person with a diagnosis of \\nfrontotemporal dementia on considerations specific to their needs and \\ncircumstances, such as: \\n• their ability to give consent \\n• their understanding of the tests \\n• their tolerance of the tests and willingness to undertake them \\n• the impact on their family and carers \\n• whether they are capable of receiving non-invasive ventilation. [2010, \\namended 2016] \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 32 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 32, 'page_label': '33', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"Non-invasive ventilation for treatment of respiratory impairment \\nin people with MND \\n1.15.17 Offer a trial of non-invasive ventilation if the person's symptoms and signs and \\nthe results of the respiratory function tests indicate that the person is likely to \\nbenefit from the treatment. [2010, amended 2016] \\n1.15.18 Consider a trial of non-invasive ventilation for a person who has severe bulbar \\nimpairment or severe cognitive problems that may be related to respiratory \\nimpairment only if they may benefit from an improvement in sleep-related \\nsymptoms or correction of hypoventilation. [2010, amended 2016] \\n1.15.19 Before starting non-invasive ventilation, the multidisciplinary team together with \\nthe respiratory ventilation service should carry out and coordinate a \\npatient-centred risk assessment, after discussion with the person and their family \\nand carers. This should consider: \\n• the most appropriate type of non-invasive ventilator and interfaces, based on\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 32, 'page_label': '33', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"patient-centred risk assessment, after discussion with the person and their family \\nand carers. This should consider: \\n• the most appropriate type of non-invasive ventilator and interfaces, based on \\nthe person's needs and lifestyle factors and safety \\n• the person's tolerance of the treatment \\n• the risk, and possible consequences, of ventilator failure \\n• the power supply required, including battery back-up \\n• how easily the person can get to hospital \\n• risks associated with travelling away from home (especially abroad) \\n• whether a humidifier is required \\n• issues relating to secretion management \\n• the availability of carers. [2010] \\n1.15.20 Before starting non-invasive ventilation, the multidisciplinary team together with \\nthe respiratory ventilation service should prepare a comprehensive care plan, \\nafter discussion with the person and their family and carers (who should be \\noffered a copy of the plan). This should cover: \\nMotor neurone disease: assessment and management (NG42)\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 32, 'page_label': '33', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='after discussion with the person and their family and carers (who should be \\noffered a copy of the plan). This should cover: \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 33 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 33, 'page_label': '34', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• long-term support provided by the multidisciplinary team \\n• the initial frequency of respiratory function tests and monitoring of \\nrespiratory impairment \\n• the frequency of clinical reviews of symptomatic and physiological changes \\n• the provision of carers \\n• arrangements for device maintenance and 24-hour emergency clinical and \\ntechnical support \\n• secretion management and respiratory physiotherapy assessment, including \\ncough augmentation (if required) \\n• training in and support for the use of non-invasive ventilation for the person \\nand their family and carers \\n• regular opportunities to discuss the person's wishes in relation to continuing \\nor withdrawing non-invasive ventilation. [2010, amended 2016] \\n1.15.21 When starting non-invasive ventilation: \\n• perform initial acclimatisation during the day when the person is awake \\n• usually start regular treatment at night, before and during sleep \\n• gradually build up the person's hours of use as necessary. [2010]\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 33, 'page_label': '34', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"• usually start regular treatment at night, before and during sleep \\n• gradually build up the person's hours of use as necessary. [2010] \\n1.15.22 Continue non-invasive ventilation if the clinical reviews show: \\n• symptomatic and/or physiological improvements for a person without severe \\nbulbar impairment and without severe cognitive problems \\n• an improvement in sleep-related symptoms for a person with severe bulbar \\nimpairment or with severe cognitive problems that may be related to \\nrespiratory impairment. [2010] \\n1.15.23 Provide the person and their family and/or carers (as appropriate) with support \\nand assistance to manage non-invasive ventilation. This should include: \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 34 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 34, 'page_label': '35', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='• training on using non-invasive ventilation and ventilator interfaces, for \\nexample: \\n－ emergency procedures \\n－ night-time assistance if the person is unable to use the equipment \\nindependently (for example, emergency removal or replacement of \\ninterfaces) \\n－ how to use the equipment with a wheelchair or other mobility aids if \\nrequired \\n－ what to do if the equipment fails \\n• assistance with secretion management \\n• information on general palliative strategies \\n• an offer of ongoing emotional and psychological support for the person and \\ntheir family and carers. [2010, amended 2016] \\n1.15.24 Discuss all decisions to continue or withdraw non-invasive ventilation with the \\nperson and (if the person agrees) their family and carers. [2010] \\n1.15.25 Before a decision is made on the use of non-invasive ventilation for a person with \\na diagnosis of frontotemporal dementia, the multidisciplinary team together with'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 34, 'page_label': '35', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"1.15.25 Before a decision is made on the use of non-invasive ventilation for a person with \\na diagnosis of frontotemporal dementia, the multidisciplinary team together with \\nthe respiratory ventilation service should carry out an assessment that includes: \\n• the person's capacity to make decisions and to give consent (see Mental \\nCapacity Act 2005) \\n• the severity of dementia and cognitive problems \\n• whether the person is likely to accept treatment \\n• whether the person is likely to achieve improvements in sleep-related \\nsymptoms and/or behavioural improvements \\n• a discussion with the person's family and/or carers (with the person's \\nconsent if they have the capacity to give it). [2010, amended 2016] \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 35 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 35, 'page_label': '36', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"1.15.26 Consider prescribing medicines to help ease breathlessness that people using \\nnon-invasive ventilation can take on an 'as-needed' basis at home, for example, \\nopioids or benzodiazepines. \\nIn February 2016 this was an off-label use of opioids and benzodiazepines. See \\nNICE's information on prescribing medicines. [2016] \\n1.15.27 Inform services that may see the person in crisis situations, such as their GP and \\nservices that provide emergency or urgent care, that the person is using \\nnon-invasive ventilation. [2016] \\nStopping non-invasive ventilation \\n1.15.28 The healthcare professionals responsible for starting non-invasive ventilation \\ntreatment in people with MND should ensure that support is available for other \\nhealthcare professionals who may be involved if there is a plan to stop \\nnon-invasive ventilation, including the legal and ethical implications. [2016] \\n1.15.29 If a person on continuous non-invasive ventilation wishes to stop treatment,\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 35, 'page_label': '36', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"non-invasive ventilation, including the legal and ethical implications. [2016] \\n1.15.29 If a person on continuous non-invasive ventilation wishes to stop treatment, \\nensure that they have support from healthcare professionals with knowledge and \\nexpertise of: \\n• stopping non-invasive ventilation \\n• the ventilator machine \\n• palliative medicines (see the NICE guideline on care of dying adults in the last \\ndays of life) \\n• supporting the person, family members and/or carers (as appropriate) \\n• supporting other healthcare professionals involved with the person's care \\n• legal and ethical frameworks and responsibilities. [2016] \\n1.15.30 If a person on continuous non-invasive ventilation wishes to stop treatment, seek \\nadvice from healthcare professionals who have knowledge and experience of \\nstopping non-invasive ventilation. [2016] \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 35, 'page_label': '36', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='stopping non-invasive ventilation. [2016] \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 36 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 36, 'page_label': '37', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='1.15.31 Healthcare professionals involved in stopping non-invasive ventilation should \\nhave up-to-date knowledge of the law regarding the Mental Capacity Act, \\nDNACPR, ADRT orders, and Lasting Power of Attorney. [2016] \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 37 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 37, 'page_label': '38', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"Context \\nMotor neurone disease (MND) is a neurodegenerative condition that affects the brain and \\nspinal cord. MND is characterised by the degeneration of primarily motor neurones, \\nleading to muscle weakness. \\nThe presentation of the disease varies and can be as muscle weakness, wasting, cramps \\nand stiffness of arms and/or legs; problems with speech and/or swallowing or, more rarely, \\nwith breathing problems. As the disease progresses, the pattern of symptoms and signs \\nbecomes similar, with increasing muscle weakness in the person's arms and legs, \\nproblems swallowing and communicating and weakness of the muscles used for breathing, \\nwhich ultimately leads to death. Most people die within 2 to 3 years of developing \\nsymptoms, but 25% are alive at 5 years and 5% to 10% at 10 years. The most common type \\nof MND is amyotrophic lateral sclerosis (ALS). There are rarer forms of MND such as \\nprogressive muscular atrophy or primary lateral sclerosis, which may have a slower rate of\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 37, 'page_label': '38', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='of MND is amyotrophic lateral sclerosis (ALS). There are rarer forms of MND such as \\nprogressive muscular atrophy or primary lateral sclerosis, which may have a slower rate of \\nprogression. \\nEvery person with MND has an individual progression of the disease. About 10% to 15% of \\npeople with MND will show signs of frontotemporal dementia, which causes cognitive \\ndysfunction and issues in decision-making. A further 35% of people with MND show signs \\nof mild cognitive change, which may affect their ability to make decisions and plan ahead. \\nMND is a disorder which can affect adults of any age. It is most common in people aged 55 \\nto 79 years, and onset below the age of 40 years is uncommon. There are approximately \\n4,000 people living with MND in England and Wales at any one time. The cause of MND is \\nunknown. About 5% to 10% of people with MND have a family history of the disease and \\nseveral abnormal genes have been identified.'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 37, 'page_label': '38', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='unknown. About 5% to 10% of people with MND have a family history of the disease and \\nseveral abnormal genes have been identified. \\nAs there is no cure for MND, care focuses on maintaining functional ability and enabling \\npeople with MND and their family members to live as full a life as possible. Early diagnosis, \\nwithout delay after investigation, may be helpful, as it allows medication and the provision \\nof aids, as well as communication about the disease and advance care planning to be \\nundertaken appropriately. \\nCare of people with MND varies across England and Wales, with MND care centres and \\nnetworks providing coordinated multidisciplinary care. However, some people with MND \\nare left isolated and their care is less than ideal. This guideline aims to consider the clinical \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 38 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 38, 'page_label': '39', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='and cost-effectiveness evidence for the care of people with MND from the time of \\ndiagnosis, including communication of the diagnosis, monitoring of disease progression, \\nmanagement of symptoms (in particular muscle weakness, excess secretions, breathing \\nand nutrition problems), ongoing support and services available, mobility, emotional and \\npsychological changes, and the preparation for end of life care. Particular emphasis is \\nplaced on the importance of a multidisciplinary team approach to the care and \\nmanagement of people with MND. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 39 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 39, 'page_label': '40', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"Recommendations for research \\nThe Guideline Committee has made the following recommendations for research. The \\nCommittee's full set of recommendations for research is detailed in the full guideline. \\n1 Organisation of care \\nIs a network-based model as effective as a clinic-based model to deliver multidisciplinary \\ncare to people with motor neurone disease (MND)? \\nWhy this is important \\nMultidisciplinary care improves survival in patients with MND. The evidence is drawn from \\nmodels of multidisciplinary care that use a clinic based approach. However there are other \\nmodels of care delivery in practice including care networks. Often these alternative models \\nof care have arisen out of necessity in large geographical regions with low density \\npopulations. These alternative models may have similar survival advantages to patients \\nwith MND and this needs to be established. \\n2 Cognitive assessment \\nWhat is the impact of assessing for cognitive and behaviour change in people with MND\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 39, 'page_label': '40', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='with MND and this needs to be established. \\n2 Cognitive assessment \\nWhat is the impact of assessing for cognitive and behaviour change in people with MND \\non clinical practice, the person and their family and carers? Does repeated assessment \\nprovide more benefit than assessment at a single point at diagnosis? \\nWhy this is important \\nClinic-based and population-based studies demonstrate that up to 15% of people with \\nMND have frontotemporal dementia. A further third of people with MND have changes in \\nbehaviour and cognition. These impairments are present at diagnosis. Their course during \\nthe disease has shown varying patterns between studies although several studies have \\nshown that cognitive and behavioural impairments predict poorer survival and increased \\ncarer burden. A randomised controlled trial is needed to assess whether formal \\nassessment at diagnosis and/or repeated assessment improves clinical practice,'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 39, 'page_label': '40', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='carer burden. A randomised controlled trial is needed to assess whether formal \\nassessment at diagnosis and/or repeated assessment improves clinical practice, \\nsubsequent care of the person and quality of life for the person, their family and carers. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 40 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 40, 'page_label': '41', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='3 Prognostic tools \\nIs the ALS Prognostic Index an accurate predictor of survival in people with MND under \\nNHS care in England and/or Wales? \\nWhy this is important \\nAccurate predictions of survival in people with MND would be of great use to clinicians and \\nto the person with MND, their family and carers. Accurate predictions would enable people \\nwith MND to be clearer about their prognosis, make plans for the rest of their life and have \\na well-prepared and dignified transition into the end of life phase. Family members would \\nsimilarly benefit in being more aware of the likely progression and prepare themselves for \\nthe death of their loved one. \\nAccurate predictions of survival would enable professionals to create and deliver more \\neffective management and care plans and access services when it is most appropriate, for \\nexample specialist palliative care. \\nThe ALS Prognostic Index (ALS-PI) was developed in a cohort of people with ALS in the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 40, 'page_label': '41', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='example specialist palliative care. \\nThe ALS Prognostic Index (ALS-PI) was developed in a cohort of people with ALS in the \\nRepublic of Ireland and externally validated in a cohort in Italy. However, it has not been \\nvalidated in people with ALS, primary lateral sclerosis or progressive muscular atrophy in \\nthe NHS in England or Wales. The tool needs to be validated in a UK population using a \\nsimplified measure of executive function. \\n4 Saliva \\nHow is excessive drooling of saliva (sialorrhoea) managed in people with MND? \\nWhy this is important \\nSialorrhoea affects up to 50% of people with MND and in 42% of these individuals the \\nsymptom is poorly controlled. There is no evidence base for clinicians to make decisions \\nwith regard to the treatment options available. Antimuscarinics are used first-line but there \\nis no evidence to inform which antimuscarinic and at what dose. Botulinum toxin is used'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 40, 'page_label': '41', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='with regard to the treatment options available. Antimuscarinics are used first-line but there \\nis no evidence to inform which antimuscarinic and at what dose. Botulinum toxin is used \\nsecond- or third-line although there is little evidence to guide dosing, which salivary \\nglands to inject and which type of botulinum toxin to use. Currently there is no baseline \\ninformation about how specialists are using these treatments and this information is \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 41 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 41, 'page_label': '42', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='required to inform comparative studies. \\n5 Nutrition \\nDoes a high calorific diet prolong survival of people with MND if initiated following \\ndiagnosis or following initiation of feeding using a gastrostomy? \\nWhy this is important \\nThere is little specific guidance on the optimal calorie intake for people with MND. There is \\ngrowing evidence that people with MND have a hypercatabolic state and have high energy \\nrequirements. A large cohort study in the UK has demonstrated that nearly half of people \\ncontinue to lose weight following gastrostomy and most show no improvement in their \\nweight. A small study has demonstrated that high fat and high carbohydrate feeding may \\nprolong survival in gastrostomy-fed people. A larger randomised trial is needed to inform \\nclinical practice. \\n6 Augmentative and alternative communication \\nWhat is the current pattern of provision and use of augmentative and alternative \\ncommunication (AAC) by people with MND in England? \\nWhy this is important'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 41, 'page_label': '42', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='What is the current pattern of provision and use of augmentative and alternative \\ncommunication (AAC) by people with MND in England? \\nWhy this is important \\nAppropriate AAC equipment can have a significant effect on quality of life for people with \\nMND. While the NHS has a responsibility to provide equipment and ongoing support in its \\nuse, there are no reliable data on the types of equipment found most useful at different \\nstages of the disease process, or the number of people with MND who may benefit from \\nAAC. A prospective census study of people with MND presenting with early onset of \\nspeech problems is needed to establish the current baseline provision and needs of this \\npopulation and how best to utilise AAC equipment. The programme will begin with the \\ncollection and analysis of basic data. It will then progress to patient-related outcomes. \\nMotor neurone disease: assessment and management (NG42)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 41, 'page_label': '42', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='collection and analysis of basic data. It will then progress to patient-related outcomes. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 42 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 42, 'page_label': '43', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content=\"Finding more information and committee \\ndetails \\nTo find NICE guidance on related topics, including guidance in development, see the NICE \\ntopic pages on motor neurone disease, dementia, diet, nutrition and obesity and end of life \\ncare. \\nFor full details of the evidence and the guideline committee's discussions, see the full \\nguideline. You can also find information about how the guideline was developed, including \\ndetails of the committee. \\nNICE has produced tools and resources to help you put this guideline into practice. For \\ngeneral help and advice on putting our guidelines into practice, see resources to help you \\nput NICE guidance into practice. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 43 of\\n45\"),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 43, 'page_label': '44', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='Update information \\nJuly 2019: We linked to the new MHRA safety advice on prescribing gabapentin. Because \\nof a risk of abuse and dependence, gabapentin is controlled under the Misuse of Drugs \\nAct 1971 as a class C substance and scheduled under the Misuse of Drugs Regulations \\n2001 as schedule 3 (as of 1 April 2019). \\nFebruary 2016: This guideline amalgamates new guidance on the assessment and \\nmanagement of motor neurone disease (MND) with NICE guideline CG105 (published July \\n2010), and replaces it. \\nNew recommendations have been added in a number of areas, including recognition and \\nreferral, information and support at diagnosis, cognitive assessments, prognostic factors, \\npsychosocial and social support, organisation of care, planning for end of life care, and \\nmanaging symptoms. \\nRecommendations are marked as [2016] if the evidence has been reviewed and the \\nrecommendation has been added or updated. \\nWhere recommendations end [2010], the evidence has not been reviewed since the'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 43, 'page_label': '44', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='recommendation has been added or updated. \\nWhere recommendations end [2010], the evidence has not been reviewed since the \\noriginal guideline. \\nWhere recommendations end [2010, amended 2016], the evidence has not been reviewed \\nbut changes have been made to the recommendations to refer to updated legislation or for \\nconsistency with new guideline recommendations. \\nMinor changes since publication \\nSeptember 2024: We added links to relevant technology appraisal guidance in the \\nsections on saliva problems and disease-modifying treatment. This is to provide easy \\naccess to relevant guidance at the right point in the guideline only and is not a change in \\npractice. \\nOctober 2022: We added text to indicate that pulse oximetry may be less reliable in \\npeople with dark skin. We also added a link to the NHS patient safety alert on the risk of \\nharm from inappropriate placement of pulse oximeter probes. See recommendation 1.15.8. \\nMotor neurone disease: assessment and management (NG42)'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 43, 'page_label': '44', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='harm from inappropriate placement of pulse oximeter probes. See recommendation 1.15.8. \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 44 of\\n45'),\n",
       " Document(metadata={'producer': 'Prince 12.5 (www.princexml.com)', 'creator': 'NICE Publications', 'creationdate': '2019-07-23T00:00:00+00:00', 'keywords': 'NG42', 'subject': 'Motor neurone disease: assessment and management (NG42)', 'author': 'National Institute for Health and Care Excellence (NICE)', 'title': 'Motor neurone disease: assessment and management', 'source': '../data/pdf_files/motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'total_pages': 45, 'page': 44, 'page_label': '45', 'source_file': 'motor-neurone-disease-assessment-and-management-pdf-1837449470149.pdf', 'file_type': 'pdf'}, page_content='August 2020: We have linked to the NICE guideline on supporting adult carers in \\nrecommendations 1.2.9 and 1.6.3. We have incorporated footnotes into the \\nrecommendations in line with accessibility requirements. \\nOctober 2019: Some footnotes were amended to reflect a change in marketing \\nauthorisation status for botulinum neurotoxin type A preparations. \\nISBN: 978-1-4731-1690-0 \\nMotor neurone disease: assessment and management (NG42)\\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\\nconditions#notice-of-rights).\\nPage 45 of\\n45')]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chunks = split_documents(all_pdf_documents)\n",
    "chunks"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4247c8cf",
   "metadata": {},
   "source": [
    "### Embedding and vectorStoreDB"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "7b8b664b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "from sentence_transformers import SentenceTransformer\n",
    "import chromadb\n",
    "from chromadb.config import Settings\n",
    "import uuid\n",
    "from typing import Any, List\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "06f143f4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading embedding model: all-MiniLM-L6-v2\n",
      "Model loaded successfully. Embedding dimension: 384\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<__main__.EmbeddingManager at 0x1218fee40>"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "class EmbeddingManager:\n",
    "    def __init__(self, model_name: str = 'all-MiniLM-L6-v2'):\n",
    "        \"\"\"\n",
    "        Initialize the embedding manager\n",
    "        \n",
    "        Args:\n",
    "            model_name: HuggingFace model for sentence embeddings\n",
    "        \"\"\"\n",
    "        self.model_name = model_name\n",
    "        self.model = None\n",
    "        self._load_model()\n",
    "\n",
    "\n",
    "    def _load_model(self):\n",
    "        \"\"\"Load the SentenceTransformer model\"\"\"\n",
    "        try:\n",
    "            print(f\"Loading embedding model: {self.model_name}\")\n",
    "            self.model = SentenceTransformer(self.model_name)\n",
    "            print(f\"Model loaded successfully. Embedding dimension: {self.model.get_sentence_embedding_dimension()}\")\n",
    "        except Exception as e:\n",
    "            print(f\"Error loading model {self.model_name}: {e}\")\n",
    "            raise\n",
    "        \n",
    "    def generate_embeddings(self, texts: List[str]) -> np.ndarray:\n",
    "        \"\"\"\n",
    "        Generate embeddings for a list of texts\n",
    "        \n",
    "        Args:\n",
    "            texts: List of text strings to embed\n",
    "            \n",
    "        Returns:\n",
    "            numpy array of embeddings with shape (len(texts), embedding_dim)\n",
    "        \"\"\"\n",
    "        if not self.model:\n",
    "            raise ValueError(\"Model not loaded\")\n",
    "        \n",
    "        print(f\"Generating embeddings for {len(texts)} texts...\")\n",
    "        embeddings = self.model.encode(texts, show_progress_bar=True)\n",
    "        print(f\"Generated embeddings with shape: {embeddings.shape}\")\n",
    "        return embeddings\n",
    "            \n",
    "## initialize the embedding manager\n",
    "\n",
    "embedding_manager=EmbeddingManager()\n",
    "embedding_manager\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "rag",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
